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Microscopic view of a lung biopsy from a patient with invasive aspergillosis. 
Blancophor staining (picture: Hein van der Lee).
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Chapter 1
General introduction
The diverse fungal kingdom contains a collection of spectacularly successful decomposers, 
symbionts, pathogens, and parasites. Fungi play an important role as degraders of organic 
matter, as industrial manufacturers of food, antibiotics and enzymes and as the best-
characterized eukaryotic model systems for scientific and biomedical research [1]. Of the 
estimated 1.5 million species of fungi [2], only 100 are known to be regularly involved in 
human and animal mycoses [3] with Aspergillus fumigatus, the focus of this thesis, being one 
of the most predominant pathogenic fungal species of humans [1].
Aspergillus fumigatus
A. fumigatus is a saprophytic mold abundantly present in soil and decaying organic matter. 
It produces large numbers of small (2 to 3 μm) airborne asexual spores (conidia), that can 
survive a wide range of environmental conditions. Due to the 10,000 to 15,000 liter of air 
we inhale each day, humans are continuously in contact with spores [4] and it is estimated 
that we inhale at least several hundred of conidia per day [5]. Despite this constant exposure, 
most humans do not develop fungal diseases, due to elimination of the fungal spores by the 
innate immune system [5].
On the other hand, A. fumigatus is certainly able to cause disease, often depending on the 
immune status of the patient [5]. Many infection sites have been described, e.g. the skin, 
soft tissues, sinuses, central nervous system, peritoneum, kidneys, bones, cardiovascular 
system, eyes, and gastrointestinal tract [5-6]. For most patients, the main portal of entry and 
site of infection of A. fumigatus is the respiratory tract [5]. In individuals with altered lung 
function such as asthma and cystic fibrosis patients, it can cause allergic bronchopulmonary 
aspergillosis, a hypersensitive response to fungal components. Noninvasive aspergilloma 
occurs in preexisting pulmonary cavities which can be caused by diseases such as tuberculosis. 
Invasive aspergillosis is the most devastating form of aspergillus disease, and usually targets 
severely immunocompromised patients [5,7-8]. Those most at risk for this life-threatening 
disease are individuals with hematological malignancies such as leukemia, solid organ and 
hematopoietic stem cell transplant patients, patients on prolonged corticosteroid therapy, 
individuals with genetic immunodeficiencies such as chronic granulomatous disease (CGD), 
and patients infected with human immunodeficiency virus (HIV) [8-9].
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Antifungal therapy
Treatment of aspergillosis may include recovery of the immune status (by reducing 
immunosuppressive therapy), surgery, and antifungal treatment [5,10]. The availability of 
new antifungals have revolutionized the field of medical mycology in the past few decades 
[11], and treatment options for Aspergillus include three classes of agents: azoles, polyenes 
and echinocandins (Figure 1) [1].
Azoles can be divided into two groups: imidazoles and triazoles. Most of the antifungal 
imidazoles are formulated only for topical use, usually because of toxicity or bioavailability 
problems that limit their potential as systemic agents [11]. The triazoles (fluconazole, 
itraconazole, posaconazole, and voriconazole) are the largest class of antifungal agents in 
clinical use [12]. They function by targeting the ergosterol biosynthetic enzyme lanosterol 
14α-demethylase (cytochrome P450), encoded by cyp51 genes in A. fumigatus [1]. Azoles 
act through a nitrogen atom in the azole ring, which binds to an iron atom in the heme group 
located in the active site of the enzyme. This inhibits the demethylation of lanosterol, causing 
a block in the production of ergosterol and the accumulation of 14-α-methyl-3,6-diol, a toxic 
sterol produced by the Δ-5,6-desaturase encoded by erg3 (Figure 1A) [1]. With ergosterol 
depleted and replaced with unusual sterols, the normal permeability and fluidity of the 
fungal membrane is altered, with secondary consequences for membrane-bound enzymes, 
such as those involved in cell wall synthesis [12].
Polyenes (amphotericin B) are amphipathic drugs, having both hydrophobic and hydrophilic 
sides. Polyenes bind to ergosterol to create drug-lipid complexes, which intercalate into the 
fungal cell membrane to form a membrane-spanning channel (Figure 1B). This causes leakage 
of cellular contents [1,12]. Although the polyenes have been used in the clinic for over 50 
years, the major limitation of their use is host toxicity, such as renal dysfunction, which is likely 
due to the structural similarities between ergosterol and cholesterol in the mammalian cell 
membrane. To overcome amphotericin B toxicity, various reformulated versions of the agent 
have been introduced, which are significantly less toxic than the conventional amphotericin 
B formulation [1,12].
The echinocandins (anidulafungin, caspofungin, and micafungin) are large lipopeptide 
molecules that act as noncompetitive inhibitors of (1,3)-β-D-glucan synthase (encoded by 
fks1), an enzyme involved in fungal cell wall synthesis. Echinocandins interfere with this 
enzyme, resulting in the loss of cell wall integrity and severe cell wall stress on the fungal cell 
[1] (Figure 1C). 
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Previous page, Figure 1. Antifungal drugs and their targets [1].
(A) Azoles act by targeting lanosterol 14α-demethylase, causing a block in the production of ergosterol. 
A toxic sterol produced by Erg3 subsequently accumulates resulting in a severe membrane stress on 
the cell. 
(B) Polyenes function by binding to ergosterol. Drug-lipid complexes are created, which intercalate into 
the fungal cell membrane to form a membrane-spanning channel. This causes cellular ions to leak out 
of the cell, destroying the proton gradient and resulting in osmotic cellular lysis. 
(C) Echinocandins act as noncompetitive inhibitors of (1,3)-β-D-glucan synthase, and thereby cause a 
loss of cell wall integrity and severe cell wall stress.
Mechanisms of azole resistance
Azoles are the largest and most widely used class of antifungal drugs. Although A. fumigatus is 
intrinsically resistant to the commonly used azole fluconazole [1], it is generally susceptible to 
the other azole antifungals (itraconazole, posaconazole, and voriconazole). These antifungals 
play a very important role in the treatment of disease caused by A. fumigatus: voriconazole 
is the first choice therapy for invasive aspergillosis [6,13], itraconazole is commonly used for 
the treatment of chronic and allergic conditions [14] and posaconazole has been shown to be 
effective in preventing invasive aspergillosis in patients with certain hematologic malignancies 
[15-16]. Furthermore, azoles are the only class of agents available in oral formulation which 
makes it also suitable for long-term or ambulant therapy for chronic and allergic infections.
The susceptibility of an A. fumigatus isolate to azoles and other antifungal agents can be 
determined using in vitro susceptibility testing. Various formats have been developed to test 
the susceptibility of aspergilli, including the European Committee for Antibiotic Susceptibility 
Testing (EUCAST) E.DEF 9.1 method [17]. For this susceptibility testing methodology, proposed 
breakpoints have been published to determine the minimum inhibitory concentration (MIC) 
boundaries between susceptible and resistant (Table 1) [18]. 
Since the first documented case of A. fumigatus resistance in 1997 [19], many azole-resistant 
strains of A. fumigatus have been isolated and characterized. In addition, mutant isolates in 
which specific genes were altered, were analyzed. Here, various resistance mechanisms are 
described. 
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Alteration of the drug target
Alteration of the drug target (Cyp51) is the principal mechanism of resistance among 
A. fumigatus isolates [20]. There are two Cyp51 enzymes in A. fumigatus, encoded by cyp51A 
and cyp51B genes [21]. Although mutations in cyp51B have been described [22-23], none 
of them has been proven to be related to an azole-resistant phenotype. In contrast, various 
resistance mutations have been described in cyp51A of clinical isolates; the most frequently 
characterized (hotspot) mutations are at codons G54 [22,24-27], L98 [28-31], and M220 
[23,25-26,32-34]. Also mutations at other codons are described including G138, P216, Y431, 
G432, G434, and G448 [35-40], although they have not been confirmed by transformation of 
the altered gene into a wildtype A. fumigatus isolate.
Mutations at codon L98 are always accompanied by a tandem repeat of 34 basepairs in the 5´ 
upstream region of cyp51A (TR34/L98H), which increases cyp51A expression [28,41]. Notably, 
it was found that the transformation of the azole-resistant cyp51A open reading frame 
(L98H) or promoter (TR34)  into a susceptible isolate could confer only moderate increases 
in resistance, but recombinants with both the tandem repeat and the L98H substitution 
exhibited full resistance [28,41], establishing the importance of the combination of both 
alterations in azole resistance. Recently also a repeat of 53 bp (TR53) was described in the 
promoter region of cyp51A. However, transformation into a wildtype isolate did not result in 
the full azole resistant phenotype as observed in the original TR53 isolate so a yet unknown 
(additional) mutation was suspected [42]. Furthermore, the presence of a 46 bp tandem 
repeat was found together with two Cyp51A substitutions (TR46/Y121F/T289A), in a renal 
transplant patient with invasive aspergillosis [43] also conferring resistance to triazoles. 
The three tandem repeats of 34, 46 and 53 basepairs are all located in the same region (Figure 
2), indicating the importance of this region in playing a role in azole resistance. Furthermore, 
a recent study identified a transposon-insertion of 1,822 bp into the promoter region of an 
azole-resistant clinical isolate, located at 370 bp upstream of the startcodon [36]. The isolate 
had higher expression levels of cyp51A as well, but the direct association with the insertion is 
currently unknown and awaits further investigation. 
The phenotype of a resistant isolate depends on the particular (cyp51A) resistance mechanism 
as well as its genetic background. Frequently the activity of more than one azole is affected, 
often referred to as cross-resistance. In Table 2, the current data linking the phenotype to the 
genotype is shown for various cyp51A mutations. 
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Table 1. Proposed interpretative breakpoints [18].
MIC (mg/l)
Antifungal agent Susceptible Intermediate Resistant
Itraconazole <2 2 >2
Posaconazole <0.5 0.5 >0.5
Vorionazole <2 2 >2
Table 2. The minimum inhibitory concentrations (MICs) of clinical isolates with various Cyp51A 
substitutions.
Cyp51A substitution
MIC (mg/l)
ReferencesITZ POS VOR
G54E >8 0.25-1 0.25-0.5 [22,44]*
G54R >8 1 0.12-0.5 [22,24-26,44]
G54V >8 ND 0.25-1 [22,44]
G54W >8 >8 0.12-0.5 [24,44]
G138C >8 1->8 4->8 [38-39]
P216L >8 1 1 [39]
M220I >8 0.5 1 [25-26]*
M220K >8 1->8 1-2 [22-23,32-34,44]*
M220R >8 2 2 [45]*
M220T >8 0.25-0.5 0.5-1 [22-23,44]
M220V >8 0.5-1 1-2 [21-22,44] 
M220W ND ND ND [45]
Y431C >8 1 4 [39]
G432S >8 0.25 0.38 [35]
G434C >8 1 4 [39]
G448S >8 0.5-1 >8 [37,39]
TR34/L98H >8 0.5-8 2->8 [28,39,46-47]
TR46/Y121F/T289A 0.5->8 0.25-4 >8 [43]*
TR53 >8 0.25 >8 [42]
ITZ, itraconazole; POS, posaconazole; VOR, voriconazole; ND, not described.
*Also from unpublished data.
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Drug efflux mechanisms
The major mechanism responsible for high-level azole resistance in clinical Candida isolates 
is overexpression of efflux pumps of the ATP-binding cassette (ABC) family and the Major 
Facilitator Superfamily (MFS) [48]. Although A. fumigatus contains a large number of these 
efflux pumps [28,49], isolates overexpressing these pumps as an azole resistance mechanism 
have rarely been described. 
In itraconazole-resistant clinical isolate AF72, the finding of a reduced intracellular 
accumulation of itraconazole was suggestive for drug efflux pumps in mediating resistance 
[19]. This isolate has been found to overexpress the atrF gene (an ABC transporter efflux 
pump) when it was grown in the presence of itraconazole [50]. However, in later reports 
this isolate turned out to contain the G54E substitution in Cyp51A [22,36,51], which itself is 
already sufficient for itraconazole resistance to develop [22]. 
There are a two other reports of efflux pump overexpression, although these have been 
mutant isolates generated in the laboratory and not clinical isolates [52-53]. In the first study, 
itraconazole-resistant A. fumigatus mutants obtained by UV mutagenesis were analyzed. 
Some of them had point mutations at Cyp51A codon G54. A part of the mutants, however, 
appeared to be resistant possibly due to the overexpression of the efflux pumps mdr3 
and mdr4 [52]. The second study included isolates obtained after ten in vitro passages in 
itraconazole-supplemented medium. As was the case in the UV mutagenesis experiments, 
several isolates had point mutations in cyp51A related to resistance. Furthermore, most of 
the mutants showed either constitutive high-level expression or induction upon itraconazole-
exposure of mdr3, mdr4, and atrF. Some mutants also showed increased expression levels of 
mdr1 or mdr2 transporters [53]. Importantly, in both studies there was no evidence linking 
the elevated expression directly with the itraconazole-resistant phenotype of any of the 
mutants analyzed [52-53]. Moreover, the increased expression might also represent a stress 
response and does not necessarily have to be related to resistance [36]. 
Deletion of the transporter-encoding gene abcA did not show increased susceptibility 
to azoles and other antifungals [54]. Furthermore, of all the above described genes (atrF, 
mdr1, mdr2, mdr3, mdr4 and abcA), only mdr1 was found as one of the most expressed 
genes in microarray experiments upon voriconazole exposure [55]. Taken together, although 
some transporters have been suggested to reduce azole susceptibility, none of them has 
been proven to play a direct role in resistance. The question thus remains whether efflux 
transporters play an active role in clinical resistance in A. fumigatus.
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Transcription factor modification
Very little is known regarding transcription factors playing a role in A. fumigatus antifungal 
resistance. In C. albicans however, gain-of-function mutations in four transcription factors 
(Tac1, Mrr1, Cap1, and Upc2), have been linked to increased antifungal resistance [56-61]. 
Tac1, Mrr1, and Cap1 are associated with increased drug efflux. In contrast, Upc2 is thought 
to cause resistance through an increase in the erg11 transcript level (erg11 is the cyp51 
homologue in Candida) [58-59], demonstrating another mechanism whereby drug target 
overexpression can occur.
It is unknown whether such mutations occur in transcription factors or their binding sites in 
A. fumigatus. Recent results showed that deletion mutants of SrbA, a transcriptional regulator 
of the sterol regulatory binding protein (SREBP) family, have an increased susceptibility 
to fluconazole and voriconazole [62]. A subsequent study showed that SrbA is a direct 
transcriptional regulator of cyp51A and, to a lesser extent, cyp51B, being the likely underlying 
mechanism of the increased susceptibility of the srbA deletion mutant [63].
Furthermore, studies of Yap1, the A. fumigatus homologue of Cap1 in C. albicans (see above) 
show that a hyperactive, truncated  form of this transcription factor attenuates susceptibility 
of A. fumigatus to voriconazole [64]. As is the case in the yeast homologue, truncated Yap1 
resistance might be mediated by activating expression of transporter genes [60,65].
Emergence of azole resistance
The first documented case of A. fumigatus resistance to an azole was itraconazole resistance, 
described in 1997 [19]. Although the frequency of azole resistance has remained low for many 
years [66], in the year 2007, a case series of patients with azole-resistant invasive aspergillosis 
was reported for the first time [31]. Thirteen isolates were obtained from nine patients with 
primary invasive aspergillosis or with breakthrough infection while receiving itraconazole or 
voriconazole. The patients were from six hospitals in The Netherlands and the isolates were 
obtained between 2002 and 2006. Although there was no apparent epidemiological link 
between the cases, twelve out of the thirteen isolates (92%) carried the TR34/L98H resistance 
mechanism in cyp51A [31].
Subsequent studies showed that the prospectively collected fungus culture collection of the 
Radboud University Nijmegen Medical Centre (The Netherlands) contained an increasing 
number of azole resistant A. fumigatus isolates over time. From the year 2000 onwards, 
patients were observed annually with an itraconazole-resistant isolate, with a maximum 
prevalence of 10.1% in 2010 (Figure 3) [29,66-67]. A recent prospective nationwide 
multicentre surveillance study additionally showed that the emergence of resistance was not 
limited to a single Medical Centre in Nijmegen, but azole resistance was observed in 6 other 
University Medical Centres in The Netherlands. Again, most of the itraconazole resistant 
isolates (90%) were found to possess the TR34/L98H mutation in the cyp51A gene [68].
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Emergence of resistance is not only observed in The Netherlands, but also in the United 
Kingdom. Here, a sudden rise in frequency was observed since 2004 [39,45]. In 2009, the 
frequency of resistance was as high as 20% of patient cases [45]. Remarkably, the distribution 
of resistance mechanisms differs between the Dutch and British azole-resistant isolates, 
with the TR34/L98H substitution being highly dominant in the Dutch isolates and several 
other cyp51A mutations being present in the British isolates [18,29,39,68]. Furthermore, in 
the United Kingdom, an increase was observed in azole-resistant isolates without cyp51A 
mutations; in 2008/2009, 54% of patients did not have a cyp51A mutation known to confer 
resistance [45]. The reasons for these differences are not clear but might be related to 
differences in the patient populations from which such isolates were cultured.
Figure 3. Itraconazole resistance among A. fumigatus isolates cultured from 1994 to 2011 in Nijmegen 
(The Netherlands). Prevalence of resistance ranges from 2% of patients in 2000 to as high as 10.1% in 
2010 (red line) of the total number of patients with a cultured A. fumigatus isolate. 
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Clinical and environmental route of resistance
Resistance may develop in patients treated with azole antifungal agents. Acquired resistance 
has especially been described in A. fumigatus isolates cultured from patients with 
aspergilloma and cavitary lung disease [25,39]. This involves infection of the patient with an 
azole-susceptible isolate that becomes resistant due to the azole pressure during treatment. 
Until recently, this mode of resistance development, ‘the clinical route of resistance’, was the 
presumed way of acquired resistance. 
Although still controversial [69], a second route of resistance development is believed to 
occur through environmental azole exposure. The environmental route of resistance is 
especially taken into account for the TR34/L98H resistance mechanism, as a single mechanism 
of azole resistance was rapidly emerging and found in >90% of resistant clinical isolates from 
different hospitals in The Netherlands [29,31,68]. The dominance of this single resistance 
mechanism is difficult to explain by resistance development in individual azole-treated 
patients, as it might be expected that multiple resistance mechanisms would develop [70]. 
Indeed, the development of a diversity of cyp51A mutations as well as non-cyp51A mediated 
resistance was shown in a study by Howard et al, where resistance most likely evolved in 
infecting isolates within the lungs of the individual patients rather than by resistant infection 
through the environmental route [39]. Furthermore, spread of resistance by person-to-
person transmission is unlikely. The patient will either respond to treatment preventing 
spread of the isolate, or treatment will fail, the patient dies and spread to other patients will 
be highly unlikely [70]. Therefore, the dominance of this single resistance mechanism would 
be more consistent with the acquisition from a common environmental source. This is also in 
line with the finding of azole-resistant aspergillosis in azole-naïve patients, strongly indicating 
that resistance does not exclusively develop during azole therapy in the patient. On the other 
hand, also azole-resistant aspergillosis in patients already receiving azole antifungal agents 
(as prophylaxis or as treatment for other fungal infections) might be possible, as the patients 
will be exposed to susceptible and resistant conidia through the environmental route. The 
resistant conidia will subsequently have a selective advantage, allow germination and cause 
disease [70].
Indeed, azole-resistant A. fumigatus isolates of the TR34/L98H genotype were present in the 
(indoor and outdoor) environment in The Netherlands. They were isolated from air samples 
from patient rooms, hospital water (filter) samples, soil, seeds and compost. Corresponding 
to the finding that the majority of clinical resistant isolates was of the TR34/L98H genotype, 
also 86% of the environmental resistant isolates harbored this mechanism of resistance [71]. 
Subsequent microsatellite typing showed that the TR34/L98H environmental isolates generally 
clustered together with TR34/L98H clinical isolates, but apart from the azole-susceptible 
environmental and clinical isolates. This indicated genetic relatedness and possibly a common 
ancestor [71]. It is unclear if spread can be prevented, but isolates of the TR34/L98H genotype 
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were also recovered from the environment in Denmark [72] and Norway [29,73], and from 
patients in various European countries such as Austria, Belgium, Denmark, France, Germany, 
Italy, Spain and the United Kingdom [28,39,74-75]. Additionally, they were recently also 
isolated in Asia [76-77].
But why are these isolates already resistant in the environment? It has been hypothesized 
that environmental resistance could be caused by the use of azole fungicides, also referred 
to as demethylation inhibitors (DMIs). They are commonly used in the environment, for 
crop protection and material preservation. Azoles are used to preserve materials such as 
mattresses, and are also used in paints and coatings. In agriculture, DMIs are used pre-
harvest as well as post-harvest to protect the crop from fungal disease and spoilage. In 
the European Union, the use of azoles in agriculture has gradually increased from the mid-
seventies, and up to 49% of the agricultural area is treated annually with azole fungicides 
[78]. Compared to the amount of azoles used in clinical medicine, the volume of DMIs used 
in agriculture is approximately 350-fold higher in The Netherlands [66], further underlining 
the comprehensive use in the environment.
Azoles may persist in soil and water for a long time (the half-life of certain azoles is over 
one year), thereby also constituting a risk of accumulation [78-82], and possibly giving the 
naturally occurring A. fumigatus a chance to develop resistance. Plant pathogenic fungi 
resistant to azoles have been reported frequently [83-88]. Remarkably, repeats and insertions 
in the 5’ upstream region of cyp51 appear to be a common resistance mechanism in azole 
resistant plant pathogens [89-94], while never described in species of clinical importance, 
except for A. fumigatus. The development of resistance in plant pathogens through exposure 
to azole fungicides as well as the finding of repeats and insertions in cyp51 promoter regions 
of these pathogens, might indicate that TR34/L98H-mediated resistance in A. fumigatus has 
been evolved as an unintended side-effect of the use of azole fungicides. Furthermore, rapid 
emergence of resistance due to a single resistance mechanism was also shown in Penicillium 
digitatum, the most destructive postharvest pathogen of citrus fruits worldwide. Imazalil 
fungicide resistance increased from 2% in the year 2000 to 60-84% during 2005-2010. As is 
the case with A. fumigatus, also a predominant resistance mechanism was found, present in 
almost 90% of the resistant population [93].
Although several reports are rather optimistic and do not consider agricultural practice as 
a cause of cross-resistance in clinical medicine [78,95-97], one publication states that extra 
care should be taken in terms of the application of azoles in agriculture, as long as there is no 
convincing proof indicating that the massive agricultural use of azoles is absolutely independent 
from the increasing incidences of resistant human pathogenic fungi [82]. There are few 
reports showing actual fungicide cross-resistance to medical azoles. The maize pathogen 
Colletotrichum graminicola, resistant to tebuconazole was also resistant to itraconazole and 
voriconazole, indicating that azole fungicides are indeed able to induce cross-resistance to 
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medical azoles [98]. In a study in 2005, 36 out of 150 environmental A. fumigatus isolates 
(24%) had a high itraconazole MIC of ≥2 mg/l. At least some of them additionally showed 
high MICs for agricultural azoles prochloraz (MIC 16 mg/l) or propiconazole (MIC ≥16 mg/l), 
giving a first indication that cross-resistance might exist in A. fumigatus [97]. The finding that 
metconazole and tebuconazole, two agricultural fungicides, exhibited activity to susceptible 
A. fumigatus isolates but were less active against the TR34/L98H resistant isolates [71], further 
supports a role for fungicides in resistance development in A. fumigatus. 
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Outline of the thesis
The thesis focuses on azole resistance in A. fumigatus, especially with respect to the 
molecular basis of resistance. The objectives of this thesis were to discover and investigate 
new mechanisms of azole resistance in A. fumigatus. This was done with the purpose to 
gain a more complete understanding of the mechanisms that can lead to azole resistance 
in A. fumigatus and to gain more insight into the molecular epidemiology of resistance 
development, so that our strategies for preventing, diagnosing and treating azole-resistant 
A. fumigatus infections can be improved.
This thesis explores the two main routes of azole resistance development/selection: azole 
resistance development during medical treatment of individual cases and the emergence of 
resistance through exposure to fungicides in the environment.
Section I. The patient route of resistance development
In chapter 2, an aspergillosis case is described in which multiple azole-resistant profiles were 
found in individual A. fumigatus colonies. We identified two new resistance mechanisms 
and showed that these were indeed associated with the resistant phenotype. In addition, 
a review of the literature is given in which all cases with therapy induced azole resistance 
are described. In chapter 3 azole-resistant isolates from another patient were investigated 
with the aim to determine the resistance mechanism. A new non-cyp51A mechanism of 
resistance was discovered using whole genome sequencing technology and sexual crossing 
experiments.
Section II. Emergence of resistance through environmental azole exposure
Chapter 4 describes our results supporting an environmental route of resistance development 
in A. fumigatus. In chapter 5 we investigate in detail the molecular epidemiology of TR34/
L98H using genotyping techniques. In chapter 6, a new emerging resistance mechanism is 
described, that is characterized by lack of activity of voriconazole. We show that this new 
resistance mechanism has spread across the Netherlands, and probably developed through 
an environmental route of resistance development.
Overall results and conclusions of the studies in this thesis are discussed and summarized in 
chapters 7 and 8.
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A. fumigatus colony growing on Sabouraud agar (picture: Ton Rijs).
Section I 
The patient route of resistance development
Microscopic image of A. fumigatus stained with lactophenol cotton blue (picture: Ton Rijs).
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Abstract 
Nine consecutive isogenic Aspergillus fumigatus isolates cultured from a patient with 
aspergilloma were investigated for azole resistance. The first cultured isolate showed a wild-
type phenotype, but four azole-resistant phenotypes were observed in the subsequent eight 
isolates. Four mutations were found in the cyp51A gene of these isolates, leading to the 
substitutions A9T, G54E, P216L, and F219I. Only G54 substitutions were previously proved 
to be associated with azole resistance. Using a Cyp51A homology model and recombination 
experiments in which the mutations were introduced into a susceptible isolate, we show 
that the substitutions at codons P216 and F219 were both associated with resistance to 
itraconazole and posaconazole. A9T was also present in the wild-type isolate and thus 
considered a Cyp51A polymorphism. Isolates harboring F219I evolved further into a pan-
azole-resistant phenotype, indicating an additional acquisition of a non-Cyp51A-mediated 
resistance mechanism. Review of the literature showed that in patients who develop azole 
resistance during therapy, multiple resistance mechanisms commonly emerge. Furthermore, 
the median time between the last cultured wild-type isolate and the first azole-resistant 
isolate was 4 months (range, 3 weeks to 23 months), indicating a rapid induction of resistance.
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Introduction
Aspergillus fumigatus is able to cause a wide range of diseases, including allergic syndromes, 
aspergilloma, and invasive aspergillosis. Azoles play an important role in the management 
of Aspergillus diseases, but chronic treatment may cause the development of resistance, 
especially in patients with cavitary lesions, such as aspergilloma [1-3]. Infection with azole-
resistant A. fumigatus is associated with a higher probability of treatment failure than 
infection due to isolates with a wild-type susceptibility [2,4-5], which is supported by 
experimental models of aspergillosis [6-11]. Surveillance studies indicate that the prevalence 
of azole resistance varies widely between countries [12-14], and there is increasing evidence 
that in addition to patient therapy, environmental exposure to azole compounds may be 
an important route of resistance development [15-16]. The most common mechanisms 
of resistance in A. fumigatus are modifications in the cyp51A gene [17]. Cyp51A encodes 
cytochrome P450 sterol 14α-demethylase and is the target for azole drugs. Azoles bind to 
the heme cofactor located in the active site of the cyp51-encoded enzyme, thereby blocking 
ergosterol synthesis. Subsequent ergosterol depletion and the accumulation of unusual toxic 
sterols lead to inhibition of fungal growth [18-19].
The objective of this study was to investigate the evolution of azole resistance development 
in a series of consecutive A. fumigatus isolates from a patient with aspergilloma. In addition, 
we reviewed the literature for other patients with development of resistant A. fumigatus 
disease.
Case report
A 48-year-old female was diagnosed with tumor necrosis factor (TNF) receptor-associated 
periodic syndrome (TRAPS) in 2000. Seven years earlier, she had undergone bilobectomy of 
the right lung because of recurrent bacterial infections, including persistent Mycobacterium 
avium infection. In 2000, she was diagnosed with aspergilloma in a cavity of the postoperative 
severely retracted right lung. Surgery was precluded due to the destroyed right lung, and 
itraconazole (ITC) treatment was initiated. Adequate serum concentrations were observed. 
She was treated from April 2000 to November 2007; in 2007, a decision was made to stop 
ITC treatment, since her computed tomography scan and chest X-rays repeatedly showed 
a complete resolution of the aspergilloma, with no sign of recurrence over 8 months. In 
addition, sputum repeatedly remained negative for Aspergillus. Over the next year, her 
condition was stable, until October 2008, when Aspergillus was again cultured from the 
sputum. She was started on ITC but was switched in weeks to voriconazole (VRC). That 
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December, posaconazole (POS) was given to replace VRC because of an insufficient clinical 
response. However, after several months there was radiological evidence for relapse of the 
aspergilloma and for Aspergillus localization in the left lung. A subsequently recovered A. 
fumigatus isolate cultured from the sputum exhibited a multi-azole-resistant phenotype, 
and treatment was switched to liposomal amphotericin B (L-AMB), which was subsequently 
given in combination with caspofungin (CAS). Despite 1 month of treatment with L-AMB and 
CAS, the patient had ongoing Aspergillus disease and died because of a severe urosepsis 
caused by extended-spectrum-β-lactamase-positive Escherichia coli.
At autopsy, Aspergillus could not be identified in the left lung, despite extensive sampling. 
The right lung was severely fibrotic and showed a cavity filled with necrotic material and 
Aspergillus hyphae on microscopy, but no evidence for invasive disease was found.
Materials and methods
Aspergillus fumigatus isolates
From our patient, nine A. fumigatus isolates were obtained within a 10-month period 
(September 2008 to June 2009). All isolates were cultured from respiratory samples, and the 
primary colonies were subcultured on agar plates supplemented with azole compounds (ITC, 
4 mg/liter; VRC, 1 mg/liter; POS, 0.5 mg/liter) [20] as part of a national surveillance study 
[21]. Isolates that grew on these agar plates were further analyzed. A previously cultured A. 
fumigatus isolate from this patient with a wild-type phenotype was also selected for further 
investigation. The isolates were identified by macroscopic and microscopic examination and 
ability to grow at 48°C.
Susceptibility testing
A broth microdilution test was performed according to the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) reference method [22]. ITC, POS, VRC, and 
amphotericin B (AMB) were assayed over a 2-fold concentration range from 16 to 0.016 
mg/liter. Visual readings were performed with a reading mirror, and an endpoint of 100% 
inhibition was used to determine the MICs. For interpretation of the azole MICs, the proposed 
breakpoints were used [14].
Cyp51 sequence analysis and microsatellite genotyping
To isolate DNA, isolates were cultured on Sabouraud agar slants. Conidia were harvested and 
added to 200 μl of breaking buffer (100 mM NaCl, 10 mM Tris-HCl, pH 8, 2% Triton X-100, 
1% sodium dodecyl sulfate, 1 mM EDTA, pH 8) with ~0.1 g glass beads (diameters, 0.4 to 0.6 
mm). After shaking by vortexing, conidia were incubated at 70°C for 30 min while shaking. 
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Then, 200 μl of phenol-chloroform-isoamyl alcohol (25:24:1) was added and samples were 
incubated for 5 min while they were shaken. After centrifugation for 5 min, the upper phase 
containing the DNA was transferred to a new tube. One microliter of DNA was used per PCR.
The cyp51A gene was amplified and subsequently sequenced as described previously 
[23]. The promoter region was amplified using previously described primers P-A7 and 
P-A5 [24] and sequenced using the forward primer (P-A7). The cyp51B gene and promoter 
region were amplified and sequenced using primer sets 5′-CCTTTATTCCCTGCGACA-3′/ 
5′-ACGGCAGAATACCCAGAA-3′ and 5′-GGAGACTGCACAACAACG-3′ / 5′-GGAACCAGTGGAAGA 
CCA-3′. To detect mutations, the sequences were compared with the cyp51A and cyp51B 
sequences with GenBank accession numbers AF338659 and AF338660, respectively.
From all isolates as well as three unrelated control isolates, six microsatellite loci (STRAf 3A, 
3B, 3C, 4A, 4B, and 4C) were amplified as described before [25]. The sizes of the fragments 
were determined, and repeat numbers were assigned [15]. Genotypes consisting of the 
number of repeats for each of the six microsatellites were created for all isolates.
Cyp51A sequence alignment and homology model
An alignment of 47 selected fungal Cyp51 protein sequences deposited in the NCBI protein 
database (http://www.ncbi.nlm.nih.gov/protein) was constructed using the ClustalW2 
multiple-sequence alignment tool (http://www.ebi.ac.uk/Tools/msa/clustalw2/). The 
Cyp51 sequences (GenBank accession numbers) included those of Ajellomyces capsulatus 
(AAU01158), Aspergillus clavatus Cyp51A (EAW10153), A. clavatus Cyp51B (EAW11788), A. 
flavus Cyp51A (EED56341), A. flavus Cyp51B (EED50354), A. fumigatus Cyp51A (EAL90099), 
A. fumigatus Cyp51B (EAL87096), A. nidulans (AAF79204), Blumeria graminis (CAE18091), 
Blumeriella jaapii (ABE01107), Botryotinia fuckeliana (AAF85983), Candida albicans 
(AAF00598), C. glabrata (AAB02329), C. krusei (AAO83898), C. tropicalis (AAA53284), 
Clavispora lusitaniae (ACH87137), Coccidioides posadasii (AAU01157), Cryptococcus 
neoformans (AAF35366), Cunninghamella elegans (Q9UVC3), Eremothecium gossypii 
(Q759W0), Erysiphe necator (AAC49811), Leptosphaeria maculans (AAN28927), Monilinia 
fructicola (AAL79180), Mycosphaerella graminicola (AAF74756), Nakaseomyces delphensis 
(CAO98836), Neosartorya fischeri Cyp51A (EAW25441), N. fischeri Cyp51B (EAW19398), 
Neurospora crassa (EAA34813), Oculimacula acuformis (AAF18468), O. yallundae 
(AAG44831), Penicillium italicum (CAA89824), P. digitatum Cyp51A (CAD27793), P. digitatum 
Cyp51B (ADO85403), P. marneffei Cyp51B (EEA25858), Phanerochaete chrysosporium 
(ACI23621), Pneumocystis carinii (ABG91757), Podosphaera fusca (ACT56506), Saccharomyces 
cerevisiae (AAA34546), Scheffersomyces stipitis (ABN68111), Schizosaccharomyces pombe 
(CAA90803), Talaromyces stipitatus (EED21732), Trichosporon asahii (ADN44281), Ustilago 
maydis (CAA88176), Venturia inaequalis (AAF71293), V. nashicola (CAC85409), Yarrowia 
lipolytica (CAG82748), and Zygosaccharomyces rouxii (CAR28109). The positions of amino 
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acid substitutions present in the patient isolates as well as their equivalents in other fungi 
were pinpointed into the alignment.
Furthermore, the locations of the observed amino acid substitutions were investigated with 
the help of a recently published homology model of the A. fumigatus Cyp51A enzyme [23].
A. fumigatus transformations
Transformation experiments were performed as described before [26]. Briefly, site-directed 
mutagenesis was used to introduce the point mutations into a cassette containing the 
cyp51A gene and promoter region together with a hygromycin selection marker gene. 
Mutagenic primers 5′-CTGGACAAGGGCTTTACTCTCATCAATTTTATGCTACCG-3′/5′-CGGTA
GCATAAAATTGATGAGAGTAAAGCCCTTGTCCAG-3′ (for P216L) and 5′-GCTTTACTCCCATCA
ATATTATGCTACCGTGGGCC-3′/5′-GGCCCACGGTAGCATAATATTGATGGGAGTAAAGC-3′ (for 
F219I) were used. Both cassettes containing either the P216L- or F219I-causing mutation 
were used for homologous gene replacement by electroporation in a cyp51A wild-type 
isolate. Recombinants were selected on hygromycin-containing medium and subcultured for 
further investigation. In addition, a cassette without any mutation in the cyp51A gene was 
incorporated by electroporation as a transformation control. The complete cassette was 
sequenced to confirm the presence of the mutation and to ensure that no other mutations 
were present. To confirm that only one copy of cyp51A was incorporated, Southern blotting 
was performed. The susceptibility profiles of the recombinants, the transformation control, 
and the transformation recipient isolate were determined by the EUCAST broth microdilution 
test as described above.
Literature review
We reviewed the literature for cases with acquired azole resistance development in A. 
fumigatus isolates during azole therapy. Only patients from whom at least one isogenic 
susceptible isolate was obtained were included, because in these cases it is very likely 
that resistance was acquired during treatment and not obtained from the environment. 
Information on Aspergillus disease, age, sex, underlying disease(s), treatment regimen, 
the number of isolates, the time needed for resistance to develop, and the resistance 
mechanisms observed was collected.
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Results
Characterization of patient isolates
Results of susceptibility testing of the nine isolates obtained from our patient are shown in 
Table 1, together with Cyp51A substitutions and the number of repeats for each microsatellite 
maker. Microsatellite typing showed identical genotypes for all isolates, indicating that the 
collection of isolates was isogenic. The unrelated control isolates showed aberrant genotypes 
(data not shown).
The first isolate showed a wild-type susceptibility phenotype, while all other isolates showed 
an ITC MIC of >16 mg/liter. VRC MICs varied between 0.5 and 8 mg/liter, and POS MICs were 
between 0.063 and >16 mg/liter. In total, four different azole susceptibility profiles were 
observed. cyp51A sequence analysis showed a conversion of alanine (A) to threonine (T) at 
codon 9 (codon 9 was changed from GCC to ACC) in all isolates. All eight isolates with a non-
wild-type azole susceptibility profile had an additional point mutation in the cyp51A gene. 
Six isolates showed a point mutation resulting in the substitution of phenylalanine (F) for 
isoleucine (I) at codon 219 (change of codon 219 from TTT to ATT). One isolate contained a 
mutation at codon 216 (changed from CCC to CTC), resulting in the replacement of proline 
(P) by leucine (L). The last isolate contained a point mutation leading to the substitution of 
glycine (G) for glutamic acid (E) at codon 54 (GGG was changed to GAG). No mutations in 
cyp51B were observed in any of the nine isolates.
Cyp51 sequence alignments and homology model
The Cyp51A amino acid substitutions observed in the patient isolates were studied in more 
detail. Cyp51 sequence alignments (Figure 1) showed that residue A9 is not well conserved. 
In contrast, G54, P216, and F219 are highly conserved within the fungal kingdom. Only C. 
posadasii showed a different amino acid at the position similar to A. fumigatus P216.
Because A9T is not well conserved and is also observed in the susceptible patient isolate 
and G54E is already described as being a cause of azole resistance [27], we focused on the 
P216L and F219I substitutions. To check for the position of these amino acids in the Cyp51A 
enzyme, P216L and F219I were pinpointed into a Cyp51 homology model. The model showed 
that both amino acids were located close to the opening of one of the two ligand access 
channels of the Cyp51 protein (Figure 2).
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                A9            G54        P216 F219
 C.albicans         ***SLSVTQQISIL***SAASYGMQPYE***DKGFTPINFVFPNL***
 C.tropicalis       ***SLSLTQQITIL***SAIPFGMAPYK***DKGFTPINFVFPNL***
 S.stipitis         ***SLSLTQQVSII***SAASYGQQPYE***DKGFTPLNFVFTNL***
 C.lusitaniae       ***SLGLLSKIALL***SAVVYGMQPYE***DKGFTPINFVFPHL***
 C.krusei           ***TFSLLQQTLLV***SAIPYGMQPYE***DKGFTPLNFVFSYL***
 C.glabrata         ***ALPLAQRVSIM***SAIPYGTKPYE***DKGFTPINFVFPNL***
 N.delphensis       ***ELPLAQRISIL***SAVPYGTRPYE***DKGFTPINFIFPNL***
 S.cerevisiae       ***ALPLAQRISLI***SAVVYGMKPYE***DKGFTPINFVFPNL***
 Z.rouxii           ***ELSLSQQISII***SAVPYGTRPYE***DRGFTPINFVFPNI***
 E.gossypii         ***ALSWTQQLSIV***SALAYGRAPYE***DKGFTPLNFVFRDL***
 Y.lipolytica       ***GWHILAGLAIL***SSIPYGIDPYE***DNGFTPINFVFPNL***
 A.fumigatus_Cyp51A ***MLWLTAYMAVA***STISYGIDPYK***DKGFTPINFMLPWA***
 N.fischeri_Cyp51A   ***MLLLTAYMAVA***STISYGIDPYK***DKGFTPINFMLPWA***
 A.clavatus_Cyp51A  ***LTLFGLYLVSA***STITYGIDPCK***DRCFTPVNFMFPWA***
 A.flavus_Cyp51A     ***FTLVSAYAAAG***STVTYGMDPYA***DRGFTPINFMLPWA***
 A.nidulans         ***PTLFSAYVLVG***STISYGMNPYN***EMGFTPINFILPWA***
 P.italicum         ***ILGIAYYTTGL***STIAYGMDPYQ***DLGFSPINFMLPWA***
 P.digitatum_Cyp51A ***IKCIAYYTTGL***STVAYGMDPYQ***DLGFTPINFMLPWA***
 B.graminis         ***SIALASGIISL***STISYGMNPYK***DMGFTPINFMLHWA***
 P.fusca            ***SFLALAGIGTF***STIPYGIDPYK***DMGFSPINFMLPSA***
 E.necator          ***IFMVTSIAFSI***STISYGIDPYK***DMGFTPINFTFYWA***
 O.acuformis        ***GVVIAAGFAAF***STVTYGIDPYK***DMGFSPINFMLHWA***
 O.yallundae        ***GVVIAAGFAAF***STVTYGIDPYK***DMGFSPINFMLHWA***
 B.jaapii           ***AVVITAGFGAF***STITYGIDPYR***DMGFSPINFMLHWA***
 M.fructicola       ***GTIIAAGVAAF***STITYGIDPYR***DMGFSPINFMLHWA***
 B.fuckeliana       ***GVVVAAGVAAF***STITYGMDPYK***DMGFSPINFMLHWA***
 N.crassa           ***VSQIGVAIASF***STITYGMDPPR***DMGFSPINFMLHWA***
 L.maculans         ***FVLAITGFASF***STVTYGMDPYA***DMGFSPVNFMLSWA***
 A.fumigatus_Cyp51B ***WVLVGIGLLSI***STISYGIDPYK***DMGFAPINFMLPWA***
 N.fischeri_Cyp51B   ***WVLVGVGLLSI***STISYGIDPYK***DMGFAPINFMLPWA***
 A.clavatus_Cyp51B  ***WMLGGVGLLSL***STISYGIDPYK***DMGFAPINFMLPWA***
 A.flavus_Cyp51B     -----------------------MDPYR***DMGFAPINFMLPWA***
 P.digitatum_Cyp51B ***YTLASIGALSF***STVSYGMDPYT***DKGFSPINFMLPWA***
 P.marneffei_Cyp51B ***YVLAGLGFAIV***NTISYGIDPYK***DMGFAPINFMLPWA***
 T.stipitatus       ***YVLAGLGFATV***NTISYGMDPYK***DMGFAPINFMLPWA***
 C.posadasii        ***WTLVLLGICAF***STISYGIDPYK***DMGFAAINFMFPWA***
 A.capsulatus       ***WALLLAGSATF***STISYGIDPYK***DMGFTPINFMFPWA***
 V.inaequalis       ***YTLASFG---F***NTVVYGIDPIK***DMGFSPINFMLPWA***
 V.nashicola        ***YTLASFG---F***NTVVYGIDPIK***DMGFSPINFMLPWA***
 M.graminicola      ***WKLVGLGFLAF***STITYGIDPYK***DMGFTPINFMLPWA***
 S.pombe            ***---LVSILLSI***SAVAYGMDPYV***DQGFSPVNFVFPWL***
 P.carinii          ***ENFTLSFVIII***STIQYGMDPYK***DGGFTPINFLAPWL***
 C.neoformans       ***SLKVAIAVVGI***SAAYYGEDPYK***DGGFTPLNFMFPNL***
 T.asahii           ***AQKLAAVFIGL***SAAAYGMDPYK***DKGFTPVNFLFPNL***
 P.chrysosporium    ***SRLVLFLLINI***SAAAYGEDPIK***DGGFTPLHFMFPNL***
 U.maydis           ***WIKTITVLVLL***SAIYYGIDPYK***DSGFTPINFVIPNL***
 C.elegans          ***TIISMGYSVLA***NAVQFGMNPVA***DQGFKPINFIFPNL***
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Figure 2. Locations of residues P216 and F219 indicated in the Cyp51A homology model. The green 
tubes represent the two ligand access channels leading to the heme center of the enzyme.
A. fumigatus recombinants
A. fumigatus recombinants were constructed with either the P216L or the F219I substitution. 
None of the recombinants had additional mutations in cyp51A, the promoter region, the 3′ 
region, or the hygromycin selection marker gene. Southern blotting confirmed that integration 
occurred at a single chromosomal locus in all recombinants (data not shown). As shown in 
Tables 1 and  2, the P216L recombinant exhibited a susceptibility phenotype similar to that 
of patient isolate v77-41, with resistance to ITC and an elevated MIC of POS. The phenotype 
of the F219L recombinant was similar to that of patient isolate v76-03 but different from the 
phenotypes of five other patient isolates with the F219I substitution (v79-63, v80-28, v80-55, 
v82-58, and v83-11) that were cultured later in the course of the disease.
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Table 2. MICs of recombinants with either the P216L or F219I substitution compared to those of the 
recipient isoalte and the transformation control isolate.
Isolate
Base change in cyp51Aa MIC (µg/ml)
codon 216 codon 219 ITC VRC POS
Transformation recipient isolate CCC TTT 0.5 0.5 0.063
Transformation control CCC TTT 0.5 0.5 0.063
Recombinant P216L CTC TTT >16 0.5 1
Recombinant F219I CCC ATT >16 0.5 1
a Bold indicates the base change.
Previously described cases of acquired azole resistance
Including the present case, eight cases with acquired azole resistance caused by A. fumigatus 
have been described (Figure 3). From each patient, between two and nine isogenic or nearly 
isogenic isolates of A. fumigatus were obtained, and the first isolate(s) showed a wild-type 
azole susceptibility phenotype. Except for patient 7, the cyp51A gene was sequenced and 
mutations at codons G54 (8 isolates from 5 patients), M220 (2 isolates from 2 patients), 
G448 (2 isolates from 2 patients), P216 (1 isolate), and F219 (6 isolates) were found. In five 
out of these seven cases, multiple resistance mechanisms emerged (patients 1, 3, 5, 6, and 
8). All patients had azole exposure before the identification of the first resistant isolate. 
The antifungals used for therapy included ITC in two patients (patients 1 and 6), and in all 
other patients, multiple antifungal treatments had been used (Figure 3), mainly because of 
the development of resistance. The patient that we present here also underwent multiple 
therapy changes, as described above. The time between the last culture of an isolate with 
a wild-type susceptibility phenotype and the first with an azole-resistant phenotype varied 
between 3 weeks and 23 months (median, 4 months).
Next page, Figure 3. Reported cases of acquired azole resistance in A. fumigatus [1-2,6,28-29]. 
The treatment schedules of all eight patients are indicated with bars, and the A. fumigatus isolates 
obtained from the patients are indicated with triangles. The corresponding resistance mechanisms are 
also indicated. wt, azole-susceptible wild-type isolate; ?, resistant isolate without any cyp51A mutations; 
ND, cyp51A sequence not determined; ITC, itraconazole; VRC, voriconazole; CAS, caspofungin; POS, 
posaconazole; AMB, amphotericin B (in various formulations). In the isolates marked with an arterisk, 
the F219I resistance mechanism was found in cyp51A. However, this isolate continued to evolve 
further azole resistance by an additional and yet unknown non-cyp51A-related resistance mechanism. 
Information regarding the treatment of patients 1, 2 and 3 was kindly provided by the author (S. 
Howard, personal communication).
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Discussion
Azole resistance has been reported to emerge in patients with chronic pulmonary aspergillosis 
and pulmonary aspergilloma during azole therapy. Here, we describe a patient with pulmonary 
aspergilloma from whom isogenic azole-resistant A. fumigatus isolates with various resistance 
phenotypes were cultured during azole therapy. The resistant isolates showed different 
mutations in the cyp51A gene resulting in G54E, P216L, and F219I substitutions. In addition, all 
isolates contained a mutation leading to the A9T substitution. It is unlikely that this mutation 
will have an impact on azole susceptibility because the sensitive isolate also contained the 
A9T substitution and A9 is not well conserved among fungal species. Mutations at codon G54 
are already known to be associated with azole resistance in A. fumigatus [1,27,30-32] and are 
even mentioned to be hot-spot mutations [33] because mutations at this site are commonly 
found in azole-resistant isolates. Clinical and laboratory-induced mutant A. fumigatus isolates 
with the G54E substitution in Cyp51A usually show the following susceptibility profile: ITC 
MIC, >8 mg/liter; VRC MIC, 0.25 to 0.5 mg/liter; and POS MIC, 1 mg/liter [27,30-31]. This 
profile is consistent with that of the isolate obtained from our patient. The Cyp51A P216L 
substitution was described before in a patient with chronic cavitary pulmonary aspergillosis 
with aspergilloma treated with ITC [2]. However, this substitution is not yet confirmed to 
be a cause of resistance by the construction of recombinants. To our knowledge, the F219I 
substitution has not been described before.
Sequence alignments revealed that residues P216 and F219 are conserved within the fungal 
kingdom, and the Cyp51A homology model showed that they are both located close to the 
opening of the ligand access channel, suggesting that these residues are important. As the 
channels are thought to be used by azole compounds to enter the active site of the protein, 
mutations at codons P216 and F219 might affect the docking of azole molecules. Previously, 
docking of azoles in a homology model of A. fumigatus Cyp51A showed an interaction of P216 
and several other closely situated residues with POS but not with VRC [19], indicating that 
mutations in this region might play a role in POS resistance. We confirmed the Cyp51A P216L 
and F219I substitutions to be the cause of azole resistance by the generation of recombinants 
in which the wild-type cyp51A gene was replaced by a cyp51A cassette containing either 
one of the two mutations. This resulted in resistance to ITC and POS, while recombinants 
remained susceptible to VRC. For P216L, this was in agreement with the phenotype of the 
clinical isolate, but for F219I, only one of six clinical isolates harboring this substitution showed 
a similar phenotype. For the remaining F219I isolates, the VRC MIC had increased from 1 mg/
liter to 8 mg/liter and the POS MIC had increased from 0.5 mg/liter to >16 mg/liter. As no 
additional cyp51A mutations were found in these five isolates, we assume that a second 
resistance mechanism not related to the cyp51A gene had evolved during POS treatment. 
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This is reasonable because resistance mechanisms other than cyp51A mutations have been 
reported before in A. fumigatus [2,28,34].
Review of the literature revealed seven other cases of aspergillosis caused by A. fumigatus in 
which azole resistance emerged during azole therapy. Because we selected only for cases in 
which at least one isogenic isolate with a susceptible phenotype was obtained, it is very likely 
that resistance was induced in the patient. The patients were probably initially colonized 
or infected with a susceptible isolate, and over time, through azole exposure, resistance 
developed in this initial isolate. In one case, the resistance mechanisms were not determined, 
but in five of the remaining seven cases (71%), at least two resistance mechanisms 
emerged, indicating that different evolutionary processes within one patient might result in 
independent adaptation of the fungus to azole exposure. Furthermore, in the case described 
here, resistance might also have accumulated sequentially as one of the resistant isolates 
further evolved to become multiazole resistant.
All patients were diagnosed with aspergilloma and chronic pulmonary aspergillosis. It 
was previously suggested that in the case of aspergilloma or cavitary aspergillus disease, 
the fungus is able to undergo multiple generations in the patient by the asexual way of 
reproduction. Sporulation (in the lung) as opposed to hyphal growth may be important to 
facilitate the expression of the azole-resistant phenotype; hyphal growth is typically found in 
acute invasive aspergillosis [16].
Our literature review showed that the median time between the last cultured wild-type 
isolate and the first azole-resistant strain was only 4 months, indicating that resistance can 
be induced soon after initiating treatment. We have to address that two of the patients 
(patients 4 and 8; Figure 3) received azole treatment for several years before the last cultured 
wild-type isolate was obtained. It is therefore possible that under azole pressure a preceding 
event unrelated to cyp51A occurred in the wild-type isolate and that the event subsequently 
resulted in the rapid acquisition of the resistance mutations. From every clinical sample, only 
one colony is usually subcultured, stored, and subjected to susceptibility testing even when 
more colonies grow. Therefore, it cannot be excluded that the resistance mechanisms found 
persisted for a longer time. Moreover, additional resistance mechanisms may have been found 
when multiple colonies had been tested. Furthermore, patients are not usually regularly 
sampled for the presence of fungi, so isolates cultured could have already been present in the 
patient for a long time. Although it is now shown that azole resistance can be induced in the 
patient within a relatively short period of time, the questions of which proportion of azole-
treated patients with aspergilloma or other cavitary lung lesions develop azole resistance and 
whether specific risk factors for resistance development can be identified remain.
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Abstract 
Azole compounds are the primary therapy for patients with diseases caused by Aspergillus 
fumigatus. However, prolonged treatment may cause resistance to develop, which is 
associated with treatment failure. The azole target cyp51A is a hotspot for mutations 
that confer phenotypic resistance, but in an increasing number of resistant isolates the 
underlying mechanism remains unknown. Here, we report the discovery of a novel resistance 
mechanism, caused by a mutation in the CCAAT-binding transcription factor complex subunit 
HapE. From one patient, four A. fumigatus isolates were serially collected. The last two 
isolates developed an azole resistant phenotype during prolonged azole therapy. Because 
the resistant isolates contained a wild type cyp51A gene and the isolates were isogenic, the 
complete genomes of the last susceptible isolate and the first resistant isolate (taken 17 
weeks apart) were sequenced using Illumina technology to identify the resistance conferring 
mutation. By comparing the genome sequences to each other as well as to two A. fumigatus 
reference genomes, several potential non-synonymous mutations in protein-coding regions 
were identified, six of which could be confirmed by PCR and Sanger sequencing. Subsequent 
sexual crossing experiments showed that resistant progeny always contained a P88L 
substitution in HapE, while the presence of the other five mutations did not correlate with 
resistance in the progeny. Cloning the mutated hapE gene into the azole susceptible akuBKU80 
strain showed that the HapE P88L mutation by itself could confer the resistant phenotype. 
This is the first time that whole genome sequencing and sexual crossing strategies have been 
used to find the genetic basis of a trait of interest in A. fumigatus. The discovery may help 
understand alternate pathways for azole resistance in A. fumigatus with implications for the 
molecular diagnosis of resistance and drug discovery.
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Introduction
Aspergillus fumigatus is a ubiquitous saprophytic mold. Although humans inhale at least 
several hundred of A. fumigatus conidia per day, it rarely causes serious medical conditions 
in healthy individuals. In contrast, immunocompromised patients such as solid organ and 
hematopoietic stem cell transplant recipients and patients receiving chemotherapy are 
at risk of developing invasive aspergillosis, a commonly fatal infection [1]. Additionally, 
A. fumigatus is able to cause a wide range of other non-invasive diseases including allergic 
syndromes and aspergilloma, many of which require treatment with antifungal agents [1,2].
Current treatment options of Aspergillus diseases include three classes of antifungal agents: 
polyenes (amphotericin B), echinocandins (caspofungin) and azoles, the latter being the 
largest and most widely used class of antifungal drugs [3,4]. Voriconazole is the recommended 
first choice therapy for invasive aspergillosis [5,6]. Itraconazole is commonly used for the 
treatment of chronic and allergic conditions [2] and posaconazole is effective in preventing 
invasive aspergillosis in patients with certain hematologic malignancies [7,8].
Although A. fumigatus is generally susceptible to these azole antifungals, acquired resistance 
is increasingly being reported over the last few years [9-12]. Evidence is also accumulating 
that patients suffering from azole-resistant Aspergillus disease may fail to respond to 
therapy [11,13-19]. The most common mechanisms of resistance in A. fumigatus are 
mutations in the cyp51 gene encoding sterol 14α-demethylase, the target for azoles. Azoles 
inhibit this enzyme, thereby blocking its function in the ergosterol biosynthesis pathway, 
resulting in ergosterol depletion and accumulation of toxic sterols [20]. The A. fumigatus 
genome contains two distinct but closely related cyp51 (erg11) genes: cyp51A and cyp51B, 
each encoding a different protein [21]. Mutations have rarely been detected in the cyp51B 
gene and have never been shown to be related to azole resistance [4]. In contrast, certain 
non-synonymous point mutations in the cyp51A gene (for example at codons G54, G138 
and M220) correspond with azole resistance [22-24]. Other mutations responsible for azole 
resistance include tandem repeats of 34, 46 and 53 bp in the cyp51A promoter region 
(generally combined with mutations in the gene itself), resulting in an increased expression 
of the cyp51A gene [13,25-27]. In addition, an Aft1 transposon was found inserted 370 bp 
upstream of the start codon, possibly modulating cyp51A expression as well [28].
As is the case for A. fumigatus, azole resistance in other fungi such as Candida may be caused 
by alterations and over-expression of the azole target 14α-demethylase. Alternatively, over-
expression of drug efflux transporters that pump the toxic azoles out of the cell have also 
been related to resistance in Candida [29,30]. A. fumigatus contains several efflux pumps 
of the ATB-binding cassette (ABC) family and the Major Facilitator Superfamily (MFS) [31]. 
Although some of these transporters have been suggested to reduce azole susceptibility 
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[31-35], none of them has been proven to play a direct role in resistance yet [28]. The 
question thus remains whether efflux transporters play an active role in azole resistance in 
A. fumigatus [34,36]. An alternative azole resistance mechanism in Candida is a defective 
sterol Δ5,6-desaturase, encoded by the erg3 gene. This allows the accumulation of less toxic 
sterols in the presence of azole antifungals [29,31,37]. However, the erg3 genes have never 
been implicated in azole resistance in A. fumigatus [37].
Today, an increasing number of azole-resistant isolates are being reported without alterations 
in the cyp51A gene or promoter region [9]. However, no alternate resistance mutations have 
yet been found in clinical A. fumigatus isolates. Attempts to find new genes involved in azole 
resistance included determining expression levels of specific transporter genes [33-35,38] 
and disruption, duplication, or truncation of a specific gene of interest followed by analysis 
of antifungal susceptibility in the recombinant [39-45]. Here, we apply a new strategy 
to unravel the resistance mechanism using a set of four sequentially isolated isogenic 
clinical A. fumigatus isolates that acquired an azole resistant phenotype during prolonged 
treatment. The isolates were obtained from a patient with chronic granulomatous disease 
(CGD) as described in detail in a previous study [46]. The first two isolates were susceptible 
to azole antifungals, but the last two isolates were azole resistant and the patient failed 
azole-echinocandin combination therapy. As the A. fumigatus isolates did not contain any 
mutations in the cyp51A gene or its promoter region, this set of isolates offered a unique 
opportunity to study the de novo acquisition of non-cyp51A azole resistance mutations. 
Our strategy included whole genome sequencing, sexual crossing experiments and gene 
replacements to identify the gene responsible for the observed resistance.
Materials and methods
Origin and characterization of A. fumigatus isolates
The patient, origin of the isolates, and characterization of the isolates were described in 
detail in a previous publication [46]. The patient was a 21 year-old male with CGD. Due to 
a pulmonary infection caused by A. fumigatus, he was treated with multiple courses of 
antifungal therapy including caspofungin, voriconazole and a combination of the two. After 
relapse of the infection half a year later various treatment regimens were implemented 
including voriconazole, caspofungin/voriconazole combination therapy and caspofungin/
posaconazole combination therapy. During this relapsing infection various respiratory 
samples were taken under routine care and four A. fumigatus isolates were obtained, 
designated isolates 1 through 4 (Figure 1). Unfortunately, despite antifungal treatment it 
was not possible to eliminate the fungus and the patient died from his pulmonary infection.
In vitro susceptibility testing of the patient isolates was performed using the EUCAST broth 
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microdilution reference method [47]. Results were interpreted using the previously proposed 
breakpoints [12]. DNA was isolated and STRAf 3A, 3B, 3C, 4A, 4B, and 4C microsatellite 
genotypes were determined [48]. The cyp51A and cyp51B coding genes and promoter 
regions were amplified and sequenced as described before [48]. Sequences of the four 
patient isolates were aligned to identify any sequence differences in cyp51A and cyp51B.
Complete genome sequencing and assembly
In order to unravel the resistance mechanism, isolates 2 and 3 (isolated 17 weeks apart, 
directly before and after the onset of azole resistance) were selected for complete genome 
sequencing (Figure 1). The isolates were cultured in liquid medium and after harvesting 
and drying mycelial mats, DNA was isolated as described elsewhere [49]. The Illumina 
Paired-End DNA sequencing Sample Prep Kit (cat #1001809) was used to process the DNA 
samples. Fragmentation of the DNA by nebulization, ligation of sequencing adapters and 
PCR amplification of the resulting product was performed according to the Illumina protocol 
Preparing Samples for Paired-end Sequencing (1005063 Rev. A). The quality and yield after 
sample preparation was measured with Lab-on-a-Chip analysis. The size of the resulting 
product was consistent with the expected size of approximately 300 bp after excision from 
an agarose gel. DNA sequencing using the Genome Analyzer II (Illumina) was performed 
according manufacturer’s protocols. Two sequencing reads of 36 cycles each using the Read 
1 sequencing and Read 2 sequencing primers were performed with the flow cell. Sequencing 
data are available at the Sequence Read Archive (SRA) at http://www.ebi.ac.uk/ena/data/
view/ under accession number ERP001097. The two complete A. fumigatus genomes that 
are publically available (clinical isolates Af293 and A1163 [50,51]) were used as reference 
sequences to aid the genome assembly. Assembly was done using Maq [52] with default 
parameters, taking into account the paired-end nature of the reads.
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Prioritization and validation of potential mutations
From the complete genome sequencing data, non-synonymous mutations were selected in 
isolate 3 (resistant) relative to isolate 2 (susceptible) and both reference isolates Af293 and 
A1163 (susceptible). Many of these mutations were expected to be unreliable because of 
low sequencing depth or low quality of the Maq consensus assembly. Potential mutations 
were prioritized based on the product of the Maq assembly quality scores in the susceptible 
and resistant assembly (further referred to as ‘product quality score’). As we did not 
know a priori what cutoffs to use, mutations with the highest product quality scores were 
selected for confirmation by conventional PCR and Sanger sequencing. Moreover, potential 
mutations with lower product quality scores were also validated for proteins potentially 
important in azole resistance (e.g. transporters), or if they occurred in the genomic vicinity 
of more reliably called mutations and could be validated in one sequencing experiment. For 
the selected mutations, primers were designed (Table 1) and used to amplify and sequence 
isolates 2 and 3 first. For confirmed mutations, isolates 1 and 4 were subsequently amplified 
and sequenced.
Sexual reproduction and analysis of the progeny
The mating type of the isolates was determined as described before [53]. Isolates 1, 2, 3 
and 4 were each crossed with isolate 47-169, a highly fertile environmental A. fumigatus 
isolate (kindly provided by C.M. O’Gorman and P.S. Dyer, School of Biology, University of 
Nottingham, Nottingham, UK). Mating experiments were performed on oatmeal agar plates 
(Difco Oatmeal agar) and inoculation was performed as described previously [54]. Plates 
were sealed with Parafilm and incubated at 30°C in the dark. Crosses were examined weekly 
and when cleistothecia developed, ascospore suspensions were obtained as described 
before [54]. The suspensions were heated at 70°C for one hour to prevent the germination 
of asexual spores [54]. Then small aliquots of the suspensions were plated onto Sabouraud 
agar plates and incubated for two days at 28°C. Germinating ascospores were transferred 
to Sabouraud agar slants and grown at 28°C for five days. The progeny were tested for their 
susceptibility to azoles as described above and DNA was isolated as described elsewhere 
[48]. The DNA was used to check for the presence or absence of the confirmed mutations 
by PCR and sequencing, using the same primers as used for validation (Table 1). In addition, 
from a selection of the progeny the microsatellite genotype was determined [48].
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Product 
quality 
score
Gene                  
(abbreviated)
Gene ID in 
Af293 / A1163
Primer 
ID
Primer sequence (5’-3’) Result of 
valida-
tion
5670 hypothetical AFUA_2G02180 
/ AFUB_019270
411.33 GCATCACCAAAACACAGTGG correct
411.34 GGCAAATCTCCCAAGATTGA
4320 erg6 AFUA_4G03630 
/ AFUB_099400
411.19 GTATCGAGCTGGGTGATGGT correct
411.20 AATACATGGGCGTGAAGAGC
3780 hapE AFUA_6G05300 
/ AFUB_092980
411.13 CCGCGACATACTAACGACCT correct
411.14 GCTGTCCCAGAGAACCGTAA
3744 erg25 AFUA_4G04820 
/ AFUB_098170
411.11 CCCAAAAAGGCAAGAAATGA correct
411.12 TCCGTTTGGACCATGATGTA
3648 alpha-amino AFUA_4G11240 
/ AFUB_068270
411.35 CGGTTCTGAGGGTAGACCAA correct
411.36 GAAGCCCTCCTGGCTAGAGT
3600 C2H2 finger AFUA_5G07960 
/ AFUB_055490
411.37 ACTTTGGGCTTTTGTTGTGG correct
411.38 GGAAGCAAGGTGGTTCTCAA
2052 origin recognition AFUA_8G04240 
/ AFUB_083310
411.92 GGTCCCTTGTGTGAAGCAAT incorrect
411.93 GTCCCCCAGTCTTTTGGAAT
2046 hypothetical AFUA_5G09590 
/ AFUB_057140
411.27 GTGGTTGATTGCAGGAGGTT incorrect
411.28 AAGCAGTCGATTCGCAGACT
1701 hypothetical AFUA_1G04630 
/ AFUB_004980
411.29 CCCTGTCAGGTGATGTCCTT incorrect
411.30 AGGAACGTCATTGCGGATAC
….. ….. ….. ….. ….. …..
1596 MRS7 family AFUA_3G08230 
/ AFUB_040880
411.25 GCTTTTCTTGGCTGTTCGAG incorrect
411.26 GTGGACTCGCTCTCTGTTCC
1008 MRS7 family AFUA_3G08230 
/ AFUB_040880
411.25 GCTTTTCTTGGCTGTTCGAG incorrect
411.26 GTGGACTCGCTCTCTGTTCC
840 MFS transporter AFUA_6G06680 
/ AFUB_072610
411.15 AGTGCCGCTGAAGATCAGTT incorrect
411.16 ATGGACGGAAAACAGACGAG
720 hypothetical AFUA_1G04630 
/ AFUB_004980
411.29 CCCTGTCAGGTGATGTCCTT incorrect
411.30 AGGAACGTCATTGCGGATAC
348 hypothetical AFUA_2G14620 
/ AFUB_030250
411.23 GCAGTGGACTCATCCTCCTC incorrect
411.24 GTGAAGCAGTCCCTCCTCTG
348 hypothetical AFUA_1G04630 
/ AFUB_004980
411.29 CCCTGTCAGGTGATGTCCTT incorrect
411.30 AGGAACGTCATTGCGGATAC
69 AtrD AFUA_4G08800 
/ AFUB_065900
411.9 TACAAGGCCGAACAAAATCC incorrect
411.10 TCAGACGAGTGTTGGACCAG
45 MFS transporter AFUA_6G06680 
/ AFUB_072610
411.15 AGTGCCGCTGAAGATCAGTT incorrect
411.16 ATGGACGGAAAACAGACGAG
42 RTA1 domain AFUA_5G01310 
/ AFUB_049810
411.17 GACGCTGACCGTGTACAGAA incorrect
411.18 GTCTGCTCCTTCTGCTTGCT
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Previous page, Table 1. Validation of potential mutations identified in the complete genome sequence 
of isolate 3 relative to isolate 2 as well as both reference strains. 
Potential mutations were prioritized using the product quality score (see Methods). Primers used for 
amplification and sequencing are indicated. The nine highest quality scores (above ‘…..’) as well as 
several mutations with lower scores (below ‘…..’) were validated. ‘Correct’ indicates that the mutation 
found by complete genome sequencing was validated using conventional PCR and sequencing 
methods; ‘incorrect’ indicates isolate 3 did not differ from isolate 2.
Growth kinetic assay
Part of the progeny was selected to evaluate growth over time. For that, conidia were 
suspended in 0.1% Tween-20. Suspensions were adjusted to 1-4.2*106 conidia/ml and diluted 
1:10 in water. 100 µl thereof was added to 100 µl of double strength RPMI 2% glucose 
medium in three individual wells of a microtiter plate. The plates were incubated at 37°C for 
12 h inside a plate reader. The optical density (OD) at 450 nm was automatically recorded 
for each well every 30 minutes without shaking. For each time point the OD of the triplicate 
was averaged and the changes in OD over time were used to generate growth curves. The 
maximum growth per hour during the exponential section of the curve was averaged for the 
susceptible and resistant progeny and to test whether differences were significant, student’s 
t-test was applied (one-tailed, heteroscedastic).
RNA isolation and cyp51A expression
A selection of the progeny and parental isolates were subjected to cyp51A expression 
analysis. The isolates were cultured twice and used for separate total RNA isolation. cDNA 
amplification and RT-PCR for cyp51A and actin expression levels were performed as described 
before [46]. The change in gene expression was determined using the cyp51A/actin ratio. 
Transformations
Gene replacement experiments were performed as described before [22,26]. Briefly, DNA 
fragments of the six genes with mutations (Table 2) were obtained by PCR amplification using 
genomic DNA of the first resistant isolate 3. As a positive control, a fragment with a mutation 
in cyp51A known to be correlated with azole resistance (the cyp51A G54E substitution in 
clinical isolate AF-72 [22]), was amplified. The primers used to amplify the six genes as well as 
the cyp51A gene for the positive control are shown in Table 2. All primers were designed to 
include the complete gene, except for alpha-aminoadipate reductase large subunit (reference 
Af293 gene AFUA_4G11240 and A1163 gene AFUB_068270). Because of the large size of this 
gene, primers were designed approximately 1000bp on both sides of the mutation. The PCR 
products were used for homologous gene replacement by electroporation into the azole 
susceptible isolate akuBKU80 [26,55]. Transformation mixtures were spread-plated on minimal-
medium plates containing itraconazole (0.5 to 4 mg/l) to select for resistant recombinants. 
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After three days of incubation at 37°C colonies were subcultured for further investigation. 
DNA was isolated and the recombinants were analyzed for the presence of the mutation by 
using the corresponding primers listed in Table 1. In successful recombinants, the complete 
mutant gene (primers Table 2) and the cyp51A gene and promoter region (as described 
above) were sequenced to ensure no other mutations were introduced. The susceptibility 
profiles of the successful recombinants (two recombinants were selected for each mutation) 
and the transformation recipient isolate akuBKU80 were determined as described above.
Table 2. Primers used to amplify the six validated genes as well as cyp51A (positive control).
Gene            
(abbreviated)
Gene ID reference iso-
lates Af293 / A1163
Primer 
ID
Forward 
/ reverse 
primer
Primer sequence (5’-3’)
hypothetical AFUA_2G02180 / 
AFUB_019270
411.55 forward CTTTTGACATTTCCATATCAGTCCT
411.56 reverse TGACTATCTGTCACAATGGTTGTTC
erg6 AFUA_4G03630 / 
AFUB_099400
411.39 forward TTTCAAGATTGTGATCTTGTGGATA
411.40 reverse GACAGCCACGTCTATAAGTTTAGGA
hapE AFUA_6G05300 / 
AFUB_092980
411.47 forward CTCTCGCGATACATTACTGTTGTTT
411.48 reverse AGTATACTCGTTAACCTGCCAATGA
erg25 AFUA_4G04820 / 
AFUB_098170
411.43 forward TTCAACACCCAGTTGTCTCATACTA
411.44 reverse CTGTCATCGATTTATGATAGCAGTG
alpha-amino AFUA_4G11240 / 
AFUB_068270
411.57 forward GTATGTGGTCCTGTCGTTCATTC
411.58 reverse GGCAGAATCATCATCCTTGAG
C2H2 finger AFUA_5G07960 / 
AFUB_055490
411.53 forward CGGTACCTTTACTGATCACTTTGAA
411.54 reverse GCTTCGTTTCACTCAATTCTATTTC
cyp51A AFUA_4G06890 / 
AFUB_063960
365.1 forward ATGGTGCCGATGCTATGG
365.2 reverse CTGTCTCACTTGGATGTG
HapE sequencing in resistant isolates without cyp51A mutations
Our fungal culture collection contains A. fumigatus clinical isolates from patients admitted 
to our hospital, as well as environmental isolates and isolates sent to our laboratory for 
identification, in vitro susceptibility testing, or research purposes. Only accredited scientists 
in our laboratory have access to the fungal collection. The collection was searched for 
isolates resistant to one or more azoles but without any cyp51A gene mutations known to 
be involved in resistance. Of these isolates hapE was amplified by PCR and subsequently 
sequenced (primers Table 2). Gene sequences were compared with isolate 2 to detect any 
mutations. 
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Results
Characterization of the isolates
The azole minimum inhibitory concentrations (MICs) of the four isolates obtained during the 
course of the disease in a CGD patient are shown in Figure 1. According to the suggested 
breakpoints [12], isolates 1 and 2 were azole susceptible, while isolate 3 and 4 were resistant 
to both itraconazole and voriconazole and had an intermediate susceptibility to posaconazole. 
The isolates did not have any nucleotide differences in their cyp51A and cyp51B genes and 
promoter regions (results not shown) and microsatellite genotyping showed that the four 
isolates had identical genotypes and were thus isogenic (results not shown).
Genome sequencing, assembly and validation of potential mutations
As no cyp51A and cyp51B mutations developed, a new, unknown resistance mutation must 
have emerged during therapy. Due to the isogenic nature of the isolates, we anticipated 
that the most straightforward approach to identify this resistance mechanism would be 
by complete genome sequencing of isolates 2 and 3 (isolated directly before and after the 
onset of azole resistance). The volume of sequence data obtained using Illumina technology 
included 8,611,525 36-nt read pairs for isolate 2 and 4,808,633 36-nt read pairs for isolate 
3. The total sequence volume was 620,029,800 nt (isolate 2) and 346,221,576 nt (isolate 3). 
After reference-guided assembly, the sequence coverage of isolate 2 was 93.7% (mapped 
against Af293) and 94.9% (mapped against Af1163). For isolate 3 this was 93.6% (mapped 
against Af293) and 94.8% (mapped against Af1163). The average sequencing depth was 
20.3 reads for isolate 2 and 11.5 for isolate 3. Sixty-nine potential mutations were identified 
in resistant isolate 3 that were non-synonymous relative to both the susceptible isolate 2 
and both reference isolates Af293/A1163 (Table S1, available at http://dx.plos.org/10.1371/
journal.pone.0050034). The potential mutations were then prioritized based on their 
product quality scores. Mutations with the highest scores as well as a selection of genes 
with lower scores were validated by PCR and Sanger sequencing. Table 1 shows that only 
the six mutations with the highest product quality scores could be confirmed,  the other 
mutations were false-positive calls. Subsequent testing of isolate 1 and 4 confirmed the 
presence of these six non-synonymous mutations in both resistant isolates 3 and 4 relative 
to the susceptible isolates 1 and 2 (Table 3).
Sexual reproduction and analysis of the progeny
To elucidate which of the six mutations was the cause of resistance, sexual crosses were 
performed. Note that this approach would also identify potential combinations of mutations 
if two or more mutations were together responsible for the resistant phenotype. Isolates 1 
to 4 were of mating type MAT1-2 and were crossed with 47-169, an isolate of the opposite 
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mating type MAT1-1. After six weeks of incubation, cleistothecia appeared on the agar plate. 
Ascospore progeny were isolated and subcultured. Ten (for isolates 1 and 2), forty (for isolate 
3) and twenty (for isolate 4) progeny isolates were randomly selected for susceptibility 
testing and azole resistant isolates were present in the progeny of isolates 3 and 4, but not 
in the progeny of isolates 1 and 2 (Table 4). The resistant progeny all exhibited a MIC of >16 
mg/l for itraconazole. In addition, these isolates showed elevated MICs for voriconazole and 
posaconazole, similar to those observed in patient isolates 3 and 4 (results not shown). In 
addition, a minority of the progeny of the resistant isolates 3 and 4 exhibited an altered 
susceptibility phenotype for itraconazole, referred to as trailing effect [56].
The forty progeny of isolate 3 were screened for the presence of the six mutations validated 
in the whole genome sequencing analysis. All mutations were present in the susceptible 
as well as in the resistant progeny, except for the mutation in the hapE gene which was 
only present in resistant isolates. Furthermore, Table 5 shows that all resistant progeny of 
isolate 3 and 4 contained the hapE mutation while the other mutations were only present 
in a part of the resistant progeny. Microsatellite typing (Table 6) showed that twelve out of 
the thirteen resistant progeny (92%) had a unique microsatellite genotype, indicating that 
unique germinating ascospores harboring the resistance mutation were isolated and not 
a single clone of resistant progeny. Taken together, these results strongly suggest that the 
mutation in hapE caused the observed resistant phenotype. 
Sixteen of the progeny as well as both parental isolates (isolate 3 and 47-169) were selected 
to determine in vitro growth curves (Figure S1, available at http://dx.plos.org/10.1371/
journal.pone.0050034). As can be observed in Figure 2, growth rate for susceptible progeny 
was significantly higher compared to the resistant progeny (p=0.015). In order to determine 
if the cyp51A expression level of progeny containing the HapE substitution was altered, RT-
PCR experiments were performed. A ~1.5-fold induction of the transcriptional profile of the 
hapE-containing progeny isolate compared to two susceptible progeny isolates was found 
(Figure 3).
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Table 3. The six confirmed non-synonymous mutations, together with results of complete genome 
sequencing and validation.
Gene function
Protein ID Af293 
/ A1163
Nucleotide in 
complete genome 
sequence isolate 
2 / 3
Validated nucle-
otide in isolate  
1 / 2 / 3 / 4
Amino 
acid sub-
stitution
Conserved hypothetical 
protein
AFUA_2G02180 
/ AFUB_019270
C / T C / C / T / T S219L
Sterol 24-c-methyltransfer-
ase, putative (Erg6)
AFUA_4G03630 
/ AFUB_099400
T / G T / T / G / G W320G
CCAAT-binding factor com-
plex subunit HapE
AFUA_6G05300 
/ AFUB_092980
C / T C / C / T / T P88L
C-4 methyl sterol oxidase, 
putative (Erg25)
AFUA_4G04820 
/ AFUB_098170
G / A G / G / A / A W218*
Alpha-aminoadipate reduc-
tase large subunit, putative
AFUA_4G11240 
/ AFUB_068270
T / C T / T / C / C F481S
C2H2 finger and ankyrin 
domain protein, putative
AFUA_5G07960 
/ AFUB_055490
T / A T / T / A / A Y347*
* refers to a premature stop codon.
Table 4. Distribution of susceptible and resistant isolates in the sexual crossing progeny of isolate 47-
169 and each of the four isolates in this study.  
Phenotype
Progeny 
isolate 1
Progeny 
isolate 2
Progeny 
isolate 3
Progeny 
isolate 4 
Susceptible 10 (100%) 10 (100%) 25 (63%) 11 (55%)
Trailing-endpoint itraconazole - - 8 (20%) 3 (15%)
Resistant - - 7 (18%) 6 (30%)
Total 10 (100%) 10 (100%) 40 (100%) 20 (100%)
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Table 6. Microsatellite typing results of the resistant progeny.
Isolate
Microsatellite Microsatellite 
genotype 3A 3B 3C 4A 4B 4C
47-169 parent 16 10 24 11 14 9 A
isolate 3 parent 47 13 13 7 9 10 B
isolate 4 parent 47 13 13 7 9 10 B
v121-42 progeny (47-169 x isolate 3) 16 13 24 7 9 9 C
v121-43 progeny (47-169 x isolate 3) 16 13 13 7 9 10 D
v121-54 progeny (47-169 x isolate 3) 16 13 13 7 14 10 E
v121-55 progeny (47-169 x isolate 3) 16 13 24 7 9 10 F
v121-59 progeny (47-169 x isolate 3) 16 13 13 11 14 10 G
v121-74 progeny (47-169 x isolate 3) 16 13 13 7 9 9 H
v121-78 progeny (47-169 x isolate 3) 16 13 24 7 14 10 I
v122-02 progeny (47-169 x isolate 4) 16 13 24 7 9 9 C
v122-08 progeny (47-169 x isolate 4) 47 13 13 7 14 9 J
v122-12 progeny (47-169 x isolate 4) 47 13 13 7 14 10 K
v122-13 progeny (47-169 x isolate 4) 47 13 24 7 9 10 L
v122-17 progeny (47-169 x isolate 4) 47 10 24 7 9 9 M
v122-18 progeny (47-169 x isolate 4) 47 13 13 7 9 9 N
Table 7. MICs of recombinants with either the G54E substitution in Cyp51A (positive control) or the 
P88L substitution in HapE. 
Substitutions MIC
Isolate Cyp51A HapE ITZ VOR POS
Transformation recipient akuBKU80 - - 0.125 0.25 0.032
Positive control Cyp51A (1) G54E - >16 0.125 0.5
Positive control Cyp51A (2) G54E - >16 0.125 1
HapE (1) - P88L >16 1 0.125
HapE (2) - P88L >16 1 0.125
MIC, minimum inhibitory concentration; ITZ, itraconazole; VOR, voriconazole; POS, posaconazole.
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Figure 2. In vitro growth curves of susceptible and resistant progeny. 
A. In vitro growth curves of susceptible (n=12) and resistant (n=4) progeny. 
B. The maximum growth per hour (6-10 hours, between dashed lines of Figure 2A) was averaged 
(±standard deviation) for susceptible and resistant progeny. The difference is significant according to a 
Student’s T-test (one-tailed, heteroscedastic).
Figure 3. Cyp51A mRNA levels in the parental isolates (47-169, isolate 3, isolate 4) and three of the 
progeny (v122-12, v121-64, v121-48). 
Isolate v122-12 contains only the HapE substitution and not the other five gene mutations. As a control, 
we selected two other progeny: v121-64 containing only the erg25 mutation and v121-48 containing 
the erg6/erg25 double mutation. S: susceptible, R: resistant.
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Transformations
Homologous gene replacement studies with the six mutated genes from isolate 3 were 
performed using cyp51A G54E as a positive control (Table 2). After selection on itraconazole-
containing medium, successful recombinants were only obtained from the positive control 
cyp51A and from candidate resistance gene hapE (two recombinants each, Table 7). 
Subsequent sequencing of the complete cyp51A gene and promoter region and the hapE 
gene showed no additional mutations, indicating that only the P88L- (HapE) or the G54E- 
(Cyp51A) causing mutation was introduced by the homologous gene replacement. The 
positive control substitution G54E in Cyp51A is known to cause resistance to itraconazole 
and posaconazole [22,33,57-58], and indeed both recombinants showed resistance to 
itraconazole and posaconazole. Moreover, both HapE P88L recombinants showed resistance 
to itraconazole with an MIC of >16 mg/l, as was also observed in patient isolates 3 and 4 (cf. 
Figure 1 and Table 7). As observed in the patient isolates, the voriconazole and posaconazole 
MICs increased two dilution steps from 0.25 to 1 and from 0.032 to 0.125, respectively (cf. 
isolates 2 and 3 in Figure 1). These results show that the HapE P88L substitution is the only 
one of the six mutations in isolate 3 capable of conferring the azole resistant phenotype.
HapE sequencing in resistant isolates without cyp51A mutations
Our collection contained eleven resistant A. fumigatus isolates without cyp51A mutations 
known to cause resistance. Eight were clinical isolates and the remaining three isolates were 
of environmental origin. Although some of the isolates did show polymorphisms in intronic 
regions of the gene, we never observed the mutation resulting in P88L or any other mutation 
within the exonic regions.
Discussion
In our study the whole genome sequencing strategy was used to identify a resistance 
mutation that arose as a de novo mutation in a CGD patient with chronic fibrotic pulmonary 
aspergillosis caused by A. fumigatus. We selected two A. fumigatus isolates, taken just 
before and just after the transition from a susceptible to an azole-resistant phenotype. 
Although the resistant strain (isolate 3) was recovered only 17 weeks after the susceptible 
strain (isolate 2), we identified no less than six non-synonymous mutations. Moreover, if we 
use the validated product quality score as a reliable cutoff (3,000), we found 16 additional 
mutations, bringing the total number of mutations to at least 22 (Table S2, available at http://
dx.plos.org/10.1371/journal.pone.0050034). These included five mutations in non-coding 
regions and 11 cases where the resistant strain was synonymous to the susceptible reference 
genomes A. fumigatus Af293 and A. fumigatus A1163 and thus unlikely to be responsible 
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for the resistant phenotype. This may indicate that A. fumigatus undergoes many genetic 
changes during human infection, possibly as a response to the stressful environment. 
Potentially, the resistant strain diverged from the dominant susceptible lineage even before 
the last susceptible strain was isolated. This minority strain may have been accumulating 
neutral or slightly deleterious mutations before finally the resistance causing mutation 
allowed it to dominate the A. fumigatus population in the CGD patient.
Because we identified more than one non-synonymous mutation, we chose sexual crossing 
as an additional selection method. After crossing the patient isolates with an azole susceptible 
isolate that did not contain any of the six mutations, the mutation in hapE was identified as 
the most likely cause of azole resistance as this was the only mutation present in all resistant 
progeny. Subsequent gene replacement experiments provided the final proof that the HapE 
P88L substitution was the cause of the resistance phenotype observed.
With respect to the sexual reproduction experiment, part of the progeny of isolates 3 and 4 
exhibited trailing growth (partial inhibition of growth over an extended range of antifungal 
concentrations [59]) in the presence of itraconazole. However, these trailing isolates did 
show clear susceptible MIC endpoints for voriconazole and posaconazole. Trailing endpoints 
caused problems when testing Candida spp. with azoles as well, but animal models and 
clinical experience argue that trailing endpoints do not indicate true resistance [56,60-
61], suggesting that the progeny with trailing endpoints for itraconazole might not be truly 
resistant. 
Furthermore, we noted that after sexual reproduction, only 18-30% of the progeny 
contained the hapE mutation instead of the expected 50%. Using in vitro growth kinetics in 
fluid medium, it was previously shown that the resistant isolates 3 and 4 have a significantly 
reduced growth rate and especially delayed germination compared to susceptible isolates 1 
and 2, possibly associated with the resistance mechanism [46]. Therefore we hypothesized 
that the lower than expected recovery rate of the hapE mutation in the progeny might be 
due to slow germination, as we isolated the germinated sexual spores based on their growth 
on the medium and not by randomly selecting ascospores by using the microscope. Possibly 
only the faster germinating spores were collected resulting in a lower percentage of the 
slower germinating, resistant (hapE mutated) progeny. Determination of the in vitro growth 
curves confirmed a significant decrease in growth rate of azole resistant compared to azole 
susceptible progeny (Figure 2 and Figure S1, available at http://dx.plos.org/10.1371/journal.
pone.0050034). Furthermore, we could speculate that the resistance mechanism is indeed 
associated with loss of fitness (alteration of growth and virulence) observed in the resistant 
isolates, as suggested before [46]. We presume that the resistant isolates described here are 
disadvantaged in the absence of azoles as a consequence of the hapE mutation. In contrast, 
for isolates with mutations in cyp51A, there is no evidence of fitness loss in vivo [Mavridou 
E, Meletiadis J, Arendrup MC, Melchers WJ, Mouton JW, Verweij PE. Impact of CYP51A 
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mutations associated with azole-resistance on in vitro growth rates and in vivo virulence of 
clinical Aspergillus fumigatus isolates. 20th European Congress of Clinical Microbiology and 
Infectious Diseases (ECCMID), Vienna, April 2010; abstract O345]. 
Remarkably, two of the five other validated mutations were situated in genes involved in the 
ergosterol biosynthesis pathway (i.e. erg6 and erg25). A. fumigatus contains two potentially 
redundant copies of these genes (erg6: AFUA_4G03630/AFUB_099400 and AFUA_4G09190/
AFUB_066290; erg25: AFUA_4G04820/AFUB_098170 and AFUA_8G02440/AFUB_084150; 
as determined by the CADRE genome browser [62,63] and literature [64,65]). Both genes 
function downstream of the cyp51 (erg11) gene, at least in Saccharomyces cerevisiae [66]. 
It has been shown that downstream genes erg3 [29,31,37,67], erg6, and erg28 [67] are 
involved in resistance in other fungi. In addition, erg6 and erg25 are both up-regulated in 
amphotericin B / fluconazole resistant C. albicans, suggesting a possible role of these two 
genes in acquired resistance [68]. Neither erg6 nor erg25 have ever been described to impact 
on azole susceptibility in A. fumigatus, but many erg genes, amongst which erg25, have 
been shown to be differentially expressed after voriconazole exposure [69]. Nevertheless, 
we found no evidence that the mutations in either erg6 or erg25 are associated with the 
resistant phenotype in isolates 3 and 4; neither from the sexual crossing- nor from the 
transformation experiments. In addition, the erg6/erg25 double mutation was found in azole 
susceptible progeny, excluding the possibility that both mutations together would result in 
the resistant phenotype (results not shown).
The hapE gene encodes the CCAAT-binding factor complex subunit HapE. Besides HapE, the 
CCAAT-binding complex (Hap-complex) consists of at least two other subunits: HapB and 
HapC. The complex is a transcription factor that specifically recognizes the regulatory CCAAT 
element found in the forward or reverse orientation in promoter regions of numerous 
eukaryotic genes [70]. The hapE gene contains four exons and the mutation is situated in 
the fourth exon, in the evolutionary conserved core domain [62,63,71], suggesting that P88 
is an important amino acid for the function of the protein. Moreover, in the human NF-YC 
(the mammalian HapE homologue) deletion of residues 43-45 (homologous to A. fumigatus 
residues 87-89), are deleterious for DNA binding [72], indicating that P88 is needed for the 
Hap-complex to bind the regulatory CCAAT element and initiate transcription.
Initially, we hypothesized that the resistance observed in the HapE-mutant might be HapX-
mediated. HapX has been shown to physically interact with the Hap-complex (as shown in 
A. nidulans [73]) and is important in adaptation to conditions of iron starvation. Conversely, 
in conditions of iron sufficiency, HapX expression is repressed [65]. HapX deficiency causes 
significant attenuation of virulence in a murine model of aspergillosis [65]. As our resistant 
patient isolates also showed reduced virulence [46], we tested the isolates for their azole 
susceptibility in the presence and absence of iron to investigate whether the resistance (and 
attenuated virulence) observed could be HapX-mediated. However, our results indicated that 
72
Chapter 3
the presence of iron did not have any effect on susceptibility (results not shown), suggesting 
that resistance may not be mediated by HapX.
We have previously observed that the cyp51A expression level of isolates 3 and 4 was four to 
six-fold higher compared to isolates 1 and 2 [46]. In addition, analysis of the sexual progeny 
showed that the hapE mutant has an increased cyp51A mRNA expression compared to 
progeny without the hapE mutation. As Hap is a transcription factor complex, the increased 
resistance might be due to a gain of function mutation if the mutated Hap-complex binds 
to a CCAAT-box in the promoter region of cyp51A and induces the expression of the 
gene. Alternatively, Hap might function as a transcriptional repressor, and the HapE P88L 
substitution could de-repress cyp51A expression. A CCAAT-box is present in the 5’ upstream 
region of A. fumigatus cyp51A, located at -197 bp from the start codon, though additional 
analyses are needed to confirm the binding of the (mutated) Hap-complex. Gain-of-function 
mutations in transcription factors have already been shown to be linked to increased 
antifungal drug resistance in C. albicans [74-79].
The NF-Y (the mammalian Hap-complex)/SREBP (sterol-regulatory element binding protein) 
combination regulates essentially all genes involved in cholesterol metabolism [80], 
indicating that the fungal ergosterol biosynthesis (the pathway analogous to the mammalian 
cholesterol biosynthesis), may also be mediated by these regulators. An in vitro null-mutant 
of the A. fumigatus SREBP transcription factor SrbA has recently been shown to be highly 
susceptible to fluconazole and voriconazole [45]. A subsequent study suggested that the 
increased fluconazole susceptibility in the absence of SrbA was partially due to loss of iron 
homeostasis [81]. Furthermore, SrbA is a direct transcriptional regulator of cyp51A, being 
the likely underlying mechanism of the increased susceptibility of the deletion mutant 
[82]. It currently remains unclear whether the declined expression is indeed the cause 
of the increased azole susceptibility and there has been no evidence for involvement of 
SrbA in resistance in clinical cases. However, these data indicate that alterations in SREBP 
transcription factors such as SrbA or NF-Y (Hap) transcription factor subunits such as HapE 
may indeed initiate changes altering cyp51A expression and subsequently lead to azole 
resistance.
In conclusion, by combining a comparative genomic and genetic approach, we have discovered 
a novel triazole resistance mutation in A. fumigatus caused by a single base substitution in 
the transcription factor subunit HapE. We were fortunate to have a set of isogenic strains, 
i.e. isolates with a similar genetic background, and a comparison of the whole genome 
sequences of isolates 2 and 3 shortlisted 69 potential non-synonymous mutations. Through 
resequencing of candidate mutations, and the addition of sexual crosses, we were able to 
significantly reduce the selection of candidate mutations for the azole resistant phenotype.
Over the last decade, an increase of azole resistance in A. fumigatus isolates has been 
observed [9-12]. Importantly, patients suffering from azole-resistant Aspergillus disease may 
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fail to respond to therapy [11,13-19]. Insight in the mutations that cause resistance can help 
to understand the epidemiology, find new targets for antifungal compounds and to develop 
diagnostic tools. The need to identify resistance mechanisms was underscored in a recent 
paper estimating that in 54% of patients with an azole resistant A. fumigatus isolate the 
resistance mechanism was not Cyp51A-mediated and thus remained unexplained [9]. This is 
a challenge for the early diagnosis of azole-resistance in patients with Aspergillus diseases. In 
these patients fungal cultures often remain negative, which precludes in vitro susceptibility 
testing. Furthermore, a recent study showed that the use of molecular tools for detection 
of cyp51A-mutations directly in clinical specimens was much more sensitive than culture 
[83]. However, knowledge of underlying resistance mechanisms is required in order to 
apply molecular techniques in patient care. The strategy that we have described will help 
to identify resistance mechanisms and improve our diagnostic tools in order to ultimately 
improve the outcome of patients with azole resistant Aspergillus diseases.
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A hapE mutation that causes azole resistance
A. fumigatus cleistothecia developed after mating on Oatmeal agar 
(picture: Hein van der Lee and Simone Camps).
Section II
Emergence of resistance through environmental exposure
Agarose gel electrophoresis image of A. fumigatus cyp51A promotor region amplicons.
Lane 1 and 7, molecular weight marker; lane 2, wildtype promotor; lane 3, TR34; lane 4, TR46; lane 5, TR53; 
lane 6, triplicate of the 34bp sequence induced after passage of A. fumigatus TR34 on tebuconazole. 
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Abstract
Azoles play an important role in the management of Aspergillus diseases. Azole resistance is an 
emerging global problem in Aspergillus fumigatus, and may develop through patient therapy. 
In addition, an environmental route of resistance development has been suggested through 
exposure to 14α-demethylase inhibitors (DMIs). The main resistance mechanism associated 
with this putative fungicide-driven route is a combination of alterations in the cyp51A gene 
(TR34/L98H). We investigated if TR34/L98H could have developed through exposure to DMIs.
Thirty-one compounds that have been authorized for use as fungicides, herbicides, 
herbicide safeners and plant growth regulators in the Netherlands between 1970 and 2005, 
were investigated for cross-resistance to medical triazoles. Furthermore, Cyp51-protein 
homology modeling and molecule alignment studies were performed to identify similarity in 
molecule structure and docking modes. Five triazole DMIs, propiconazole, bromuconazole, 
tebuconazole, epoxiconazole and difenoconazole, showed very similar molecule structures 
to the medical triazoles and adopted similar poses while docking the protein. These DMIs 
also showed the greatest cross-resistance and, importantly, were authorized for use between 
1990 and 1996, directly preceding the recovery of the first clinical TR34/L98H isolate in 1998. 
Through microsatellite genotyping of TR34/L98H isolates we were able to calculate that 
the first isolate would have arisen in 1997, confirming the results of the abovementioned 
experiments. Finally, we performed induction experiments to investigate if TR34/L98H could 
be induced under laboratory conditions. One isolate evolved from two copies of the tandem 
repeat to three, indicating that fungicide pressure can indeed result in these genomic changes.
Our findings support a fungicide-driven route of TR34/L98H development in A. fumigatus. 
Similar molecule structure characteristics of five triazole DMIs and the three medical triazoles 
appear the underlying mechanism of cross resistance development. Our findings have major 
implications for the assessment of health risks associated with the use of triazole DMIs.
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Introduction
Aspergillus fumigatus is the most frequent cause of Aspergillus diseases in humans, which 
include allergic syndromes, aspergilloma and chronic or acute invasive aspergillosis. Antifungal 
agents of the azole class play a prominent role in the management of Aspergillus diseases. 
Three medical triazoles, itraconazole, voriconazole and posaconazole, are clinically licensed 
for the prevention and treatment of Aspergillus diseases [1]. It has become apparent that 
A. fumigatus can develop resistance to the medical triazoles. Azole resistance is commonly 
due to mutations in the cyp51A-gene, encoding the target enzyme of antifungal azoles, and 
both preclinical evidence and clinical experience suggests that reduced in vitro susceptibility 
is associated with increased probability of failure to azole therapy [2-4]. Azole resistance may 
develop during azole therapy, which has been primarily reported in patients with aspergilloma 
or other Aspergillus cavities that received long-term azole therapy [5]. This route of resistance 
development is characterized by recovery of azole-resistant A. fumigatus isolates exclusively 
from patients receiving azole therapy and by a high diversity of resistance mechanisms. 
Sometimes multiple resistance mechanisms were found in different A. fumigatus colonies 
recovered from a single patient [5]. The morphotype of A. fumigatus appears to be important 
as the fungus commonly sporulates in cavities, thus creating spores that harbor cyp51A-
mutations [6].
In the Netherlands, we observed azole resistance in A. fumigatus isolates from azole-naïve 
patients and in patients with invasive aspergillosis, which is characterized by hyphal growth 
in the absence of asexual reproduction. One explanation for this observation could be that 
a second route of resistance development may exist through environmental exposure of A. 
fumigatus to 14α-demethylase inhibitors (DMIs) [4,6-7]. DMIs are abundantly used for crop 
protection against phytopathogenic molds, for prevention of spoilage post harvest and for 
preservation of materials. Evidence that supports such a route of resistance development 
is the dominance of a single resistance mechanism in over 90% of Dutch azole-resistant 
A. fumigatus isolates, recovered from epidemiologically unrelated patients [6-8]. This 
mechanism consists of a 34-bp insertion in the promoter region of the cyp51A gene combined 
with a substitution at codon 98 of leucine to histidine (TR34/L98H) [9]. TR34/L98H isolates were 
cultured from patients that were azole-naïve as well as those with previous azole exposure, 
and were also recovered from the environment [10]. Genetic analysis showed clustering 
of clinical and environmental TR34/L98H isolates compared to wild type controls [7,10]. 
TR34/L98H isolates exhibit a multi-azole-resistant phenotype and azole-resistant invasive 
aspergillosis was associated with a high mortality rate of 88% [8,11]. In the Netherlands the 
first TR34/L98H isolate was cultured in 1998 and since then the prevalence of clinical isolates 
harboring TR34/L98H has increased over time [7-8].
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Theoretically there are significant risks associated with the environmental route of resistance 
development in fungi. First there is the potential of migration of the resistance trait through 
sexual or asexual reproduction. It has been shown for phytopathogens that resistance 
mechanisms may develop locally and subsequently spread across countries [12]. There are 
early indications that suggest that migration is occurring in TR34/L98H as isolates harboring 
this resistance mechanism have now been reported in other European countries [13], and 
more recently in azole-resistant isolates in China [14]. The other risk of the environmental 
route of resistance development is the emergence of multiple resistance mechanisms over 
time due to continued azole pressure. There are recent reports that indicate that in addition 
to TR34/L98H other ‘environmental’ resistance mechanisms may be emerging [15-16].
Therefore, it is of great importance to explore the relationship between the use of DMIs and 
the emergence of TR34/L98H in A. fumigatus as this may enable effective measures to be taken 
that prevent further increase of TR34/L98H isolates or of the emergence of new resistance 
mechanisms. The aim of our current research was to determine if the route of TR34/L98H 
development could have been fungicide driven. Our hypothesis was that cross-resistance 
could develop if DMIs and medical triazoles share similar molecule characteristics. This was 
investigated through molecule alignment and docking studies using a homology model of the 
Cyp51A protein. Furthermore, temporal relationships between DMI exposure and TR34/L98H 
emergence were investigated. Finally, we investigated if the TR34/L98H substitutions could 
be induced through DMI-exposure under laboratory conditions. We were able to identify 
five triazole DMIs that exhibit highly similar molecule characteristics to medical triazoles and 
could have caused the emergence of TR34/L98H in A. fumigatus.
Materials and methods
Susceptibility testing
A collection of 25 clinical wild type A. fumigatus isolates, 25 clinical azole-resistant TR34/L98H 
isolates, 17 environmental wild type isolates, and 13 environmental TR34/L98H isolates were 
selected for investigation of the in vitro activity of fungicides. In addition, two clinical isolates 
were included that have a tandem repeat as underlying resistance mechanism similar to TR34/
L98H: one isolate harbored a 53-bp tandem repeat and the other a 46-bp tandem repeat in 
combination with two substitutions in the cyp51A-gene at codons 121 and 289. Finally, four 
isolates were included that had a resistance mechanism that arose through azole therapy, 
consisting of point mutations in the cyp51A-gene. All isolates were previously identified 
by sequencing parts of the β-tubulin gene and the calmodulin gene. Furthermore, the full 
coding sequence and promoter region of the cyp51A-gene was sequenced and microsatellite 
genotyping was performed [7]. Sequences were aligned with a reference cyp51A sequence 
(GenBank accession no. AF338659) to identify mutations. All isolates were stored in 10% 
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glycerol at −80°C and subcultured on Sabauroud slants at 37°C.
Between 1970 and 2005 33 compounds were authorized by the Dutch Board for the 
Authorization of Plant Protection Products and Biocides for use as fungicides, herbicides, 
herbicide safeners and plant growth regulators, in The Netherlands. Of these 31 were available 
for testing including: amitrole, benomyl, biteranol, bromuconazole, carbendazim, cyazofamide, 
cyproconazole, difenoconazole, epoxiconazole, fenamidone, fenarimol, fenchlorazole-ethyl, 
fuberidazole, imazamethabenz-methyl, imazilil, metconazole, myclobutanil, nuarimol, 
paclobutrazole, penconazole, prochloraz, propiconazole, prothioconazole, pyrimethanil, 
tebuconazole, thiabendazole, thiophanate-methyl, triadimefon, triadimenol I, triadimenol II, 
triflumizole (Sigma Aldrich). The compounds were dissolved in DMSO and autosterilized for 30 
minutes at room temperature. The minimal inhibiting concentration (MIC) was determined 
using a microbroth dilution format according to the CLSI M38-A2 reference method [17].
Docking studies
The structure of wild type Cyp51A protein A. fumigatus was derived from the crystal 
structure of human (PDB code: 3I3K) and Mycobacterium tuberculosis (Mt) (PDB code: 
1EA1) lanosterol 14α-demethylase by homology modeling. Both proteins share 38% and 
24% sequence identity with Cyp51A of A. fumigatus, respectively and contain ligands in 
the active site bound to heme. The three-dimensional structures have been predicted by 
YASARA’s homology modeling experiment (http://www.yasara.org). The experiment consists 
from building four models based on different alignment variants. The missing loops were 
modeled and optimizations of structures ware performed. The model with the best Z-score 
derived from the crystal structure of human lanosterol 14α -demethylase was used for the 
presented studies.
In a recent publication by Fraczek et al. the Mycobacterium and human structures were 
also both compared and confirmed the choice for the human lanosterol 14α-demethylase 
as the best template for the A. fumigatus model [18]. The structures of tested fungicides 
and medical triazoles (Table 1) were downloaded from PubChem (http://pubchem.ncbi.nlm.
nih.gov/). We used FlexX for the docking experiment [19-20]. The coordination of ligands 
to the iron atom of heme was treated as pharmacophore during the docking procedure. 
The water molecule present in the active site according to the crystal structure of 1EA1 was 
treated dynamically. The program checked automatically whether the presence of the water 
molecule had favorable contribution to the docking pose and only in such a case the water 
molecule was reported back, otherwise it was neglected. The flexibility of hydrogen atoms of 
Y107, Y121 and S297 was introduced to find an optimal docking pose for the ligand. Docking 
the respective compounds back into their crystal structure validated the docking procedure. 
The root mean square deviation (RMSD) of the positions for fluconazole (PDB code 1EA1) was 
0.28 Å and for ketoconazole (PDB code 313K) 0.44 Å. All the binding modes present in the 
crystal structures were conserved [21-22].
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Table 1. Antifungal susceptibilities of medical triazoles and compounds used as fungicide, herbicide, 
herbicide safener and plant growth regulator.
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Microsatellite genotyping
Microsatellite genotyping was used to determine the genetic distances between TR34/L98H 
A. fumigatus isolates. A collection of 144 consecutive TR34/L98H isolates were used that 
originated from two prospective surveillance studies that were performed in the Netherlands. 
The first study included A. fumigatus isolates that were collected in Dutch hospitals between 
1994 and 2007. A total of 1,912 A. fumigatus isolates were obtained from 1,219 patients from 
the Radboud University Nijmegen Medical Center [7]. In addition, 147 A. fumigatus isolates 
from 101 patients, from 28 other medical centers in the Netherlands were collected [4,7]. 
The second culture collection included 1,792 A. fumigatus isolates that were collected from 
1,192 patients in seven University Medical Centers in the Netherlands between 2007 and 
2009 [8]. Both studies included an unselected collection of A. fumigatus isolates (clinically 
relevant as well as colonizing isolates) and used agar supplemented with itraconazole to 
detect for azole-resistance.
From six loci, consisting of three tri- and three tetranucleotide repeats, fragments were 
amplified by using fluorescently labeled primers. The sizes of the fragments were determined 
by addition of the GeneScan LIZ[500] marker and subsequent analysis of the fragments on the 
Applied Biosystems 3730 DNA analyzer. Assignment of repeat numbers in each marker was 
determined from the GeneScan data by using the Peak Scanner version 1.0 software (Applied 
Biosystems) [23]. By plotting the number of observed new genotypes versus the time on a 
semi-logarithmic scale, the year that the first new genotype emerged in The Netherlands was 
calculated with a 95% confidence interval by using the software package GraphPad Prism 
v5.00.
Induction experiments
Induction experiments were performed with the medical triazole itraconazole (5 mg/l), 
the triazole DMIs bromuconazole (8 mg/l), difenoconazole (8 mg/l), epoxiconazole (16 and 
32 mg/l), propiconazole (32 mg/l) and tebuconazole (8 mg/l) and all five DMIs combined 
together in concentrations ranging between 0.063-4 mg/l of each DMI. Wild type isolate 
CM237 and akuBKU80 as well as recombinant A. fumigatus isolates akuBKU80-TR3 containing 
the 34-bp tandem repeat and akuBKU80-L98H2 containing the L98H substitution were used. 
A solution of 1×106 of conidia was spread on a GYEP agar plate (glucose 2%, yeast extract 
0,3%, peptone 1% and agar 2%) containing one or a combination of DMIs and subsequently 
passaged on GYEP agar slants with the same concentration of DMI(s). Agar plates and slants 
were incubated at 37°C, and isolate akuBKU80-TR3 was also incubated at 25°C and 48°C. After 
10 passages sequencing of the cyp51A promoter and full coding gene was performed to 
detect mutations.
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Statistical analysis
In order to express differences in MIC50 between wild type and TR34/L98H for the different 
compounds we first log transformed the MIC50 data and then computed point biserial 
correlations as correlation effect sizes (r) [24]. Values of r = 0 indicate similarity between 
MIC50’s and values of r = 1 indicate the largest relative dissimilarity. These correlation effect 
sizes cannot be computed in cases where all samples have identical MIC50 values, such as with 
compounds that show no in vitro activity against both wild type and TR34/L98H isolates. In 
those cases the correlation effect size was considered r = 0.
Results
Activity of fungicides against A. fumigatus
In the Netherlands 33 compounds have been authorized by the Dutch Board for the 
Authorization of Plant Protection Products and Biocides for use as fungicides, herbicides, 
herbicide safeners and plant growth regulators, between 1970 and 2005, of these 19 were 
DMIs (Table 1; Figure 1; Figure 2A). We were able to obtain 31 of these compounds as dry 
powder and investigated the in vitro activity against 38 TR34/L98H A. fumigatus isolates from 
clinical and environmental origin and 42 wild type controls. In addition, two azole-resistant 
isolates from environmental origin that harbor a transcriptional enhancer as a resistance 
mechanism and four isolates with point mutations in the cyp51A-gene that arose through 
patient therapy were also tested (Table 2). Differences in MIC50 between the wild type and 
TR34/L98H against all different compounds were computed as correlation effect sizes (r). The 
correlation coefficient is used as a measure of the size of an effect with a value of −1 indicating 
a negative correlation between the two variables, a value of 0 indicating no correlation and 
a value of 1 indicating a positive correlation. For the medical triazoles the effect sizes were 
0.99 for itraconazole, 0.82 for voriconazole and 0.85 for posaconazole representing a positive 
correlation of dissimilarity between the MIC50’s of the wild type and TR34/L98H isolates. 
Dissimilarity between the MIC50’s was found for 20 compounds, with the greatest differences 
(r>0.90) found for propiconazole, difenoconazole, epoxiconazole (r = 0.96), bromuconazole 
(r = 0.95), metconazole (r = 0.94), imazalil (r = 0.94), and tebuconazole (r = 0.93) (Figure 
2B). These compounds were DMIs from the triazole class, with the exception of imazalil. 
Isolates with a 46 bp or 53 bp tandem repeat insertion showed similar correlation effect sizes 
as TR34/L98H isolates (data not shown), while isolates that had become resistant through 
patient azole therapy generally showed lower r-values (Table 1) [25].
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Molecule alignments and docking
We used a homology model of the A. fumigatus CYP-protein to predict the preferred 
orientation of DMI-compounds to form a stable complex with the 14α-lanosterol demethylase 
enzyme. A crystal structure of the A. fumigatus Cyp51A protein is not available, therefore to 
see structural similarities in Cyp51s for azole inhibition we superimposed the fluconazole-
bound Mycobacterium tuberculosis (Mt) structure (PDB code 1EA1), the ketoconazole-
bound human structure (PDB code 313K) and ketoconazole-bound A. fumigatus homology 
structure. Both fluconazole and ketoconazole bind to the heme iron via the nitrogen of an 
azole ring. The dihalogenated phenyl group, a common structural moiety of ketoconazole and 
fluconazole, occupied the same spaces at the active site of the heme molecule but interacts 
with the binding pockets lined by different residues when the human Cyp51, the Mt Cyp51 
and the A. fumigatus Cyp51 homology model are aligned. In human and A. fumigatus Cyp51, 
residues Y145 and Y121, respectively formed van der Waals contacts with the dichlorophenyl 
group of ketoconazole, whereas their side-chain hydroxyl group made hydrogen bonds to the 
D-ring propionate (C2H5COO
−) of the heme. Residue Y131 (PDB code 313K) that is located in 
the B′ helix of the homology structure (Y107) is invariant in the Cyp51 family and involved 
in hydrogen-bond formation with heme A-ring propionate in all three structures. In the Mt 
structure, Y145-corresponding F89 is away from the active site due to the conformational 
flexibility of the B–C–helix region. Instead, R95 and R96 of Mt Cyp51 are near the heme and 
fluconazole difluorophenyl group (Figure 3). Thus, ketoconazole could bind to Mt enzyme, 
utilizing the same space as fluconazole for the dihalogenated phenyl ring, while the remainder 
of ketoconazole would occupy the access channel observed in the human enzyme although 
the channel would have to be open by relocation of some of the side chains like F78 and 
M433 (grey structure Figure 3). In the Mt structure, the hydroxyl group of fluconazole made 
a water-mediated hydrogen bond to the heme A-ring propionate. This water molecule is not 
observed in the human structure because the cycle ether group of ketoconazole filled in the 
space of water. In addition, in Mt and A. fumigatus Cyp51s an invariant H259/H296 residue 
from helix I is pointed into the active site, whereas the confirmation of the corresponding 
H314 in human Cyp51 prevents its interaction with the inhibitors. The itraconazole, 
posaconazole and voriconazole molecules were docked into the A. fumigatus homology 
structure. They showed the same binding pattern as described for the crystal structures and 
were able to align to the presented poses of fluconazole (representative of voriconazole) 
and ketoconazole (representative of itraconazole and posaconazole). The compounds from 
the groups of imidazoles, pyrimidines and triazoles adopted similar poses upon docking in 
the active site of the A. fumigatus as those observed for the medical triazoles. The largest 
dissimilarities were in the cases of compounds that lack a phenyl group next to the 5- or 
6-member aromatic ring that coordinates to the iron center. 
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Figure 1. Chemical structures of antifungal compounds.
Three medical antifungal compounds and 31 compounds that were authorized by the Dutch Board for 
the Authorization of Plant Protection Products and Biocides for use as fungicides, herbicides, herbicide 
safeners and plant growth regulators. The compounds are presented according to structural group.
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Previous page, Figure 2. Overview of introduction of the 31 compounds by year and correlation effect 
sizes.
A) Overview of compounds by year of authorization by the Dutch Board for the Authorization of Plant 
Protection Products and Biocides (data from the Dutch Foundation for Phytofarmacy, Nefyto). The five 
triazole DMIs that exhibited the most identical docking by molecule alignment are underlined in blue. 
B) Correlation effect sizes (r) of compounds and medical triazoles comparing differences in the median 
MIC of wild type and TR34/L98H isolates. The fungicides are represented by grey dots and those 
belonging to the DMIs by black. The medical triazoles are indicated in red, and the five triazole DMIs 
that exhibited the most identical docking by molecule alignment are indicated in blue. 
*Correlation effect sizes could not be computed if in at least one of the two groups all variables were 
constant. This was the case with compounds that showed no in vitro activity against both wild type and 
TR34/L98H A. fumigatus isolates, and the correlation effect size was considered 0.
Table 2. Activity of medical triazoles and five DMIs against clinical and environmental A. fumigatus 
isolates with different cyp51A-mediated resistance mechanisms.
Resistance mechanism 
cyp51A gene*
Median MIC (mg/l)
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– – 42 0.125 0.5 0.063 1 1 2 2 1
34 bp TR L98H 38 >16 4 0.5 16 16 >16 >16 16
46 bp TR Y121F, T289A 1 2 >16 0.5 >16 >16 >16 >16 16
53 bp TR – 1 >16 16 0.25 16 >16 >16 >16 16
– G54W 1 >16 0.25 >16 0.5 0.125 0.5 0.5 0.5
– G54E 1 >16 0.25 1 0.25 0.25 0.5 0.5 0.5
– M220I 1 >16 1 0.5 4 4 16 16 4
– M220V 1 >16 2 1 4 2 8 4 4
*TR, tandem repeat.
&ITC, itraconazole; VCZ, voriconazole; POS, posaconazole.
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Figure 3. 3D representation of three aligned structures of Cyp51 with the ligands in their active site, 
constructed by using the Yasara software.
In green human Cyp51 bound with ketoconazole from PDB: 3I3K; in gray Mt bound with fluconazole 
from PDB: 1EA1; in cyan A. fumigatus bound with ketoconazole from the homology model. The ligands 
are represented in balls and sticks, only the residues important for binding a particular ligand are 
depicted in the picture and represented in sticks. Numbering of the residues corresponds with their 
colors to the models.
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Figure 4. Two-dimensional structure of voriconazole with indicated pharmacophores that were used 
to align and filter the 31 compounds (Table 1).
The figure was constructed by using Marvin Sketcher form ChemAxon (www.chemaxon.com).
Figure 5. Analysis of fungicide binding modes compared to the medical triazoles.
A) Binding modes of propiconazole. This fungicide exhibits the most similar binding modes compared 
to the medical triazoles located in the active site of human and A. fumigatus Cyp51. 
B) Binding modes of tebuconazole. This fungicide exhibits the most similar binding modes compared 
to the medical triazoles located in the active site of Mt Cyp51. The main difference between A and B is 
the interactions with residue H296 in the active site, which is lacking in A.
A                                                              B
100
Chapter 4
We performed a flexible alignment of the compounds on the structure of voriconazole in order 
to find the most similar compounds. The pharmacophores used as a filter for the alignment 
that consist of 5/6-member aromatic ring containing at least one nitrogen atom, a hydrogen-
bond donor or acceptor and the aromatic functional group (Figure 4). The structures classified 
to groups of benzimidazoles, cyaninoimidazoles together with prochloraz, imazamethabenz 
from imidazolinone, and pyrimethanil from pyrimidines and fenamidone and amitrole from 
triazoles were filtered out from the set of the ligands as not similar to the voriconazole 
molecule. The remaining 20 of 31 structures were considered to be similar to the medical 
triazoles. We focused our analysis of the docking poses on the compounds that satisfied the 
given pharmacophores for alignment.
Docking poses of fungicides similar to medical triazoles
The triazole DMIs that have three nitrogen atoms in the aromatic ring coordinated to the 
iron atom of heme made a hydrogen bond contact to residue S297, present in the active 
site of the A. fumigatus Cyp51 homology model. Residue H296, also present in the active 
site, interacted with most of the fungicides with the exception of imazalil, triflumizole, 
fenarimol, nuarimol, penconazole, metconazole that instead interacted with a bridging water 
molecule. Propiconazole, myclobutanil, difenoconazole lack any interaction with residue 
H296 or a bridging water molecule. Most of the DMIs share the core structure with medical 
triazoles and due to this similarity they adopt much the same poses in the active site of 
A. fumigatus as the medical triazoles. Propiconazole and bromuconazole exhibit the most 
alike poses with the core structure being the most similar to itraconazole and posaconazole 
(Figure 5A). Tebuconazole and epoxiconazole also adopted the most alike poses being most 
similar to voriconazole, except they interacted with residue H296 in the active site (Figure 
5B). The analysis of the top three poses proposed by the docking program showed that 
these compounds were able to adopt also poses where they interacted with a bridging water 
molecule instead of H296. This makes the binding modes of propiconazole, bromuconazole, 
tebuconazole and epoxiconazole most identical to those represented by the medical triazoles. 
Difenoconazole (Table 1) was different in structure from the rest of the cross-resistant DMIs. 
Instead of one aromatic ring (Figure 5A and  and 4B) it has a biphenyl moiety, upon docking 
this part was placed into the access channel where the long tail of medical azoles is normally 
located.
The above mentioned five triazole DMIs were also among the compounds with the highest 
r-value and showed complete loss of in vitro activity against A. fumigatus isolates harboring 
TR34/L98H (Figure 2B, Table 1). Moreover, these five DMIs were authorized for use in the 
Netherlands between 1990 and 1996 (Figure 2A), which preceded the first known isolation of 
a clinical TR34/L98H isolate in 1998 [7]. Imazalil and metconazole also showed a high correlation 
effect size (Figure 2A), but, unlike the five abovementioned triazole DMIs, retained in vitro 
4101
Triazole fungicides can cause cross-resistance to medical triazoles
activity against TR34/L98H isolates (median MIC of 2 mg/l) (Table 1). Docking studies and 
molecule alignments showed that imazalil and metconazole were less similar to the medical 
triazoles and therefore less likely to have caused the emergence of TR34/L98H in A. fumigatus.
Microsatellite genotyping
A. fumigatus isolates from two Dutch surveillance studies were used to investigate the evolution 
of TR34/L98H genotypes over time [7-8]. The collections were obtained prospectively over a 
16 year period and included 3,847 isolates from 2,512 patients. All isolates were screened 
for azole resistance by subculture on agar supplemented with itraconazole. The collections 
included 144 consecutive TR34/L98H isolates which were genetically characterized by short 
tandem repeat genotyping [23]. By plotting the number of observed new genotypes versus 
time on a semi-logarithmic scale, we calculated a rate of change of 1.37±0.05 genotype-1.
year-1. Using the rate of change to calculate the year of first emergence of TR34/L98H, 
indicated that TR34/L98H had developed in the year 1997 (95% CI: 1993.7-1999.7) (Figure 6).
Figure 6. The evolution of new microsatellite genotypes over time based on short tandem repeat typing 
of 144 TR34/L98H A. fumigatus isolates, cultured between 1998 and 2009 in the Netherlands.
By plotting the number of observed new genotypes versus time on a semi-logarithmic scale, a rate 
of change of 1.37±0.05 genotype-1.year-1 was calculated. As the first TR34/L98H isolate was cultured 
in 1998, the rate of change indicates that the first strain would have emerged around 1997 (95% CI: 
1993.7-1999.7). This analysis also indicates that TR34/L98H had developed from a single ancestor.
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Induction of TR34/L98H
We investigated if the TR34/L98H substitutions could be induced during exposure to DMIs under 
laboratory conditions. A wild type A. fumigatus isolate and recombinants containing either 
the 34-bp insertion or the L98H substitution were exposed to itraconazole, bromuconazole, 
difenoconazole, epoxiconazole, propiconazole, tebuconazole or a mixture of these DMIs. The 
induction experiments generally resulted in a resistant phenotype within three passages. In 
three out of twelve clones of A. fumigatus cultured under itraconazole pressure, cyp51A-
substitutions G138C or P216L were detected. These substitutions have been reported in 
patients who developed azole-resistant Aspergillus disease during itraconazole therapy [5]. 
TR34/L98H was not found in any of the clones that were exposed to itraconazole, single DMI 
compounds or to a mixture of DMIs. However, following exposure of the A. fumigatus conidia 
containing the 34-bp insertion in the cyp51A-gene promoter to 8 mg/l of tebuconazole 
resulted in one clone in which after three passages a triplicate of the 34 bp sequence was 
detected in the promoter region. 
Discussion
Although the hypothesis of a fungicide-driven route of azole resistance development in 
A. fumigatus is controversial [26], we provide evidence that such a route may exist. Five 
triazole DMIs were identified that exhibited very similar molecule characteristics to the 
medical triazoles, resulting in the most identical binding modes and the greatest level of 
cross-resistance. These five DMIs were authorized for use between 1990 and 1996, which 
was in keeping with our calculated date of origin of TR34/L98H based on microsatellite typing, 
and precedes the first clinical TR34/L98H isolate in 1998. Continued triazole DMI pressure and 
lack of an apparent fitness cost in TR34/L98H isolates are probably important factors that have 
facilitated the ability of TR34/L98H to sustain in the field in competition with wild type isolates.
Although the relation between the use of antimicrobial agents outside human medicine and 
the development of resistance to clinically used compounds has been shown for bacteria, we 
show for the first time evidence that the same principle may occur in molds. Culture-based 
surveillance studies increasingly report TR34/L98H in clinical and environmental isolates in 
Europe and, most recently, in China [14]. Moreover, there is very recent evidence that two 
new ‘environmental’ azole resistance mechanisms have emerged in A. fumigatus in the 
Netherlands, of which one has rapidly migrated across the country similar to TR34/L98H [27]. 
However, surveillance studies based on positive cultures may underestimate the prevalence 
of resistance. Detection of azole resistance mechanisms directly in clinical specimens from 
patients with chronic lung diseases showed that in culture-negative, PCR-positive samples 
cyp51A-mutations were detectable in as many as 55.1% of respiratory samples [28]. These 
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observations indicate that we are just beginning to understand the scale of the problem, but 
it suggests that azole resistance in A. fumigatus has become a public health problem and 
threatens an increasing population of (immunocompromised) patients.
Our study was limited by the fact that we were unable to induce the full TR34/L98H resistance 
mechanism during DMI-pressure under laboratory conditions, using an isolate that is 
deficient in DNA break repair. Previously, microsatellite genotyping showed shorter genetic 
distances for TR34/L98H isolates compared with wild type isolates [10], which suggests that 
TR34/L98H isolates may have originated from a common ancestor. If this would be the case, 
the development of TR34/L98H would be extremely infrequent in the environment and would 
explain why we were unable to induce TR34/L98H under laboratory conditions. However, this 
may point to other reasons for the emergence of TR34/L98H. TR34/L98H isolates may have 
other properties, such as increased fitness or virulence, or high sporulation efficacy, that have 
made isolates harboring TR34/L98H more successful in the field than wild type A. fumigatus. 
However, at present there is no evidence that supports increased virulence in TR34/L98H 
isolates. Animal studies indicate that the virulence of TR34/L98H is similar to that of wild 
type isolates, although only one TR34/L98H isolate was used [3]. An alternative explanation 
for our inability to induce TR34/L98H could be that this resistance mechanism developed 
through sexual or parasexual reproduction rather than asexual reproduction, which was not 
tested in the laboratory. However, we did observe one isolate in which two copies of the 
tandem repeat evolved into three, supporting the role of DMIs in inducing genomic changes 
in cyp51A of A. fumigatus. Another limiting factor of our studies was the lack of sequence-
based evolutionary analysis. In A. fumigatus no genes have been described that are suitable 
for this type of analysis and therefore we used microsatellite data.
The relation between the use of the triazole DMIs and cross-resistance to medical triazoles 
in A. fumigatus has major implications for the assessment of health risks associated with 
the use of DMIs. Molecule structure similarity and activity of triazole DMIs against A. 
fumigatus appear to be the key features that cause cross-resistance to medical triazoles. 
Further research should be aimed at understanding the conditions under which resistance 
mechanisms develop in the environment and which Aspergillus morphotype is most prone to 
develop resistance mechanisms. Reversal of resistance development may be achievable by 
restriction of certain triazole DMIs, but laboratory population studies and genetic mapping 
would be required to predict the impact of changes in DMI-pressure. In addition, there is 
limited insight in the use of fungicides for agricultural and non-agricultural applications.
The continued use of DMIs with activity against opportunistic human fungal pathogens is 
a risk for the management of fungal diseases caused by these pathogens. The number of 
classes of drugs available for treating non-invasive and invasive fungal diseases is limited 
and the triazoles are the only class of antifungal agents that can be administered orally. 
A fungicide-driven route of resistance development in TR34/L98H could indicate that such 
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mechanisms may also occur in other Aspergillus species or other opportunistic fungi. It is 
therefore of great importance to perform abovementioned research as it may allow the 
implementation of evidence-based strategies aimed at elimination of the fungicide-driven 
route of azole resistance development in opportunistic fungi.
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Abstract
A rapid emergence of azole resistance has been observed in Aspergillus fumigatus in The 
Netherlands over the past decade. The dominant resistance mechanism appears to be of 
environmental origin and involves the TR34/L98H mutations in cyp51A. This resistance 
mechanism is now also increasingly being found in other countries. Therefore, genetic 
markers were used to gain more insights into the origin and spread of this genotype. Studies 
of 142 European isolates revealed that those with the TR34/L98H resistance mechanism 
showed less genetic variation than azole-susceptible isolates or those with a different genetic 
basis of resistance and were assigned to only four CSP (putative cell surface protein) types. 
Sexual crossing experiments demonstrated that TR34/L98H isolates could outcross with azole-
susceptible isolates of different genetic backgrounds, suggesting that TR34/L98H isolates can 
undergo the sexual cycle in nature. Overall, our findings suggest a common ancestor of the 
TR34/L98H mechanism and subsequent migration of isolates harboring TR34/L98H across 
Europe. 
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Introduction
Aspergillus fumigatus is a saprophytic fungus that is capable of causing a wide range of 
diseases in various hosts. Invasive aspergillosis is the most severe manifestation of Aspergillus 
infection in humans, and this disease is associated with substantial mortality and morbidity. 
Medical triazoles, such as itraconazole, voriconazole, and posaconazole, play an important 
role in the management of Aspergillus diseases. However, azole resistance is an emerging 
problem in A. fumigatus and has been shown to be associated with increased probability of 
treatment failure [1-9]. 
Azole resistance is commonly due to mutations in the cyp51A gene, which encodes 
14-α-demethylase in the ergosterol biosynthesis pathway. In azole-resistant clinical A. 
fumigatus isolates, a wide variety of cyp51A mutations, such as substitutions at codons G54, 
G138, P216, F219, M220, and G448, have been found [2,10-11]. This is in contrast with a 
different pattern of resistance observed in isolates from The Netherlands. Here, a resistance 
mechanism consisting of the L98H substitution together with a 34-bp tandem repeat (TR34) 
in the promoter region of this gene (TR34/L98H) was found to be present in over 90% of 
itraconazole-resistant isolates, which also showed reduced susceptibility to voriconazole and 
posaconazole [5,12]. TR34/L98H isolates were recovered primarily from azole-naïve patients 
and were also recovered from the environment [12-13]. These observations suggest that 
azole-resistant Aspergillus is acquired by patients from an environmental source rather than 
arising through azole therapy. Recently, we provided evidence that exposure of A. fumigatus 
to 14-α-demethylase inhibitor (DMI) fungicides might provide a selective pressure leading to 
the emergence of TR34/L98H resistant isolates in the environment [14]. On the basis of in vitro 
cross-resistance, molecule alignment studies, and docking simulations, five triazole fungicides 
that were highly similar to antifungal triazoles used in medicine were identified [14]. The 
TR34/L98H resistance mechanism has been shown to be endemic in The Netherlands [12] and 
is also increasingly being reported in other European countries [2,5,15-17]. Furthermore, the 
TR34/L98H genotype was recently reported outside Europe, in China and India [18-19]. 
At present, it is unknown if the high frequency of the TR34/L98H genotype in azole-resistant 
isolates is due to migration from a common ancestral lineage or repeated independent 
development in genetically unrelated strains. Preliminary genotyping studies in TR34/L98H 
isolates using microsatellites showed shorter genetic distances between TR34/L98H isolates 
than those between wild-type controls [5], and another study showed that TR34/L98H isolates 
nest within a single population and have not spread across A. fumigatus populations [20]. 
To gain more insights into the origin and spread of the TR34/L98H resistance mechanism, we 
studied the genetic relatedness of European A. fumigatus isolates containing the TR34/L98H 
mutations by analyzing several genetic markers. We also assessed the possible involvement of 
the recently described sexual cycle of A. fumigatus [21] in generating novel genetic diversity 
among isolates bearing the TR34/L98H genotype.
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Materials and methods
Selection of TR34/L98H and control isolates
A. fumigatus isolates containing the TR34/L98H resistance mechanism and originating between 
1998 (the year in which the first TR34/L98H isolates were recovered in The Netherlands) 
[5] and 2007 were selected from the fungal culture collection of the Radboud University 
Medical Centre. Dutch TR34/L98H isolates, including isolates of clinical and environmental 
origin, were randomly selected. As controls, for each TR34/L98H isolate, an isolate with a 
susceptible phenotype, which was matched by year of isolation to the TR34/L98H isolate, 
was randomly selected. The controls also included both clinical and environmental isolates. 
To compare the TR34/L98H resistance mechanism with other resistance mechanisms, the 
culture collection was also searched for isolates with an azole-resistant phenotype that was 
not due to the TR34/L98H mechanism. Finally, TR34/L98H A. fumigatus isolates that originated 
from other European countries were included (Table S1, available at http://jcm.asm.org/
content/50/8/2674/suppl/DCSupplemental). 
In vitro susceptibility testing
In vitro activity of itraconazole, voriconazole, and posaconazole was tested according to 
the EUCAST broth microdilution reference method [22]. The MIC was determined by the 
lowest antifungal concentration with a complete inhibition of growth after 48 h. MICs were 
interpreted based on recently proposed breakpoints [23]. 
DNA extraction and cyp51A sequencing
DNA was isolated, and the full coding sequence of the cyp51A gene, as well as the promoter 
region, was determined by amplification and subsequent sequencing as previously described 
[10]. Sequences were compared to a wild-type A. fumigatus cyp51A gene sequence (GenBank, 
National Center for Biotechnology Information [http://www.ncbi.nlm.nih.gov/], accession 
number AF338659) to detect mutations. 
CSP typing, microsatellite analysis, and mating type determination
CSP (putative cell surface protein) types were determined by PCR amplification and 
subsequent sequencing by following established protocols [24-25]. CSP types were assigned 
according to the CSP typing nomenclature described by Klaassen et al. [26]. 
Six microsatellite loci (STRAf 3A, 3B, 3C, 4A, 4B, and 4C) were analyzed as described previously 
[13,27]. The obtained genotypes were imported into BioNumerics v6.0 (Applied Maths, 
Sint-Martens-Latem, Belgium). A minimum spanning tree (MST) was constructed based on 
categorical treatment of the data, i.e., alleles were scored as either identical or nonidentical 
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and the difference in numbers of repetitions at each locus between different genotypes was 
not taken into account. 
Mating types were determined by a multiplex PCR-based mating type test, as described 
previously [28]. The null hypothesis of a 1:1 ratio of the two mating types was tested using 
the χ2 test, with a P value of <0.05 considered significant [21]. 
Sexual reproduction
To investigate the segregation of genetic markers and the TR34/L98H resistance mechanism 
following sexual reproduction, the wild-type isolate AfIR974 [21] was crossed with the clinical 
isolate v23-66, which harbored the TR34/L98H resistance mechanism. Mating experiments 
were performed on oatmeal agar plates (Difco oatmeal agar), and inoculations were 
performed as described previously [21]. Plates were sealed with Parafilm and incubated 
at 30°C in the dark. Crosses were examined weekly, and when cleistothecia developed, 
ascospore suspensions were obtained as described previously [21]. Ascospore suspensions 
were plated onto Sabouraud agar plates, and germinating ascospores were transferred to 
Sabouraud agar slants. Fifteen progeny were selected for further analysis, including in vitro 
susceptibility testing and mating type determination. In addition, the progeny were screened 
for the presence of the TR34/L98H resistance mechanism using the following PCR-based 
assays. The presence of the TR was investigated by amplifying part of the promoter region 
of the cyp51A gene using appropriate primers (5′-TGAGTTAGGGTGTATGGTATGCTGGA-3′ 
and 5′-AGCAAGGGAGAAGGAAAGAAGCACT-3′). For the L98H substitution, two PCRs 
were performed: an L98-specific PCR (primers 5′-CCTCTTCCGCATTGACATCCTGGA-3′ 
and 5′-TGACGGCAATCTTGCTCAATGTTGTTTA-3′) and an L98H-specific PCR (primers 
5′-ACGAGTTTATTCTCAACGGCAAGGA-3′ and 5′-TTCGGTGAATCGCGCAGATAGTCC-3′). The 
cycling program consisted of a 2-min denaturation step at 94°C, followed by 35 cycles of 
30 s at 94°C, 45 s at 60°C, and 45 s at 72°C and a final elongation step of 5 min at 72°C. 
Products of the TR detection PCR were separated on a 2% agarose gel together with a size 
marker. Amplicons of 188 bp in size do not contain a TR, while the presence of a TR will lead 
to amplicons of 222 bp (188 bp plus an extra 34-bp repeat). Amplification products of the 
L98- and L98H-specific PCRs were mixed and run on a 2% agarose gel with a size marker. The 
L98-specific product is 341 bp in size, while the L98H-specific product is 223 bp in size. 
After the first sexual cross with a TR34/L98H isolate succeeded, additional TR34/L98H isolates 
were subjected to sexual crossing. For that, AfIR957 (MAT1-1) [21] and AfIR928 (MAT1-2) 
[21,29] were crossed with various clinical isolates of the opposite mating type that contained 
the TR34/L98H resistance mechanism. The progeny of each cross were assessed both for the 
presence of the TR34/L98H mutations (by the PCR-based assays as described above) and for 
their CSP type.
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Results
TR34/L98H and control isolates
The distribution of isolates over time is shown in Table 1. In total, 55 azole-resistant TR34/L98H 
isolates and 55 azole-susceptible wild-type controls that had been cultured between 1998 and 
2007 in The Netherlands were selected. Of these, 86 were clinical isolates which originated 
from patients admitted to the Radboud University Nijmegen Medical Centre (71 isolates) or 
other Dutch hospitals (15 isolates). The remaining 24 isolates were of environmental origin 
and were recovered from soil, seeds, compost, leaves, water filter samples, and air samples 
(see Table S1, available at http://jcm.asm.org/content/50/8/2674/suppl/DCSupplemental).
The fungal culture collection comprising over 2,000 isolates of A. fumigatus contained seven 
resistant isolates without the TR34/L98H resistance mechanism that were cultured between 
1998 and 2007 in The Netherlands (Table 1). Three isolates were of clinical origin and 
harbored a point mutation in the cyp51A gene, leading to the M220K, M220I, or M220V 
substitution. These mutations are known to be correlated with azole resistance [30-32]. The 
other four azole-resistant isolates were obtained from the environment and did not have any 
mutation in the cyp51A gene. 
Table 1. Distribution of azole-resistant and azole-susceptible wild-type Dutch A. fumigatus isolates 
examined in this study according to the year of isolation.
Year of isolation
No. of isolates with each phenotype and resistance mechanism
Wild-type Resistant TR34/L98H Resistant non-TR34/L98H
1998 2 2 -
2000 2 2 -
2001 2 2 -
2002 7 7 1
2003 4 4 -
2004 7 7 1
2005 6 6 -
2006 7 7 -
2007 18 18 5
Total 55 55 7
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In vitro susceptibility testing
Results of in vitro susceptibility testing of the Dutch isolates are shown in Table 2. According to 
the proposed breakpoints [23], all of the 55 TR34/L98H isolates were resistant to itraconazole 
and all except two showed resistance or intermediate susceptibility to voriconazole. 
Ten isolates were susceptible to posaconazole, while the other 45 showed intermediate 
susceptibility or resistance to this drug. Of the seven non-TR34/L98H resistant isolates 
exhibiting resistance to azoles, five were itraconazole resistant, and of these, four isolates 
also showed intermediate or resistant phenotypes for voriconazole and/or posaconazole. The 
remaining two isolates were resistant to voriconazole, with a MIC of 4 mg/liter, while being 
susceptible to both itraconazole and posaconazole.
Table 2. Results of in vitro susceptibility testing of Dutch A. fumigatus isolates.
Resistance mechanism 
(number of isolates)
MIC geometric mean (range) (mg/liter)a
ITZ VOR POS
Wild-type (55) 0.19 (0.031-1) 0.5 (0.25-2) 0.06 (0.016-0.5)
TR34/L98H (55) 26.82 (4-32) 4.42 (1-32) 0.49 (0.25-1)
non-TR34/L98H (7) 8.83 (0.5-32) 2.20 (0.5-4) 0.67 (0.25-32)
aFor the purpose of the analysis, all values >16 mg/l were indicated as 32 mg/l.
ITZ, itraconazole; VOR, voriconazole; POS, posaconazole. 
CSP genotyping and mating type
CSP typing showed that the azole-susceptible wild-type control isolates were spread across 11 
CSP types (Table 3). The seven Dutch azole-resistant non-TR34/L98H isolates were distributed 
over CSP types t01, t02, t03, and t04A. In contrast, the 55 Dutch isolates with the TR34/L98H 
resistance mechanism grouped in only three CSP types: t02, t04B, and t11. Remarkably, CSP 
types t04B and t11 consisted exclusively of TR34/L98H isolates, while t02 types contained 
azole-susceptible and TR34/L98H and non-TR34/L98H resistant isolates. CSP types t02, t04B, 
and t11 all contained clinical as well as environmental TR34/L98H isolates. The distribution 
of CSP types over time within the group of TR34/L98H isolates is shown in Figure 1. The first 
Dutch TR34/L98H isolates that were recovered from a patient in 1998 were of CSP type t11. 
TR34/L98H isolates of a second and third CSP type were then found in 2000 and 2002 (t04B 
and t02, respectively). From 2002 until 2007, no further new CSP types were observed among 
the Dutch TR34/L98H isolates.
The multiplex PCR showed isolates of complementary MAT1-1 and MAT1-2 mating types to 
be present in all isolate groups; within the 55 wild-type isolates, a distribution ratio of 36% 
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to 64% was found for MAT1-1/MAT1-2, while in the 55 TR34/L98H isolates, a ratio of 55% to 
45% was detected, and in the final 7 non-TR34/L98H resistant isolates, a ratio of 57% to 43% 
for MAT1-1/MAT1-2 was found. There was no significant deviation from a 1:1 ratio in any of 
these groups according to a χ2 statistical analysis. With regard to CSP types, TR34/L98H isolates 
of both MAT1-1 and MAT1-2 mating types were present within all three CSP types (t02, t04B, 
and t11) (data not shown). 
Table 3. Distribution of CSP types in the Dutch and European A. fumigatus isolates.
CSP type
Number (frequency [%]) of isolates from each group (n)
Dutch
wild-type
(55)
Dutch resistant
non-TR34/L98H
(7)
Dutch resistant
TR34/L98H
(55)
Other European
TR34/L98H
(25)
t01 15 (27.3) 4 (57.1) - -
t02 4 (7.3) 1 (14.3) 12 (21.8) 12 (48)
t03 7 (12.7) 1 (14.3) - -
t04A 16 (29.1) 1 (14.3) - -
t04B - - 20 (36.4) 8 (32)
t05 2 (3.6) - - 1 (4)
t08 5 (9.1) - - -
t09 1 (1.8) - - -
t10 1 (1.8) - - -
t11 - - 23 (41.8) 4(16)
t13 2 (3.6) - - -
t14 1 (1.8) - - -
t18 1 (1.8) - - -
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Figure 1. Distribution of CSP types of 55 TR34/L98H A. fumigatus isolates isolated between 1998 and 
2007 in The Netherlands.
Other European TR34/L98H isolates
The Radboud fungus culture collection contained 25 TR34/L98H isolates from seven other 
European countries (Austria, Belgium, Denmark, France, Italy, Norway, and United Kingdom) 
(see Table S1, available at http://jcm.asm.org/content/50/8/2674/suppl/DCSupplemental). 
Only the isolate from Norway was of environmental origin; the other 24 isolates were of 
clinical origin. CSP typing of these TR34/L98H isolates showed that they grouped to the same 
CSP types as the TR34/L98H isolates originating from The Netherlands (i.e., t02, t04B, and 
t11). There was only one exception: one of the five TR34/L98H isolates originating from Italy 
was of CSP type t05 (Table 3). 
Microsatellite typing of Dutch and European isolates
A minimum spanning tree (MST) was constructed based on the six STRAf microsatellite 
loci, with the majority of isolates having a unique genotype (Figure 2). The Dutch TR34/L98H 
isolates formed a cluster that was almost entirely separate from the azole-susceptible wild-
type isolates. In three cases, a clinical and an environmental TR34/L98H isolate had identical 
microsatellite genotypes. 
The TR34/L98H isolates from other European countries also clustered with the Dutch TR34/
L98H isolates. TR34/L98H isolates of two particular microsatellite genotypes were found in 
both The Netherlands and other European countries (see the dual-colored dots in Figure 
2). In addition, isolates from Belgium and Italy also shared the same genotype. The non-
TR34/L98H resistant isolates did not cluster together and instead were more distributed 
throughout the tree. 
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Figure 2. Minimum spanning tree showing the genotypic relationship between the azole-resistant and 
azole-susceptible A. fumigatus isolates. 
Each circle corresponds to a unique genotype, and the size of the circle corresponds to the number of 
isolates with that genotype (1, 2 or 3 isolates). Connecting lines correspond to the number of different 
microsatellite loci between the genotypes. Short bold line, 1 difference; black line, 2 differences; long 
grey line, 3 differences; dotted line, 4 or more differences. 
Red, azole-resistant TR34/L98H, The Netherlands (n = 55); yellow, azole-susceptible wild-type, The 
Netherlands (n = 55); blue, azole-resistant non-TR34/L98H, The Netherlands (n = 7); pink: azole-resistant 
TR34/L98H, other European countries (n = 25).
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Sexual crosses with TR34/L98H isolates
In order to gain insight into the impact of sexual reproduction on the genetic markers, the 
wild-type isolate AfIR974 (MAT1-1, CSP type t02) was crossed with the clinical isolate v23-66, 
containing the TR34/L98H resistance mechanism (MAT1-2, CSP type t04B). After approximately 
2 months of incubation, cleistothecia were formed and ascospores were isolated. As shown 
in Table 4, 15 progeny, of which eight (53%) harbored the TR34/L98H resistance mechanism 
and seven did not, were analyzed. The presence of TR34/L98H always corresponded with 
an azole-resistant phenotype. The presence of new combinations of both mating and 
CSP types in the progeny and the generation of new microsatellite genotypes provided 
evidence for recombination during the heterothallic sexual cycle [21]. The combination of all 
genotypic markers (presence of TR34/L98H, six STRAf microsatellites, CSP and mating type) 
resulted in unique genotypes for 80% of the progeny. Surprisingly, in two of the progeny 
(AfIR974-v23-66-10 and AfIR974-v23-66-14), the number of repeats in the STRAf 3A marker 
increased from 80 to 82, a result which is suggestive of microvariation [33-34]. 
In addition, six TR34/L98H isolates were subjected to sexual crossing to determine whether 
they could outcross with isolates from a different CSP type that was not observed among the 
Dutch TR34/L98H resistant isolates. Clinical TR34/L98H isolates of CSP types t02, t04B, and t11 
and of each mating type were crossed to the environmental isolates AfIR957 (MAT1-1, CSP 
type t05) and AfIR928 (MAT1-2, CSP type t03). Four out of six crosses were fertile (see Table 
S2, available at http://jcm.asm.org/content/50/8/2674/suppl/DCSupplemental). Analysis of 
the progeny from each successful cross revealed the presence of isolates that were of the 
TR34/L98H genotype and of CSP types t03 and t05 (see Table S2). This demonstrated that the 
presence of the TR34/L98H mechanism is not necessarily restricted to CSP types t02, t04B, 
and t11.
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Discussion
There are an increasing number of studies reporting the TR34/L98H mutations as a key 
underlying resistance mechanism in azole-resistant A. fumigatus isolates. The TR34/L98H 
mechanism was found to be widespread in The Netherlands and is also found in other 
European and Asian countries [2,5,15-16,18-19,35-37]. TR34/L98H isolates have been 
recovered from the environment in The Netherlands, Denmark, and Norway [5,13,16], 
and there is increasing evidence that this resistance mechanism has developed through a 
fungicide-driven route of resistance development [14]. The present study was undertaken to 
gain insights into the origin and spread of this resistance genotype. 
The first key finding was that isolates with the TR34/L98H azole resistance mechanism 
originating from The Netherlands and seven other European countries are genetically less 
diverse than azole-susceptible wild-type isolates and isolates bearing other forms of azole 
resistance (for the latter two groups, only isolates originating from The Netherlands were 
tested). The two genotyping methods used, CSP and microsatellites, gave different levels of 
discrimination. CSP typing has a lower discriminatory power than microsatellite analysis and 
has been suggested to be more suitable for typing at the subpopulation level [26]. This typing 
method revealed the significant result that Dutch isolates with the TR34/L98H genotype were 
found only in three CSP types, namely, t02, t04B, and t11. This contrasted with the distribution 
of CSP types in the azole-susceptible wild-type control group from The Netherlands, where 
isolates were found in 11 different CSP groups, similar to previously published results [25-26]. 
Importantly, two CSP types (t04B and t11) were observed to comprise exclusively TR34/L98H 
isolates, with no non-TR34/L98H resistant or azole-susceptible isolates found within these 
groups. This is consistent with a previous report in which isolates from Australia (where TR34/
L98H-mediated resistance has not been described to date) were analyzed which also failed to 
detect isolates of these two CSP types [25]. However, the absence of azole-susceptible isolates 
in these CSP types may simply be due to a very low frequency of occurrence. Meanwhile, 24 
out of 25 TR34/L98H isolates (96%) of European origin other than The Netherlands grouped 
to the same three CSP types, indicating a close genetic relationship despite the geographic 
distances involved. Results of the microsatellite analysis were consistent with the CSP typing, 
demonstrating a clustering of all TR34/L98H isolates, distinct from most wild-type, azole-
susceptible isolates. This was also shown in collections of Dutch isolates [5,13]. Another study 
concluded that resistant clinical isolates were more distributed among susceptible isolates, 
although most TR34/L98H isolates clustered within the same clade of the phylogenetic tree 
[38]. From the data presented here, a close genetic relationship between all European TR34/
L98H isolates can be inferred. However, it should be cautioned that as no azole-susceptible 
isolates from European countries other than The Netherlands were included in the analysis, 
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we can conclude only that the TR34/L98H grouping is distinct specifically from the Dutch 
azole-susceptible isolates. 
Considering the CSP typing and microsatellite results as a whole, it is possible to speculate 
about the evolutionary origin and spread of the TR34/L98H azole resistance genotype within 
Europe. The relatively close genetic relationships and limited CSP type diversity of the TR34/
L98H isolates, compared to those of the azole-susceptible wild-type isolates, indicates that 
the independent and repeated emergence of the TR34/L98H mechanism seems unlikely. An 
alternative explanation is that the TR34/L98H isolates developed from a common ancestor or 
restricted set of genetically related isolates. A common origin of the TR34/L98H mechanism 
was previously suggested based on the microsatellite typing of 144 Dutch TR34/L98H isolates, 
from which it was calculated that the first TR34/L98H isolate would have emerged in the 
Netherlands in 1997 [14]. The appearance and spread of the TR34/L98H mutation from 
an apparent common source is in marked contrast to the evolution of the non-TR34/L98H 
resistant isolates detected in the present study. These were distributed throughout the total 
set of isolates (Figure 2), consistent with the hypothesis that mutations, such as at codon 
M220 in cyp51A, can be induced in isolates through prolonged patient exposure to medical 
triazoles [39]. One TR34/L98H isolate from Italy was of CSP type t05, but it still grouped 
with the other TR34/L98H isolates in the microsatellite analysis. Further work is required to 
determine if CSP type t05 azole-resistant isolates are widespread in Italy and/or have spread 
to other countries. 
A second key finding of the present study was that sexual reproduction, recently discovered in 
A. fumigatus [21], can occur between isolates of different CSP types and TR34/L98H genotypes 
to give rise to isolates with novel combinations of the TR34/L98H resistance mechanism in 
other CSP types. The finding that TR34/L98H isolates are sexually fertile provides a possible 
explanation for their genetic diversity. It is hypothesized that very few sexual cycles in the 
field would give rise to progeny exhibiting the degree of CSP variation observed in this study. 
Indeed, this is supported by the presence of both MAT1-1 and MAT1-2 isolates in the t02, 
t04B, and t11 CSP types. The accessory role of sexual reproduction was also suggested 
by a recent report which found that the TR34/L98H genotype was nested within a single, 
predominantly asexual population [20]. Figure 1 suggests that sexual reproduction played 
a role in the early stages of development of azole resistance, as all three CSP types were 
already present in TR34/L98H isolates in The Netherlands by the year 2002. Moreover, the 
Norwegian isolate from 2000, not included in the analysis of Dutch isolates, grouped to CSP 
type t02, indicating that all three CSP types were already present in the initial years of TR34/
L98H emergence. After sexual reproduction, subsequent asexual reproduction would most 
probably lead to persistence of these isolates and CSP types, given that after 100 (in vitro) 
asexual generations, no variations in CSP type were found (C.H.W. Klaassen, unpublished 
data). In the meantime, the number of repeats in microsatellite markers might undergo 
5123
Molecular epidemiology of isolates harboring the TR34/L98H mechanism
subtle changes during asexual reproduction (C.H.W. Klaassen, unpublished data), leading to 
the observed diversity in microsatellite markers. 
Overall, our findings suggest a common origin of the TR34/L98H mechanism and the 
subsequent migration of TR34/L98H isolates across Europe. A similar spread of fungicide 
resistance has been shown before in plant pathogens: in the wheat pathogen Mycosphaerella 
graminicola, mutations causing resistance arose locally and were then spread across Europe 
through wind-dispersed ascospores [37,40], and in the grape pathogen Botrytis cinerea, 
resistant isolates probably migrated from French to German wine-growing regions [41]. More 
research into the genesis of the TR34/L98H mechanism is needed in order to understand the 
conditions that facilitate azole resistance development in the environment so that measures 
can be implemented to prevent the emergence of new resistance mechanisms.
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Abstract
Azole-resistance is an emerging problem in Aspergillus fumigatus and complicates the 
management of patients with Aspergillus diseases. Selection of azole resistance may occur 
through exposure to azole fungicides in the environment. In the Netherlands a surveillance 
network was used to investigate the epidemiology of resistance selection in A. fumigatus.
Clinical A. fumigatus isolates were screened for azole resistance in eight University Hospitals 
using azole agar dilution plates. Patient information was collected and azole-resistant 
A. fumigatus isolates were analyzed using gene sequencing, susceptibility testing and 
genotyping. Recombination experiments were performed to link identified mutations to 
resistance phenotypes. Air sampling was performed to investigate the presence of resistant 
isolates in the environment.
Between December 2009 and January 2011 1,315 A. fumigatus isolates from 921 patients 
were screened. A new Cyp51A-mediated resistance mechanism (TR46/Y121F/T289A) emerged 
in 21 azole-resistant isolates from 15 patients in six hospitals. Eleven patients had no history 
of previous azole exposure. TR46/Y121F/T289A isolates were highly resistant to voriconazole 
(MIC ≥16 mg/l). Eight patients presented with invasive aspergillosis, and all five patients 
receiving primary therapy with voriconazole failed. Recombinant experiments confirmed 
the link between TR46/Y121F/T289A and the resistant phenotype. TR46/Y121F/T289A was 
recovered from 6 of 10 sampled environmental sites. 
We describe the emergence and migration of a new pan-azole resistance mechanism in 
A. fumigatus. The similar epidemiology and clinical characteristics of TR46/Y121F/T289A to 
the TR34/L98H resistance mechanism point towards a fungicide-driven route of resistance 
selection. We believe that the current use of azole fungicides in our environment has serious 
side effects, such as the continued selection and migration of resistance traits in A. fumigatus 
and the loss of the azole class for the management of patients with Aspergillus diseases.
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Introduction
The medical triazoles itraconazole, voriconazole and posaconazole are the primary antifungal 
agents currently used in the management of infections caused by the saprophytic mould 
Aspergillus fumigatus. These triazoles are clinically licensed for the prevention and treatment 
of both non-invasive Aspergillus diseases as well as invasive aspergillosis [1]. Acquired 
resistance in A. fumigatus has long been perceived as a manageable problem as resistance 
development during azole therapy has been reported with only a very low frequency [2-4]. 
However, culture may underestimate the presence of resistance [5], and A. fumigatus isolates 
that harbor a resistance mechanism are commonly resistant to multiple triazoles [6-9].
In the Netherlands a second route of resistance development was suggested where clinical 
A. fumigatus isolates may have become resistant through environmental exposure to 
14α-demethylase inhibitors (DMIs) [6,10-12]. DMIs inhibit fungal Cyp51A activity and are 
abundantly used for crop protection and material preservation. Five DMIs showed in vitro 
activity against A. fumigatus, and were, similar to the clinically licensed azoles, from the 
triazole class [11]. The environmental mode of resistance development is of major importance 
as over 90% of Dutch clinical azole-resistant isolates are believed to have originated through 
this mode of resistance development [6,7,12]. The first resistance mechanism that is believed 
to be of environmental origin consists of a substitution at codon 98 in the cyp51A gene in 
combination with a 34 base pair tandem repeat in the gene promoter (TR34/L98H). DMIs 
that exhibit similar docking poses to the medical triazoles showed complete loss of activity 
against A. fumigatus isolates that harbor TR34/L98H, giving further evidence for a possible 
environmental route of resistance development in A. fumigatus [11].
TR34/L98H first emerged in Dutch clinical A. fumigatus isolates in 1998 and a National 
surveillance study indicated that this resistance mechanism is now endemic in Dutch hospitals 
and infections may occur in azole-treated as well as in azole-naïve patients [6,7]. TR34/L98H is 
increasingly reported in other European countries, and more recently also in China and India 
[6,13-21]. Molecular typing studies indicate that the fungicide-driven route of resistance 
development carries the risk of migration of this resistance trait, similar to azole-resistant 
phytopathogenic fungi [22].
In our current study we investigated the emergence of a new azole resistance mechanism 
in A. fumigatus. Our hypothesis was that this new azole resistance mechanism has emerged 
through an environmental route of resistance selection. We investigated the underlying 
resistance mechanism, describe the epidemiology and clinical implications, and performed 
environmental sampling to determine if the new resistance mechanism was present in our 
environment.
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Methods
Surveillance network
Between May 2009 and January 2011 all Aspergillus isolates cultured from clinical samples 
that were processed in medical microbiology laboratories of the eight University Medical 
Centres in the Netherlands were routinely screened for the presence of azole-resistance, 
irrespective of the clinical relevance of the culture result. An on-line questionnaire was 
completed in seven out of eight centres for every collected isolate, which included questions 
about isolate and patient characteristics. In one centre the questionnaire was only fulfilled 
for resistant isolates.
Screening: four-well azole-agar dilution plates
Aspergillus colonies that grew in primary cultures were subcultured on a specially developed 
four-well azole-agar dilution plate (4D-plate) [23]. All wells contained RPMI-1640 agar 
and three wells were each supplemented with one of the azoles; itraconazole (4 mg/l), 
voriconazole (1 mg/l) or posaconazole (0.5 mg/l). The fourth well contained no azole and 
served as growth control. The 4D-plates were incubated at 37°C and growth was assessed 
after 48 hours. For every isolate that was able to grow on any of the azole-containing wells, 
the primary culture isolate was sent to the Radboud University Nijmegen Medical Centre 
for further analysis. For those isolates that grew only on the control well, the web-based 
questionnaire was completed, but the isolate was considered azole-susceptible and not 
further analyzed. At the screening sites the Aspergillus isolates were identified to the species 
level by conventional methods, i.e. the ability to grow at 48°C and macro- and microscopic 
culture morphology.
Phenotypic analyses
All A. fumigatus isolates that grew on one or more azole-containing agar wells were 
investigated for their antifungal susceptibility to itraconazole, voriconazole, posaconazole, 
and the DMI tebuconazole using the CLSI M38-A2 broth microdilution reference method [24].
Genotypic analyses
For resistant isolates that were confirmed to exhibit a non-wild type phenotype, the full coding 
sequence of the cyp51A gene and promoter region was determined by PCR amplification and 
sequencing to detect any mutations (reference cyp51A sequence: GenBank AF338659) [25]. 
Molecular identification was performed by sequencing the highly conserved β-tubulin and 
calmodulin gene, as described previously [26].
Microsatellite genotyping was used to investigate genetic distances between the isolates by 
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analysis of six microsatellites (STRAf 3A, 3B, 3C, 4A, 4B, and 4C), as described previously [6]. If 
multiple resistant isolates were obtained from one patient, only the first isolate was included. 
For every resistant isolate, two control isolates were selected that had been cultured 
between one month before and one month after the date of isolation of the resistant isolate. 
One control isolate harbored the TR34/L98H resistance mechanism, while the other exhibited 
a wild type phenotype. From the microsatellite data, allele sharing distance matrices were 
generated and these matrices were used as input for the Neighbor program of the PHYLIP 
software package to produce the dendrogram [27].
Cyp51A homology model
The locations of the observed amino acid substitutions of the presumed novel resistance 
mechanism were investigated with help of a structural model of the A. fumigatus Cyp51A 
enzyme. This homology model was described previously and was constructed based on the 
human Cyp51 crystal structure [11].
A. fumigatus recombinants
To confirm the link of the presumed new resistance mechanism with the azole-resistant 
phenotype, A. fumigatus recombinants were created as described before [28]. Alterations 
were introduced into a cyp51A cassette and subsequently the mutated cassette was 
electroporated into a susceptible A. fumigatus transformation recipient isolate. Susceptibility 
testing of the recombinants, the transformation recipient and transformation control isolate 
(i.e. A. fumigatus transformed with a wildtype cassette) was performed as described above.
Patient characteristics
The web-based database was used to retrieve clinical information of the patients with a 
culture yielding A. fumigatus. For patients harboring an azole-resistant isolate the following 
additional information was recorded: the presence of Aspergillus disease, azole exposure 
within 12 weeks preceding the culture of the resistant isolate, treatment and outcome at 
12 weeks. Invasive aspergillosis was classified according to the European Organization for 
Research and Treatment of Cancer and Mycoses Study Group (EORTC)/MSG consensus 
definitions for those patients with cancer [29]. Human experimentation guidelines from the 
Committee on Research Involving Human Subjects Arnhem–Nijmegen were followed in the 
conduct of this research.
Environmental sampling
The presence of A. fumigatus resistant to medical triazoles in the environment was 
investigated through sampling at the Radboud University Nijmegen Medical Centre, the 
University Medical Centre Groningen, and 8 domestic homes (six in the Nijmegen area and 
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two in the Groningen area). Indoor sites and one site in the direct outdoor proximity were 
sampled. Air samples were obtained using an air sampler type Casella (Cat No E7627/Z-24). 
Cultures of airborne viable fungi were performed on Sabouraud agar. For selection of azole-
resistant fungi Sabouraud agar supplemented with itraconazole (4 mg/l) or voriconazole (1 
mg/l) were used. The volume of air that was sampled was 14,000 l (700 l/min; 20 min) to 
detect azole-resistant spores. The plates were incubated at 37°C and inspected twice daily 
for four days.
Any colony that grew on the agar supplemented with azoles was subcultured on a Sabouraud 
agar slant and was identified as A. fumigatus using colony morphology and microscopic 
characteristics. A. fumigatus isolates were screened for the presence of an insertion in the 
promoter region of the cyp51A gene by previously described PCR primers and conditions 
[22]. Tandem repeats of different sizes could be identified on the basis of the size of the 
amplified PCR fragment.
Isolates containing the TR34 were screened for the presence of the L98H substitution by using 
two PCR reactions: a L98- and a L98H specific PCR (primers described elsewhere) [22]. Azole-
resistant isolates without TR34/L98H were selected for sequencing the cyp51A gene- and 
promoter region as described above [25].
Results
Emergence of the new resistance mechanism
In January 2010 a clinical A. fumigatus isolate originating from Nijmegen grew on the well 
containing voriconazole, and not on those containing itraconazole or posaconazole. In vitro 
susceptibility testing showed no activity of voriconazole (MIC >16 mg/l), and attenuated 
activity of itraconazole (MIC 2 mg/l) and posaconazole (MIC 0.5 mg/l) (Table 1). Sequence 
analysis of the cyp51A gene showed the presence of two mutations leading to substitutions 
Y121F and T289A. In addition, a 46 base pair tandem repeat was found in the gene 
promoter (TR46/Y121F/T289A). A second isolate was cultured in January 2010 from a patient 
in Amsterdam which exhibited a similar voriconazole-resistant phenotype and identical 
TR46/Y121F/T289A resistance mechanism (Table 1).
The culture collection of the surveillance network was then investigated for isolates with 
a voriconazole MIC of ≥16 mg/l. Since May 2009, when screening of isolates using the 
4D-plates had begun, five of 33 azole-resistant isolates were identified with a voriconazole 
MIC of ≥16 mg/l. Sequence-based analyses of the cyp51A gene of these isolates identified a 
third isolate, harboring the TR46/Y121F/T289A resistance mechanism, that had been cultured 
on December 31st 2009 in Utrecht. This was considered to be the first clinical isolate from our 
surveillance network to harbor the TR46/Y121F/T289A resistance mechanism.
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Prevalence of the TR46/Y121F/T289A resistance mechanism
From December 2009 to January 2011, 1,315 A. fumigatus isolates from 921 patients were 
screened for resistance in seven out of eight university centres. In one centre the total number 
of isolates screened was unknown, as they did not complete the on-line questionnaire for 
their susceptible isolates. The overall prevalence of azole resistance was 6.8% (63 of 921 
patients). 47 of 63 patients (74.6%) harbored the TR34/L98H resistance mechanism and 13 
patients (20.6%) TR46/Y121F/T289A. No cyp51A mutations were found in azole-resistant A. 
fumigatus isolates from three patients (4.7%). The prevalence of TR46/Y121F/T289A was 1.4% 
(13 of 921 patients) in this 14 month period. Besides this, two isolates with TR46/Y121F/T289A 
and two isolates with TR34/L98H were recovered from the centre which had not recorded the 
total number of screened isolates. Therefore, within 14 months (December 2009 to January 
2011) TR46/Y121F/T289A was detected in 21 clinical A. fumigatus isolates obtained from 15 
patients in six different University hospitals in the Netherlands (i.e. Amsterdam (2 hospitals), 
Groningen, Leiden, Nijmegen, Utrecht) (Table 1).
Characterization of TR46/Y121F/T289A isolates
The 21 TR46/Y121F/T289A isolates were identified as A. fumigatus based on sequence 
analysis of the β-tubulin and calmodulin genes and voriconazole showed no in vitro activity 
against any of the isolates (MIC ≥16 mg/l). The activity of itraconazole and posaconazole 
was attenuated in the majority of the isolates (Table 1). The DMI tebuconazole, which has 
been shown to exhibit activity against wild-type A. fumigatus isolates, showed no in vitro 
activity against TR46/Y121F/T289A isolates. One isolate with TR46/Y121F/T289A contained two 
additional substitutions; M172I and G448S.
The location of Y121 and T289 in the Cyp51A protein structure was checked based on the 
Cyp51A homology model. The model showed that Y121 was in direct contact with the haem 
group in the centre of the enzyme, while T289 was situated in one of the two ligand access 
channels (Figure 1).
A. fumigatus recombinants were constructed with the presumed TR46/Y121F/T289A 
resistance mechanism (Table 2). As shown in Table 3, the TR46/Y121F/T289A recombinants 
showed no susceptibility of voriconazole, while the MIC of posaconazole increased from 
<0.031 to 0.25-0.5 mg/l. For itraconazole the MIC appeared to remain similar to that of the 
control isolate. Tebuconazole was active against the wild-type recipient isolate, but showed 
no activity against the TR46/Y121F/T289A recombinant (Table 2).
Microsatellite genotyping showed that clinical TR46/Y121F/T289A isolates clustered together. 
TR46/Y121F/T289A and TR34/L98H were separated into different clades and apart from wild 
type control isolates (Figure 2).
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Figure 1. The location of the Y121F and T289A substitutions in the Cyp51A homology model. The two 
ligand access channels are indicated in green.
Table 2. Primer sequences used to obtain the TR46, Y121F and T289A alterations into the cyp51A 
cassette. TR46 was introduced by PCR amplification of the promoter region of a clinical isolate harboring 
this repeat and subsequently ligating it into the cassette, as was described before for TR34 [28]. Y121F 
and T289A were subsequently introduced by site- directed mutagenesis [28].
Cyp51A alteration Primer sequences (5’- 3’)
TR46 GGAATAGACGCCGTTTACCA
GCCATACTGCCGGTTAAGAA
Y121F TTCGGATCGGACGTGGTGTTTGATTGTCCCAATTC 
GAATTGGGACAATCAAACACCACGTCCGATCCGAA
T289A CCATCAACAGGGCTATCATCATGTGCGCAATCTCTT
AAGAGATTGCGCACATGATGATAGCCCTGTTGATGG
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Table 3. Phenotype of the transformation recipient, transformation control without any mutations in 
the cassette and two TR46/Y121F/T289A recombinants obtained from two separate electroporation 
experiments.
MIC (mg/l)*
Isolate ITZ VCZ POS TBZ
Transformation recipient 0.25 0.5 <0.031 2
Transformation control 0.25 0.5 <0.031 2
TR46/Y121F/T289A 0.5 >8 0.5 >8
TR46/Y121F/T289A 0.5 >8 0.25 >8
*ITZ, itraconazole; VCZ, voriconazole; POS, posaconazole; TBZ, tebuconazole.
Figure 2. Allele sharing distance matrices of the microsatellite genotypes of the clinical and environmental 
resistant TR46/Y121F/T289A isolates, compared with TR34/L98H and wild type controls. Red dots, 
TR46/Y121F/T289A isolates from clinical origin; red squares, TR46/Y121F/T289A isolates from 
environmental origin; blue dots, TR34/L98H isolates; green dots, wild type isolates.
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Clinical characteristics
Among the 15 patients identified with a TR46/Y121F/T289A isolate, eight were diagnosed 
with azole-resistant invasive aspergillosis (Table 1). Three of these patients were classified 
as probable disease and four as proven. One patient could not be classified according to 
the EORTC/MSG consensus definitions [29]. This patient showed bone destruction of the 
skull on CT scan and A. fumigatus was recovered repeatedly from the ear, without any other 
explanation. All patients with invasive aspergillosis due to TR46/Y121F/T289A were azole-
naive, except one patient with probable and one patient with proven invasive aspergillosis. 
At 12 weeks after recovery of the TR46/Y121F/T289A isolate four patients had died, and 
two patients had persisting infection. All patients who died had received primary therapy 
with voriconazole, while the only two patients who survived received primary therapy with 
liposomal amphotericin B (Table 1).
Environmental sampling
A total of 140 azole-resistant A. fumigatus colonies were identified, recovered from 21 
locations at 9 different sites (outdoor and indoor). From three samples (entrance of one 
of the hospitals and two domestic homes) A. fumigatus colonies could not be recovered 
due to abundant growth of zygomycetes. Analysis of the cyp51A gene and the promoter 
region showed that 126 (90%) isolates harbored TR34/L98H, while 14 (10%) harbored the 
new TR46/Y121F/T289A resistance mechanism. Both resistance mechanisms were found 
in the Nijmegen and Groningen area. In 6 out of 10 sampled sites the TR46/Y121F/T289A 
resistance mechanism was found, while TR34/L98H was recovered from 9 of 10 sites (Table 
4). The genotypes of 11 out of the 14 environmental TR46/Y121F/T289A isolates grouped 
together with the clinical TR46/Y121F/T289A isolates, irrespective of the geographic site of 
recovery, whereas susceptible control isolates and TR34/L98H isolates generally clustered in 
different clades (Figure 2).
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Table 4. Recovery of azole-resistant A. fumigatus isolates through environmental air-sampling of 14,000 
litre per location.
Site City Location Number of 
resistant 
colonies
TR46/Y121F/
T289A
TR34/L98H
1 Nijmegen Hospital restaurant 3 - 3
Hospital pediatrics department 9 2 7
Hospital outside 5 - 5
2 Schaijk Living room 2 - 2
Basement 3 - 3
Back yard 7 - 7
3 Schaijk Living room 1 - 1
Conservatory 5 - 5
Back yard 3 - 3
4 Overasselt Kitchen 6 1 5
Basement 7 - 7
Back yard 7 - 7
5 Schaijk Living room 6 - 6
Basement 3 - 3
Back yard 3 - 3
6 Berghem Living room - - -
7 Schaijk Hall 13 3 10
Balcony 6 - 6
8 Groningen Entrance hospital* - - -
Outside hospital 29 2 27
9 Scharmer Living room 4 1 3
Back yard 6 3 3
10 Garmerwolde Living room* - - -
Back yard 12 2 10
*For these sites the agar plates, supplemented with azoles, were rapidly overgrown with zygomycetes 
thereby precluding the opportunity to select suspected azole-resistant A. fumigatus colonies.
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Discussion
We describe the emergence and migration of a new azole-resistance mechanism in 
A. fumigatus, a major cause of fungal diseases in humans. The new TR46/Y121F/T289A 
resistance mechanism conferred high resistance to voriconazole and was associated with 
treatment failure in patients with invasive aspergillosis. Isolates harboring TR46/Y121F/T289A 
were recovered from the environment indicating that selection through a fungicide-driven 
route could have taken place.
TR34/L98H was the first resistance mechanism that has been recovered from both clinical 
specimens and from the environment in the Netherlands. This resistance mechanism first 
emerged in clinical A. fumigatus isolates in 1998 [4,6]. A Dutch survey, performed between 
2007 and 2009, showed that TR34/L98H was widespread and that the prevalence varied 
between 0.8 and 9.5% [7]. TR34/L98H was found in azole-resistant A. fumigatus isolates 
that were recovered from environmental sources, such as soil and compost [10]. A second 
resistance mechanism reported in the Netherlands was a 53 base pair tandem repeat 
(TR53) without mutations in the cyp51A gene. TR53 was associated with a pan-azole resistant 
phenotype and was reported to have caused Aspergillus osteomyelitis in a paediatric patient 
in 2006 [30]. Although a TR53 isolate was recovered from the environment (unpublished 
observations), there is currently no evidence for migration of this resistance mechanism. 
Our current study describes TR46/Y121F/T289A as the third resistance mechanism that has 
emerged in clinical and environmental isolates.
Similar to TR34/L98H [11], the fungicide-driven route of resistance development could have 
caused the emergence of TR46/Y121F/T289A. Both resistance mechanisms consist of a 
combination of genomic changes that include a tandem repeat [15,28]. The new resistance 
mechanism included three genomic changes, and it appears unlikely that these would have 
evolved during azole therapy in all individual cases. Until now only point mutations have been 
described to have developed in azole-resistant A. fumigatus isolates through patient therapy 
[14,25]. Both TR34/L98H and TR46/Y121F/T289A were recovered from epidemiologically 
unrelated patients, most of which were azole-naïve and both resistance mechanisms were 
recovered from the environment. Furthermore, genetic typing showed clustering of TR34/
L98H and TR46/Y121F/T289A in separate clades apart from wild type isolates.
The evolving epidemiology of TR34/L98H indicates that this resistance mechanism is not 
restricted to the Netherlands, but is increasingly being observed in other European member 
states [6,13-19], and outside Europe [20,21]. Genotyping indicates that TR34/L98H isolates 
represent offspring of a common ancestor [22], and could have developed locally, possibly in 
the Netherlands, and subsequently spread across countries through wind dispersed conidia 
or ascospores. Given the rapid migration of TR46/Y121F/T289A in Dutch hospitals, it can be 
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anticipated that this resistance mechanism will spread, similar to TR34/L98H.
Resistance threatens the outcome of patients with Aspergillus diseases, especially those 
with azole-resistant invasive aspergillosis. Nearly 80% of TR34/L98H isolates were resistant 
to voriconazole and in patients with azole-resistant invasive aspergillosis the case-fatality 
rate was 88% [7]. Voriconazole, which is recommended for the primary therapy of invasive 
aspergillosis, was uniformly inactive against TR46/Y121F/T289A isolates and all patients with 
proven or probable invasive aspergillosis that had received primary therapy with voriconazole 
failed. As the activity of itraconazole and posaconazole was also reduced in the majority of 
the isolates, the azole class appears not to be a treatment option in patients with infection 
with A. fumigatus harboring TR46/Y121F/T289A.
Systematic surveillance through a network of clinical microbiology laboratories proved to be 
a useful strategy to detect the emergence and spread of the new resistance mechanism in 
A. fumigatus. Given the observed spread of azole resistance across Europe we believe that 
international surveillance programs are warranted. Our surveillance network is limited by the 
fact that screening is performed with cultures and therefore culture-negative azole-resistant 
cases will not be detected. Furthermore, there is no control group of patients with azoles-
susceptible Aspergillus disease. A case-control design would help to quantify the implications 
of azole resistance with respect to treatment outcome and might identify risk factors.
We believe that our observations are very worrisome as they indicate that continued use of 
triazole DMIs in our environment with activity against A. fumigatus will not only help resistance 
traits to sustain in the environment, but will also cause new resistance mechanisms to 
emerge. The potential of migration, as observed with TR34/L98H, indicates that the fungicide-
driven route of resistance selection will not remain a regional problem. Unless we are able 
to implement measures that prevent fungicide-driven resistance selection, the clinical use 
of azoles will become severely compromised. It is therefore important to understand the 
conditions that allow for selection of resistance in the environment and to investigate which 
preventive measures might be effective.
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Germinating Neosartorya fumigata (teleomorph of A. fumigatus) ascospore on Sabouraud  agar 
(picture: Ton Rijs and Simone Camps).
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General discussion
Fungi are vastly underestimated as a problem of high disease impact for plants and animals. 
Fungal infections are emerging and current data indicate that fungi pose an increasing threat 
to plant and animal biodiversity [1]. This might be facilitated by high host- and environmental 
adaptation capacities of fungi. One example of environmental adaptation, described in this 
thesis, is the emergence of azole resistance in A. fumigatus, which is an increasingly important 
and threatening problem in the treatment of Aspergillus diseases.
A. fumigatus may follow two routes of resistance development: (i) during medical treatment 
of individual cases and (ii) through exposure to fungicides in the environment. Induction of 
resistance during medical treatment involves infection of the patient with an azole-susceptible 
A. fumigatus isolate that becomes resistant during therapy. This reflects in principle only 
individual patients. It is not expected that these resistant isolates will further spread, because 
a high diversity of resistance mechanisms has been found in individual patients. Furthermore 
patient-to-patient transmission is, if ever, extremely rare. The environmental route of 
resistance development or selection concerns exposure of A. fumigatus to azole fungicides, 
which are widely used in our environment. The widespread and intensive use of azole 
fungicides might induce resistance or select for resistant A. fumigatus isolates, and might 
create a selective pressure and optimal environment for resistant isolates to grow and spread. 
It is unknown whether azoles itself are mutagenic, thereby having the capacity to induce 
resistance. Another possibility is that other (environmental) factors such as ultraviolet light 
induce azole resistance by causing genetic alterations. In the latter situation, environmental 
resistance mechanisms such as TR34/L98H, might have pre-existed in minute amounts in 
the population even before fungicides were applied. The mutations would then confer no 
advantage to the growth or survival of A. fumigatus, hence it would remain at a very low 
frequency. Once fungicides were applied, isolates harboring the resistance mechanism had 
a selective advantage (‘the survival of the fittest’) [2] and a building up of resistance would 
occur after repeated fungicide applications. Interestingly, evidence is now accumulating that 
antimicrobial resistance might also be predating human use of antibiotics in some cases [3]. 
Thus, not only ‘induction’ is a possible cause of resistance, but also ‘selection’ (of pre-existing 
variants) is a possibility. 
Scale of the problem
In the year 2008, the emergence of environmental azole resistant Aspergillus fumigatus 
was already predicted [4]. Four years later, in many European countries (Austria, Belgium, 
Denmark, France, Germany, Italy, The Netherlands, Norway, Spain and the United Kingdom) 
and in Asia (China, Japan, Iran) azole resistance through the environmental route has been 
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described [4-13]. The prevalence of azole resistance in Nijmegen, The Netherlands increased 
from 0 to almost 8% within a period of 10 years [14] which is relatively fast on evolutionary 
time scales. What will happen if we do nothing? I expect that azole resistant A. fumigatus 
continues to spread globally and that the prevalence might increase further. Furthermore, 
more environmental resistance mechanisms will emerge and spread all over the world, such 
as the Cyp51A TR46/Y121F/T289A alterations described in this thesis. If the trend continues, 
the prevalence of azole resistance will increase to at least 50% within the years to come. A 
recent report describes that the overall mean burden estimate of all forms of aspergillosis 
is approximately 2,400,000 affected individuals annually (only in Europe) [15]. If spread 
continues and prevalence further increases, azole resistance will be highly problematic for 
millions of people around the world. 
To further discuss resistance,  different aspects need to be examined in detail. Therefore, I will 
address the problem of azole resistance in A. fumigatus from different perspectives.
If I were a patient
Resistance is associated with treatment failure [4,6,16-18] and animal studies show that 
the efficacy of azoles is reduced in mice infected with resistant isolates [19-20]. The current 
treatment options for patients with azole resistant aspergillosis are limited but might include 
an increase of drug exposure, the application of combination therapy, or non-azole class 
drugs. If I were a patient, I would say that it is of key importance to investigate these options 
without further delay to treat patients with infections caused by azole resistant A. fumigatus 
effectively. In addition, the possibilities of preventive measures for risk groups (i.e. vaccination) 
should be investigated. Furthermore, I would like to have a more personalized therapy based 
on my underlying immune status, and the resistance mechanism (susceptibility phenotype) 
of the A. fumigatus isolate causing the infection.
Besides investigating alternative treatment strategies, another important pillar in treating 
fungal infections is early detection of infection. I would like to be monitored for resistance such 
that treatment might be changed as rapid as possible, if required. Culture and subsequent 
in vitro susceptibility testing methods are very time consuming, although screening methods 
using azole-containing agars can shorten the laboratory turnaround time [21]. Another 
disadvantage of monitoring by classic culturing methods is a high culture negativity. Therefore, 
molecular tools might be used to detect resistance mutations directly in biological samples. 
These methods should be further developed and validated.
If I owned a pharmaceutical company
Azoles are the major drug class in the management of Aspergillus diseases. Current treatment 
options for patients suffering from azole resistant A. fumigatus disease are limited, and there 
are no drugs in phase III development that act on a new target. There is one new triazole 
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in phase III development (isavuconazole) [22], but it is not active against azole-resistant A. 
fumigatus in vitro [12]. In vivo models of azole-resistant infection are awaited to establish 
if this drug might be useful as treatment for patients with azole resistant Aspergillus 
diseases. A new intravenous formulation of posaconazole is underway which is believed to 
overcome the problems of exposure with the current oral solution. As posaconazole shows 
an attenuated activity against most A. fumigatus isolates that harbor a cyp51A-mediated 
resistance mechanism, increasing exposure in patients with azole resistant disease might 
be an option. Recent in vivo experimental data suggest that liposomal amphotericin B is 
effective irrespective of the presence of an azole resistance mechanism [23]. The efficacy of 
this drug in the treatment of central nervous system infection however is lower than that of 
voriconazole [24].
Discovery of new pathogen-specific targets is very complicated, as fungi are metabolically 
similar to mammalian cells. However, disease burden of invasive aspergillosis is high and new 
antifungal agents are required. If I were the owner of a pharmaceutical company, I would 
test newly developed azoles, antifungals with other targets, new formulations of current 
drugs, antibody-based therapeutics or prophylactic vaccinations [25] for their activity against 
(resistant) A. fumigatus.
If I were a farmer
Although there is accumulating evidence supporting the hypothesis that resistance has 
evolved in the environment under the selective pressure of azole fungicides, the link is not 
yet fully proven [15]. As a farmer I need fungicide treatment for maintaining healthy crops 
and reliable, high-quality yields [2]. According to scientific research, the five fungicides 
cross-reacting with medical azoles are bromuconazole, difenoconazole, epoxiconazole, 
propiconazole and tebuconazole. Bromuconazole is currently not permitted for use in The 
Netherlands [personal communication P. van der Haas, Mertens B.V. Horst, The Netherlands] 
so this agent does not represent a danger nowadays. Simply prohibiting the use of the 
other four fungicides is not feasible, as this might result in crop disease epidemics and 
subsequent food shortages and economic losses. However, in some cases I can choose for 
another antifungal. For example, I can apply prothioconazole instead of epoxiconazole or 
propiconazole. Difenoconazole and tebuconazole are used both singly and in combination 
with other fungicides [personal communication P. van der Haas, Mertens B.V. Horst, The 
Netherlands]. Maybe I should use them only in mixtures with effective multi-site or other 
non-cross-resistant fungicides to prevent survival of resistant A. fumigatus, but unfortunately 
this is not cost-effective. In the meantime, an analysis should be made to investigate whether 
other azole fungicides or fungicides of a different targeting class could be used in non-medical 
applications, with the purpose to keep the medical azoles effective for treatment of patients.
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If I were a policy maker
During the last years, azole resistance in A. fumigatus gained some political attention. 
The Dutch National Institute for Public Health and the Environment (Rijksinstituut voor 
Volksgezondheid en Milieu, RIVM) yearly publishes a report ‘State of Infectious Diseases in 
the Netherlands’. This report describes the current insight into developments of infectious 
diseases in the Dutch population and it is compiled for policymakers at the Ministry of 
Health, Welfare and Sport (Ministerie van Volksgezondheid, Welvaart en Sport, VWS). The 
report of the year 2009 described for the first time the emergence of azole resistance in 
A. fumigatus. Moreover, the report warned for a further increase and stated that treatment 
options of the life threatening infections would then be substantially limited [26]. In the year 
2010, the Dutch politician Marianne Thieme addressed several questions to the Ministry 
of Housing, Spatial Planning and the Environment (Volkshuisvesting, Ruimtelijke Ordening 
en Milieubeheer, VROM) and to the Ministry of Agriculture, Nature and Food Quality 
(Landbouw, Natuur en Voedselkwaliteit, LNV), regarding the harmful effects of resistant fungi 
in hospitals [27]. Furthermore, in the same year the Bureau Risk Assessment and Research 
Programming (Bureau Risicobeoordeling en onderzoeksprogrammering, BuRO) presented 
their risk assessment to the Ministries of LNV, VROM, and VWS. It was concluded that current 
knowledge is limited and that additional research needs to be performed before measures 
can be taken to prevent further increase and spread of resistance. The same conclusions 
were drawn by experts of the European Centre for Disease Prevention and Control (ECDC), 
who held two meetings to discuss the increasing problem of azole resistance in A. fumigatus 
(in April 2011 and January 2012).
Unfortunately, a few years after the first warning signs emerged, still little is known about 
the impact of azole resistant A. fumigatus. If I were a policy maker, I would say that it would 
be justified to direct more funds into the research of azole resistant aspergillosis. There 
is an urgent need for in-depth understanding of azole resistance to provide an improved 
knowledge base for governmental policy making. The lack of funding and the lack of research 
reminds me of the Q-fever outbreak, where the Dutch government also acted very restraint 
and slow, and the problem was not treated with high priority [28]. The problem of azole 
resistance also reminds me of the overuse of antibiotics in animal husbandry, which is known 
to have caused resistance in the human population.
I would emphasize that international surveillance studies and extensive programs of 
resistance monitoring into the field are warranted to investigate the size of the emerging 
problem of azole resistance more precisely. Possibly, geographic variations in the occurrence 
of resistance might be found. Regions with the highest incidence of resistance (‘hot spots’) 
might indicate the most intensive use of the at-risk fungicide(s) [29]. It needs to be analyzed 
what the effect will be in case the use of the five fungicides that had a high level of cross 
resistance is discontinued or reduced. It should be investigated whether it will result in a 
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decrease of the proportion of resistant A. fumigatus present in our environment. For example, 
field competition studies using various proportions of susceptible and resistant isolates could 
be used to observe the effect with and without fungicide pressure. Although limiting the use 
of the five azole fungicides might prevent additional resistance mechanisms to emerge, this 
might not be enough to stop resistance selection. Additional fungicides might cause cross-
resistance to other Aspergillus species or other medically important fungi present in our 
environment. Therefore, monitoring should not be limited to A. fumigatus. In addition, non-
agricultural studies are also warranted because azoles are also widely applied in industry.
When an increased knowledge about azole resistance in A. fumigatus is obtained, we, as 
policy makers, should discuss how to perform effective prevention and control. Obviously, 
policy making should not be restricted to the Netherlands, but should be at European scale 
or even worldwide.
If I were a postdoc
The emerging problem of azole resistance in Aspergillus fumigatus and the postulated 
relationship with azole fungicide use has been met with skepticism and disbelief by physicians 
and researchers [30]. Obtaining research funding is problematic, as applications for funding 
have been refused because some reviewers do not endorse the scale and importance of the 
problem. 
If I were a postdoc, I would like to investigate all the above mentioned research questions. But 
further research should not be limited to analyzing the effect of fungicide use, determining 
optimal treatment strategies, and policy making. It should also be aimed at understanding the 
exact conditions under which resistance mechanisms develop. Are azoles itself mutagenic or 
do other (environmental) factors play an important role in resistance development? 
During medical treatment, azole resistance emerged in patients with chronic pulmonary 
aspergillosis and pulmonary aspergilloma, but not in patients with acute invasive aspergillosis 
[31]. Probably, in the case of aspergilloma or cavitary Aspergillus disease, the fungus is able 
to undergo multiple generations by the asexual way of reproduction. Sporulation (in the lung) 
may be important to facilitate the expression of the azole resistant phenotype, as opposed 
to hyphal growth which is typically found in acute invasive aspergillosis [32]. Possibly, not 
the asexual, but the sexual cycle is essential for the environmental developed resistance. 
Sexual reproduction would be expected to maintain genetic variation within populations, 
with the constant opportunity to generate novel genotypes. This is critical to allow response 
to environmental change, enable long-term survival and evolution of the species, and might 
produce offspring with increased resistance to antifungal agents [33-34]. It was proposed 
before that sexual recombination would promote a pathogen’s ability to evolve quickly in 
response to fungicides [35] and sexual crossing between isolates of the phytopathogen 
Tapesia yallundae has been shown to result in progeny with markedly increased resistance to 
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azole fungicides compared to the original parental isolates [36].
The A. fumigatus ‘environmental’ resistance mechanisms are complex as they contain at least 
two genomic changes, including the insertion of a tandem repeat in the cyp51A promoter 
region (TR34, TR46, or TR53). A resistance mechanism involving more than one genomic alteration 
could develop through multiple sequential events or through a single event. For example, in 
the case of TR34/L98H either the 34 basepair tandem repeat or the L98H substitution was 
introduced first, and then through continued evolution the other alteration was induced, 
or intragenic recombination occurred among the two pre-existing variants (TR34 and L98H) 
already present. The latter situation was found in M. graminicola, where combinations of 
cyp51 mutations evolved through intragenic recombination and subsequently reached high 
frequencies due to reduced azole sensitivity compared with the parental genotypes [37]. For 
that to occur, recombination (e.g. by the sexual cycle) is a prerequisite.
It appears that, in contrast to asexual reproduction, more specific conditions are needed 
to induce sexual reproduction in A. fumigatus. In the laboratory, specific nutrients and 
temperature were required, as well as a lot of patience as cleistothecia developed only after 
weeks or months of incubation. These observations do suggest that the sexual cycle may 
be an infrequent event (this has also been suggested by others [38]), at least compared to 
the abundant production of conidia by the relatively rapid asexual cycle. This might explain 
why only three environmental resistance mechanisms have been found (i.e. TR34/L98H, 
TR46/Y121F/T289A, and TR53) if the sexual cycle is indeed involved in the origin of these 
mechanisms.
Because asexual reproduction is extremely efficient in A. fumigatus, with lower metabolic 
costs, the ability to reproduce under a wider range of conditions and within a shorter period 
of time, the resistance trait would subsequently be able to migrate, for example through 
wind-dispersed conidia. Fungicides will provide selection pressure for the resistant genotype 
to persist and increase in frequency. This phenomenon has also been observed in plant 
pathogens, where resistant genotypes are able to rapidly increase in frequency due to strong 
fungicide selection coupled with an absence of fitness costs associated with the mutation 
[35].
Evidence to support the hypothesis that sexual reproduction plays a role in resistance 
development may be provided by induction experiments during sexual reproduction. For 
that, the actual sexual cycle should take place using pressure of the five azole fungicides 
that showed in vitro cross resistance and exhibited similar molecule structure to the medical 
triazoles.
Furthermore, I would sample in the environment for the sexual state of A. fumigatus 
(ascospores) with the purpose to identify the ecological niche in which it develops. Possibly, 
there are specific conditions in the Netherlands that facilitate the selection of azole resistance 
during sexual reproduction. Identification of these conditions would be informative to 
develop effective limiting- and preventive measures.
156
Chapter 7
References
1.  Fisher MC, Henk DA, Briggs CJ, Brownstein JS, Madoff LC, et al. (2012) Emerging fungal threats 
to animal, plant and ecosystem health. Nature 484: 186-194.
2. Brent K, Hollomon D (2007) Fungicide resistance in crop pathogens: how can it be managed? 
Fungicide Resistance Action Committee (FRAC) Monograph No 1, Global Crop Protection 
Federation, Brussels.
3.  Bhullar K, Waglechner N, Pawlowski A, Koteva K, Banks ED, et al. (2012) Antibiotic resistance 
is prevalent in an isolated cave microbiome. PLoS One 7: e34953.
4.  Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, et al. (2008) Emergence of azole 
resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 5: 
e219.
5.  Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Melchers WJ, Verweij PE, et al. (2007) A new 
Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole 
antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 51: 
1897-1904.
6.  Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, et al. (2009) Frequency and evolution 
of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect 
Dis 15: 1068-1076.
7.  Mortensen KL, Mellado E, Lass-Florl C, Rodriguez-Tudela JL, Johansen HK, et al. (2010) 
Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, 
Denmark, and Spain. Antimicrob Agents Chemother 54: 4545-4549.
8.  Warris A, Klaassen CH, Meis JF, de Ruiter MT, de Valk HA, et al. (2003) Molecular epidemiology 
of Aspergillus fumigatus isolates recovered from water, air, and patients shows two clusters of 
genetically distinct strains. J Clin Microbiol 41: 4101-4106.
9.  van der Linden JW, Arendrup MC, Verweij PE (2011) Prospective international surveillance of 
azole resistance in Aspergillus fumigatus (SCARE-Network). 51st Interscience Conference on 
Antimicrobial Agents and Chemotherapy (ICAAC); Chicago; abstract M-490.
10.  Rath PM, Buchheidt D, Spiess B, Arfanis E, Buer J, et al. (2012) First reported case of azole-
resistant Aspergillus fumigatus due to TR/L98H mutation in Germany. Antimicrob Agents 
Chemother 56: 6060-6061.
11.  Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, et al. (2011) Azole resistance in 
Aspergillus fumigatus isolates from the ARTEMIS global surveillance is primarily due to the 
TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 55: 4465-4468.
12.  Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, et al. (2011) Isolation of 
multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in 
the cyp51A gene in India. J Antimicrob Chemother 67: 362-366.
7157
General discussion
13.  Seyedmousavi S, Hashemi SJ, Zibafar E, Zoll J, Hedayati MT, et al. (2013) Azole-resistant 
Aspergillus fumigatus, Iran. Emerg Infect Dis 19: 832-834.
14.  Snelders E, Melchers WJ, Verweij PE (2011) Azole resistance in Aspergillus fumigatus: a new 
challenge in the management of invasive aspergillosis? Future Microbiol 6: 335-347.
15.  European Centre for Disease Prevention and Control (ECDC) Expert panel (2013) Risk 
assessment on the impact of environmental usage of triazoles on the development and 
spread of resistance to medical triazoles in Aspergillus species. Available from http://ecdc.
europa.eu/en/publications/Publications/risk-assessment-impact-environmental-usage-of-
triazoles-on-Aspergillus-spp-resistance-to-medical-triazoles.pdf
16.  van der Linden JW, Jansen RR, Bresters D, Visser CE, Geerlings SE, et al. (2009) Azole-resistant 
central nervous system aspergillosis. Clin Infect Dis 48: 1111-1113.
17.  van Leer-Buter C, Takes RP, Hebeda KM, Melchers WJ, Verweij PE (2007) Aspergillosis-and a 
misleading sensitivity result. Lancet 370: 102.
18.  Verweij PE, Mellado E, Melchers WJ (2007) Multiple-triazole-resistant aspergillosis. N Engl J 
Med 356: 1481-1483.
19.  Mavridou E, Bruggemann RJ, Melchers WJ, Mouton JW, Verweij PE (2010) Efficacy of 
posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the 
cyp51A gene. Antimicrob Agents Chemother 54: 860-865.
20.  Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW (2010) Impact of cyp51A 
mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a 
murine model of disseminated aspergillosis. Antimicrob Agents Chemother 54: 4758-4764.
21.  van der Linden JWM, Arendrup MC, van der Lee HAL (2009) Azole containing agar plates as 
a screening tool for azole resistance of Aspergillus fumigatus. 4th Trends in Medical Mycology 
(TIMM); Athens; abstract O1.1.
22.  Livermore J, Hope W (2012) Evaluation of the pharmacokinetics and clinical utility of 
isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metab Toxicol 8: 
759-765.
23.  Seyedmousavi S, Melchers WJ, Mouton JW, Verweij PE (2012) Efficacy and dose-response 
relationships of liposomal amphotericin B (L-AmB) against different azole-resistant Aspergillus 
fumigatus isolates in a non-neutropenic murine model of disseminated aspergillosis. 52th 
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Fransisco; 
abstract M-988.
24.  Schwartz S, Ruhnke M, Ribaud P, Reed E, Troke P, et al. (2007) Poor efficacy of amphotericin 
B-based therapy in CNS aspergillosis. Mycoses 50: 196-200.
25.  Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH (2010) An insight into the 
antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 9: 719-727.
158
Chapter 7
26.  Bijkerk P, Roede BM, van Lier EA, Kretzschmar ME (2010) Staat van Infectieziekten in 
Nederland 2009. National Institute for Public Health and the Environment (Rijksinstituut 
voor Volksgezondheid en Milieu, RIVM). Available from http://www.rivm.nl/bibliotheek/
rapporten/210211006.pdf.
27.  Thieme M (2010) Kamervragen aan de ministers van VROM en LNV over de resistente 
schimmels in ziekenhuizen die tot infecties en zelfs doden leiden. Available from https://
www.partijvoordedieren.nl/tweedekamer/kamervragen/i/1814.
28.  Ombudsman DN (2012) “Het spijt mij” Over Q-koorts en de menselijke maat. Available from 
http://www.nationaleombudsman-nieuws.nl/sites/default/files/rapport_2012-100_over_q-
koorts_en_de_menselijke_maat.pdf. 
29.  Brent K, Hollomon D (2007) Fungicide resistance: the assessment of risk. Fungicide Resistance 
Action Committee (FRAC) Monograph no. 2, Global Crop Pretection Federation, Brussels.
30.  Enserink M (2009) Farm fungicides linked to resistance in a human pathogen. Science 326: 
1173.
31.  Camps SM, van der Linden JW, Li Y, Kuijper EJ, van Dissel JT, et al. (2012) Rapid induction of 
multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study 
and review of the literature. Antimicrob Agents Chemother 56: 10-16.
32.  Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ (2009) Azole resistance in Aspergillus 
fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 9: 789-795.
33.  Dyer PS, Paoletti M (2005) Reproduction in Aspergillus fumigatus: sexuality in a supposedly 
asexual species? Med Mycol 43 Suppl 1: S7-14.
34.  Gow NA (2005) Fungal genomics: forensic evidence of sexual activity. Curr Biol 15: R509-511.
35.  Boukef S, McDonald BA, Yahyaoui A, Rezgui S, Brunner PC (2012) Frequency of mutations 
associated with fungicide resistance and population structure of Mycosphaerella graminicola 
in Tunisia. Eur J Plant Pathol 132: 111-122.
36.  Dyer PS, Hansen J, Delaney, Lucas JA (2000) Genetic control of resistance to the sterol 
14alpha-demethylase inhibitor fungicide prochloraz in the cereal eyespot pathogen Tapesia 
yallundae. Appl Environ Microbiol 66: 4599-4604.
37.  Brunner PC, Stefanato FL, McDonald BA (2008) Evolution of the CYP51 gene in Mycosphaerella 
graminicola: evidence for intragenic recombination and selective replacement. Mol Plant 
Pathol 9: 305-316.
38.  Kwon-Chung KJ, Sugui JA (2009) Sexual reproduction in Aspergillus species of medical or 
economical importance: why so fastidious? Trends Microbiol 17: 481-487.
7159
General discussion
Microscopic image of squashed cleistothecia with released asci and ascospores. In addition, hyphal 
fragments and asexual spores can be observed (picture: Ton Rijs and Simone Camps).
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Summary 
Aspergillus fumigatus is the most prevalent airborne fungal pathogen, and causes severe 
and often fatal invasive infections in immunocompromised hosts. Additionally, A. fumigatus 
is also able to cause a wide range of non-invasive diseases including allergic syndromes and 
aspergilloma. Azoles are the largest and most widely used class of antifungal drugs to treat 
infections caused by A. fumigatus. Although A. fumigatus is generally susceptible to these 
antifungals, acquired resistance is increasingly being reported over the last few years.
In this thesis new mechanisms of resistance in A. fumigatus were discovered and investigated. 
The thesis consists of two sections. Section I focuses on individual cases of azole resistance 
during medical treatment (the clinical route of resistance) and contains chapters 2 and 3. 
Section II comprises chapters 4, 5 and 6 and addresses the emergence of resistance through 
a possible environmental route (chapter 1).
Section I. The clinical route of resistance development
Patients who are infected by an azole-susceptible isolate may develop azole-resistant disease 
during (chronic) azole therapy. During the course of disease, A. fumigatus may acquire one or 
more mutations in the cyp51A gene, which encodes the target for azole molecules. A number 
of mutations in cyp51A have been identified that have been shown to be associated with 
resistance. These include, for example, mutations resulting in substitutions at codons G54, 
M220, and G448. However, not all resistant isolates have mutations in their cyp51A gene, 
indicating that other yet unknown mechanisms might also be the cause of resistance.
In chapter 2, a patient is described in which multiple resistance mechanisms were induced 
during azole therapy. In this study, nine sequential A. fumigatus isolates were obtained from 
a patient with aspergilloma. Although the first isolate showed wildtype azole susceptibility, 
the other isolates were all resistant to itraconazole with a minimum inhibitory concentration 
(MIC) of >16 mg/l. The voriconazole MICs varied between 0.5 and 8 mg/l, and posaconazole 
MICs were between 0.5 and >16 mg/l.
Because the most common mechanisms of resistance in A. fumigatus are mutations in the 
cyp51A gene, this gene was sequenced in all isolates. One of the isolates had the G54E 
substitution which was proved to be associated with azole resistance before. The other isolates 
had either a P216L or F219I substitution in Cyp51A. Residues P216 and F219 both appeared 
to be very conserved among fungal species, indicating that these positions are important. A 
Cyp51A homology model based on the Mycobacterium tuberculosis crystal structure of the 
enzyme subsequently showed that P216 as well as F219 were located close to the opening 
of one of the ligand access channels. It is believed that through these channels, azoles dock 
to the heme centre of the Cyp51A enzyme, thereby blocking its function. This indicates that 
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both P216 and F219 residues are important and might play a role in azole resistance by 
blocking the entrance of azoles into the heme centre. The final proof was provided by the 
construction of recombinant A. fumigatus, in which the wildtype cyp51A was exchanged with 
a cyp51A cassette containing either one of the two mutations. Indeed, recombinants showed 
resistance as was observed in the patient isolates. However, five patient isolates with the 
F219I substitution probably continued to evolve further resistance as the voriconazole MIC 
further increased from 1 to 8 mg/l and the posaconazole MIC increased from 0.5 to >16 mg/l. 
Because no additional cyp51A mutations were found, an additional but unknown mechanism 
must have evolved in these isolates.
A review of the literature yielded seven other cases with proven acquired azole resistance 
caused by A. fumigatus. As might be expected, all patients had azole exposure before the 
identification of the first resistant isolate. The median time between the last cultured wildtype 
isolate and the first azole resistant strain was only 4 months, indicating that resistance can 
be induced relatively soon after initiating treatment. Furthermore, as also observed in 
our patient, the emergence of multiple mechanisms of resistance was common. Cyp51A 
mutations were observed in most but not all resistant isolates. The isolates of one of the 
reviewed patients are further investigated in chapter 3. 
This patient suffered from chronic granulomatous disease and had a pulmonary infection 
caused by A. fumigatus. Four sequential isogenic A. fumigatus isolates were obtained from 
his respiratory samples and he was treated with multiple courses of antifungal therapy. In 
vitro susceptibility testing showed that the first two isolates were azole susceptible, while 
the last two isolates were resistant to itraconazole and voriconazole and had an intermediate 
susceptibility to posaconazole. Because no alterations were found in the cyp51A gene, a new, 
unknown resistance mechanism must have emerged during therapy.
To identify the resistance mechanism, the second and third isolate (isolated directly before 
and after the onset of azole resistance) were subjected to whole genome sequencing. Six 
non-synonymous mutations were found in the resistant isolate compared to the susceptible 
isolate. To elucidate which of the six mutations was the cause of resistance, sexual crosses 
were performed. For that, the resistant isolate was crossed with a susceptible A. fumigatus 
isolate of the opposite mating type. The P88L substitution in HapE was found in all resistant 
progeny, but never in the susceptible progeny, strongly indicating that this mutation was 
actually causing the resistant phenotype. Subsequent cloning of the mutated hapE gene 
into susceptible A. fumigatus showed that P88L in HapE could indeed confer the resistant 
phenotype.
HapE is a transcription factor subunit and the substitution is located in the evolutionary 
conserved core domain, suggesting that P88 is an important amino acid for the function of 
the protein. We hypothesize that the mutated Hap-complex might bind to a CCAAT-box in the 
promoter region of cyp51A, thereby inducing the expression of the gene and subsequently 
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leading to azole resistance. Alternatively, Hap might function as a transcriptional repressor, 
and the HapE P88L substitution could de-repress cyp51A expression. Indeed, cyp51A 
expression level of the resistant patient isolates was higher compared to the susceptible 
isolates, and a CCAAT-sequence is present in the cyp51A promoter. Importantly, the P88L 
substitution in HapE is the first non-cyp51A resistance mutation found in clinical A. fumigatus 
isolates to date.
Section II. The environmental route of resistance
Although still controversial, we hypothesize that in addition to development of resistance in 
azole-treated patients, resistance could also develop (or being selected for) in the environment. 
Several points are in favor of an environmental route, for example the finding of a dominant 
resistance mechanism (TR34/L98H in cyp51A) that was found in over 90% of resistant clinical 
isolates from different hospitals in The Netherlands. As described in the first section, in 
epidemiologically unlinked patients many resistance mechanisms would be expected. 
Furthermore, the TR34/L98H genotype was also found in azole-naïve patients, strongly 
indicating that resistance does not exclusively develop during azole therapy in the patient. The 
finding of A. fumigatus isolates of the TR34/L98H genotype in the  environment, which cluster 
together with clinical isolates, indicate genetic relatedness and possibly a common ancestor. 
Fungicides commonly used in the environment, for example those used in agriculture, could 
be the cause of the widespread occurrence of resistance in the environment. In chapter 4 
the results further arguing for an environmental route of resistance development/selection 
in A. fumigatus are described. Thirty-one compounds that have been authorized for use as 
fungicides, herbicides, herbicide safeners and plant growth regulators were investigated for 
cross-resistance to medical triazoles. Of these, five triazole demethylation inhibitors (DMIs), 
namely bromuconazole, difenoconazole, epoxiconazole, propiconazole, and tebuconazole, 
showed the highest degree of cross-resistance to the medical azoles. In addition, Cyp51A 
homology modeling and molecule alignment studies were performed and these five DMIs 
showed very similar molecule structures to the medical triazoles and also adopted similar 
poses while docking the protein. These DMIs were authorized for use between 1990 and 
1996, directly preceding the recovery of the first clinical TR34/L98H isolate in 1998. By studying 
molecular evolution it was calculated that the first TR34/L98H isolate would have arisen in 
1997. Finally, induction experiments were performed to investigate if TR34/L98H could be 
induced under fungicide pressure. One isolate evolved from two copies of the tandem repeat 
(TR34) to three, indicating that fungicide pressure can indeed result in these genomic changes.
In chapter 5 the molecular epidemiology of resistance through the TR34/L98H resistance 
mechanism is investigated. For that, 142 isolates were studied by analyzing several genetic 
markers. Results of microsatellite analysis showed that isolates with the TR34/L98H azole 
resistance mechanism originating from The Netherlands and seven other European countries 
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are genetically less diverse than azole susceptible wildtype isolates and isolates bearing other 
forms of azole resistance. Furthermore, Dutch isolates with the TR34/L98H genotype as well 
as the majority of the European isolates carrying this resistance mechanism grouped to the 
same three CSP types. Sexual crossing experiments demonstrated that TR34/L98H isolates are 
fertile and could outcross with azole-susceptible isolates of different genetic backgrounds, 
indicating that TR34/L98H isolates can undergo the sexual cycle in nature. Considering the 
results of this chapter as a whole, it is possible to speculate about the evolutionary origin 
and spread of the TR34/L98H azole resistance genotype within Europe. The relatively close 
genetic relationships and limited CSP-type diversity of the TR34/L98H isolates, as compared to 
azole susceptible wildtype isolates indicates that the independent and repeated emergence 
of the TR34/L98H mechanism seems unlikely. An alternative explanation might be that the 
TR34/L98H isolates developed from a common ancestor or restricted set of genetically-related 
isolates. A common origin of the TR34/L98H mechanism was also suggested in the previous 
chapter, in which it was calculated that the first TR34/L98H isolate would have emerged in the 
Netherlands in 1997.
Chapter 6 describes a new resistance mechanism which probably also emerged and spread 
via the environmental pathway. Between December 2009 and January 2011 21 azole-resistant 
isolates of 15 patients from six different Dutch hospitals were obtained, all harboring TR46/
Y121F/T289A alterations in Cyp51A. The majority of the patients had no history of previous 
azole exposure. All isolates were highly resistant to voriconazole with a MIC of ≥16 mg/l. 
Eight patients presented with invasive aspergillosis, of which six failed primary voriconazole 
therapy. Recombinant experiments confirmed the link between TR46/Y121F/T289A and the 
resistant phenotype. Furthermore, both Cyp51A-substitutions (Y121F and T289A) might 
be able to interfere with the docking modes of azole compounds, as shown in the Cyp51 
homology model. TR46/Y121F/T289A was recovered through air sampling in hospitals as 
well as in domestic homes, supporting the environmental pathway. At present, the TR46/
Y121F/T289A resistance mechanism has emerged in addition to TR34/L98H and the 2010 
annual prevalence had increased to 7.2%, of which TR46/Y121F/T289A accounted for 1.4% 
of underlying resistance mechanisms. We concluded that the increasing prevalence of azole-
resistance may be accelerated by the emergence of this new resistance mechanism and that 
emergence and migration of this new resistance mechanism might be threatening the use of 
primary therapy with voriconazole.
The general discussion of the thesis is represented in chapter 7. Both routes of azole 
resistance development/selection (i.e. during medical treatment of individual cases and 
through exposure to fungicides in the environment) appear to have different characteristics 
and induce specific resistance mechanisms. 
Treatment induced resistance often reflects substitutions in Cyp51A, such as at codons G54, 
P216, F219, M220, and G448. Other genes (such as hapE) are also involved, although less is 
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known about non-cyp51A resistance mechanisms. Furthermore, more than one resistance 
mechanism may arise, and resistance might accumulate. It is still unknown which proportion 
of azole-treated patients develop azole resistance and whether specific risk factors for 
resistance development can be identified. Furthermore, patients might be monitored for 
development of resistance such that treatment might be changed as quickly as possible after 
resistance emerged. 
Resistance development/selection through the use of fungicides (the environmental route 
of resistance) might be even more worrisome. The continued use of triazole DMIs in our 
environment with activity against A. fumigatus will help resistance traits to sustain in the 
environment and will cause new resistance mechanism to emerge. The potential of global 
migration, as observed with the TR34/L98H resistance mechanism, indicates that fungicide-
driven route of resistance development/selection will not remain a regional problem. We 
expect that unless we are able to implement measures that prevent environmental resistance 
development and spread, the clinical use of azoles will be severely compromised.
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Samenvatting 
Aspergillus fumigatus is de meest voorkomende pathogene schimmel die via de lucht wordt 
verspreid. Deze schimmel kan ernstige en vaak fatale invasieve infecties veroorzaken bij 
immuungecompromitteerde patiënten. Ook kan A. fumigatus diverse niet-invasieve ziekten, 
zoals allergische beelden en aspergilloom veroorzaken. Azolen zijn de meest gebruikte klasse 
van antischimmelgeneesmiddelen voor de behandeling van A. fumigatus infecties. Ondanks 
het feit dat A. fumigatus over het algemeen gevoelig is voor deze middelen, wordt resistentie 
in de laatste jaren steeds vaker gevonden.
In dit proefschrift worden nieuwe resistentiemechanismen in A. fumigatus beschreven en 
verder onderzocht. Het proefschrift bestaat uit twee secties. Sectie I focust op het ontstaan 
van azoolresistentie bij patiënten gedurende de  behandeling met azolen (de klinische route 
van resistentie) en bevat hoofdstuk 2 en 3. Sectie II omvat hoofdstukken 4, 5 en 6 en behandelt 
de opkomst van resistentie die in de omgeving is ontstaan of geselecteerd (hoofdstuk 1).
Sectie I. De klinische route van resistentievorming
Patiënten die geïnfecteerd zijn met een azoolgevoelig A. fumigatus isolaat kunnen resistente 
ziekten ontwikkelen gedurende de behandeling met azolen. Gedurende de behandeling kan 
A. fumigatus één of meerdere mutaties verwerven in met name het cyp51A gen, dat codeert 
voor het doeleiwit van de azolen: het Cyp51A enzym. Diverse mutaties geassocieerd met 
resistentie zijn in cyp51A geïdentificeerd, zoals mutaties die leiden tot substituties op codons 
G54, M220 en G448. Niet alle resistente isolaten hebben mutaties in hun cyp51A gen. Er zijn 
dus ook andere, nog onbekende, mechanismen die resistentie kunnen veroorzaken.
In hoofdstuk 2 wordt een patiënt beschreven waarin meerdere resistentiemechanismen 
zijn geïnduceerd tijdens de behandeling met azolen. In deze studie werden negen 
achtereenvolgende A. fumigatus isolaten verkregen van deze patiënt, die leed aan een 
aspergilloom. Ondanks dat het eerste isolaat een wildtype azoolgevoeligheid had, waren alle 
volgende isolaten (gekweekt ná het starten van de therapie) ongevoelig voor itraconazol met 
een minimale remmende concentratie (MRC) van >16 mg/l. De voriconazol MRC’s varieerden 
tussen de 0,5 en 8 mg/l en posaconazol MRC’s waren tussen 0,5 en >16 mg/l.
Omdat de meest voorkomende mechanismen van resistentie in A. fumigatus mutaties in 
het cyp51A gen zijn, werd dit gen gesequencet in alle isolaten. Één van de isolaten had 
een G54E substitutie. Uit eerdere studies is gebleken dat deze substitutie geassocieerd is 
met azoolresistentie. De overige isolaten hadden een P216L ofwel een F219I substitutie in 
Cyp51A. Residuen P216 en F219 bleken beide geconserveerd te zijn binnen de fungi. Dit geeft 
een indicatie van het belang van deze posities. Een Cyp51A homologie model gebaseerd op 
de Mycobacterium tuberculosis kristalstructuur van het enzym liet vervolgens zien dat P216 
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alsmede F219 dicht bij de opening van één van de twee kanalen ligt. Door deze kanalen 
dringen azolen waarschijnlijk het haemcentrum van Cyp51A binnen en daardoor wordt de 
functie van het enzym geblokkeerd. Dit duidt erop dat zowel P216 als F219 belangrijk is 
en een rol in azoolresistentie zou kunnen spelen doordat de azolen nu niet meer door het 
kanaal kunnen. Het uiteindelijke bewijs werd geleverd door de constructie van A. fumigatus 
recombinanten, waarin het wildtype cyp51A uitgewisseld werd met een cyp51A cassette met 
daarin één van de twee mutaties. De recombinanten waren inderdaad resistent, net zoals de 
oorspronkelijke patiëntenisolaten. Vijf isolaten afkomstig van deze patiënt ontwikkelden nog 
verdere resistentie: de voriconazol MRC steeg van 1 tot 8 mg/l en de posaconazol MRC nam 
toe van 0.5 tot >16 mg/l. Omdat er geen andere cyp51A mutaties gevonden werden, is er een 
additioneel onbekend mechanisme ontstaan in deze isolaten.
Literatuurstudie leverde zeven andere gevallen op waarin bewezen verworven azoolresistentie 
in A. fumigatus is beschreven. Zoals verwacht hadden alle patiënten azooltherapie 
voorafgaande aan identificatie van het eerste resistente isolaat. De mediane tijd tussen het 
laatst gekweekte wildtype isolaat en het eerste azoolresistente isolaat was maar 4 maanden, 
wat er op duidt dat resistentie relatief snel na de start van de behandeling kan ontstaan. 
Bovendien kwam de ontwikkeling van meerdere resistentiemechanismen vaak voor. Cyp51A 
mutaties werden geobserveerd in de meeste, maar niet in alle resistente isolaten. De isolaten 
van één van de patiënten werden verder onderzocht in hoofdstuk 3. 
Deze patiënt leed aan chronische granulomateuze ziekte en had een pulmonaire infectie 
veroorzaakt door A. fumigatus. Vier isogene A. fumigatus isolaten werden achtereenvolgens 
uit zijn respiratoire monsters verkregen en hij werd behandeld met diverse antifungale 
geneesmiddelen. In vitro gevoeligheidsbepalingen lieten zien dat de eerste twee isolaten 
azoolgevoelig waren, terwijl de laatste twee isolaten resistent waren voor itraconazol 
en voriconazol en een intermediaire gevoeligheid hadden voor posaconazol. Omdat er 
geen veranderingen werden gevonden in het cyp51A gen, moet er een nieuw, onbekend 
resistentiemechanisme zijn ontstaan tijdens de behandeling.
Om dit resistentiemechanisme te identificeren, werd het gehele genoom van het tweede 
en het derde isolaat (geïsoleerd vóór en ná het ontstaan van azoolresistentie) gesequencet. 
In het resistente isolaat werden zes niet-synonieme mutaties gevonden. Om te achterhalen 
welke van de zes mutaties resistentie veroorzaakte, werden kruisingen uitgevoerd door 
middel van geslachtelijke voortplanting. Het resistente isolaat werd gekruist met een gevoelig 
A. fumigatus isolaat van het tegengestelde ‘mating type’. De P88L substitutie in HapE werd in 
alle resistente nakomelingen gevonden, maar nooit in de gevoelige nakomelingen. Vervolgens 
werd het gemuteerde hapE gen in een gevoelige A. fumigatus stam gekloneerd en inderdaad 
had P88L in HapE resistentie tot gevolg.
HapE is een transcriptiefactor en de substitutie is gesitueerd in het evolutionair geconserveerde 
‘kern’ domein, wat suggereert dat P88 een belangrijk aminozuur is voor de functie van het 
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eiwit. We verwachten dat het gemuteerde Hap-complex aan een CCAAT-box in de promotor 
regio van cyp51A bindt en daarbij de expressie van het gen induceert. Dit leidt vervolgens 
tot azoolresistentie. Een andere mogelijkheid is, dat Hap als een transcriptionele repressor 
werkt, en dat de HapE P88L substitutie de remming van cyp51A expressie kan opheffen. 
Inderdaad was cyp51A expressie van de resistente patiëntenisolaten hoger dan de gevoelige 
isolaten, en er is een CCAAT sequentie aanwezig in de Cyp51A promotor. P88L is de eerste 
non-cyp51A resistentiemutatie gevonden in een klinisch A. fumigatus isolaat.
Sectie II. De omgevingsroute van resistentie
Wij hebben de hypothese geponeerd, dat behalve resistentie-ontwikkeling in azoolbehandelde 
patiënten, resistentie ook kan ontstaan in de omgeving. Verschillende factoren wijzen hierop, 
bijvoorbeeld de sterke dominantie van eenzelfde resistentiemechanisme: TR34/L98H in cyp51A 
werd in meer dan 90% van de resistente klinische isolaten uit verschillende ziekenhuizen in 
Nederland gevonden. Zoals al beschreven in de eerste sectie, zou men in epidemiologisch 
ongerelateerde patiënten een grotere diversiteit aan resistentiemechanismen verwachten. 
Bovendien werd het TR34/L98H genotype ook in azool-naïeve patiënten gevonden, wat er 
op wijst dat resistentie niet alleen tijdens azoolbehandeling in de patiënt kan ontstaan. We 
hebben ook duidelijke aanwijzingen gevonden dat A. fumigatus isolaten met het TR34/L98H 
genotype geïsoleerd uit patiënten en uit de omgeving genetisch verwant zijn aan elkaar en 
mogelijk een gemeenschappelijke voorouder hebben. Fungiciden worden veelvuldig gebruikt 
in het milieu, bijvoorbeeld in de landbouw. Dit zou de oorzaak kunnen zijn van het voorkomen 
van resistentie in het milieu. In hoofdstuk 4 worden verdere resultaten beschreven die 
duiden op een omgevingsroute van resistentie in A. fumigatus. Eenendertig middelen die 
toegelaten zijn voor gebruik als fungicide, herbicide, herbicide safener en/of groeiregulator 
werden getest op kruisresistentie met medische azolen. Van deze middelen waren er vijf 
triazol demethylatie inhibitors (DMI’s) met hoge kruisresistentie tegen de medische azolen 
(bromuconazol, difenoconazol, epoxiconazol, propiconazol, en tebuconazol). Deze DMI’s 
hadden een molecuulstructuur vergelijkbaar aan de medische azolen. Het Cyp51A model 
liet ook zien dat de vijf middelen zich op eenzelfde manier positioneerden in het doelenzym. 
De DMI’s werden toegelaten voor gebruik tussen 1990 en 1996, precies voorafgaand aan de 
isolatie van de eerste TR34/L98H stam in 1998. Door het bestuderen van moleculaire evolutie 
is berekend dat het eerste TR34/L98H isolaat in 1997 ontstaan zou zijn. Inductie-experimenten 
werden vervolgens uitgevoerd om te onderzoeken of TR34/L98H geïnduceerd zou kunnen 
worden onder fungicide druk. Één isolaat evolueerde van twee naar drie kopieën van de 
tandem repeat (TR34), dus fungicide druk zou deze genomische veranderingen tot gevolg 
kunnen hebben. 
In hoofdstuk 5 wordt de moleculaire epidemiologie van resistentie door het TR34/L98H 
resistentiemechanisme onderzocht. Daarvoor werden genetische markers van 142 isolaten 
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bestudeerd. De resultaten van microsatelliet analyse lieten zien dat isolaten met het 
TR34/L98H resistentiemechanisme uit Nederland en zeven andere Europese landen genetisch 
minder divers zijn dan azoolgevoelige wildtype isolaten en isolaten met andere vormen van 
resistentie. Bovendien groepeerden Nederlandse isolaten van het TR34/L98H genotype en de 
meerderheid van de Europese TR34/L98H isolaten in dezelfde drie CSP types. Geslachtelijke 
voortplanting toonde aan dat TR34/L98H isolaten fertiel zijn en dat deze isolaten kunnen 
paren met azoolgevoelige isolaten met diverse genetische achtergronden. Dit duidt erop dat 
TR34/L98H isolaten in de natuur de sexuele cyclus kunnen ondergaan. Met de resultaten van 
dit hoofdstuk kunnen we speculeren over de evolutionaire bron en de spreiding van het TR34/
L98H azoolresistentie genotype binnen Europa. De relatief hechte genetische verwantschap 
en gelimiteerde diversiteit van CSP types, in vergelijking tot azoolgevoelige wildtype isolaten 
duiden niet op een onafhankelijk en herhaaldelijk ontstaan van het TR34/L98H mechanisme. 
Een alternatieve verklaring kan zijn dat de TR34/L98H isolaten uit een gemeenschappelijke 
voorouder of een beperkte set van genetisch gerelateerde isolaten zijn ontstaan. De 
gemeenschappelijke oorsprong van het TR34/L98H resistentiemechanisme is ook in het vorige 
hoofdstuk gesuggereerd, waarin werd berekend dat het eerste isolaat in Nederland in 1997 
ontstaan zou zijn.
Hoofdstuk 6 beschrijft de ontwikkeling van een nieuw resistentiemechanisme, dat 
waarschijnlijk ook via de omgevingsroute is ontstaan. Van december 2009 tot en met januari 
2011 werden 21 azoolresistente isolaten van 15 patiënten uit zes verschillende Nederlandse 
ziekenhuizen verkregen, allen met de TR46/Y121F/T289A veranderingen in Cyp51A. De meeste 
patiënten hadden geen voorafgaande azoolmedicatie ontvangen. Alle isolaten waren resistent 
voor voriconazol met een MRC van ≥16 mg/l. Acht patiënten presenteerden zich met een 
invasieve aspergillose, waarvan er zes faalden op primaire voriconazol therapie. Recombinant 
experimenten bevestigden de associatie tussen TR46/Y121F/T289A en het resistente 
fenotype. Bovendien liet het Cyp51A homologiemodel zien dat beide substituties (Y121F en 
T289A) mogelijk interfereren met de docking van azoolmoleculen in het enzym. Het TR46/
Y121F/T289A genotype werd ook geïsoleerd door luchtbemonstering in ziekenhuizen en in 
huiselijke omgeving, wat een omgevingsgerelateerde weg suggereert. Het TR46/Y121F/T289A 
resistentiemechanisme is ontstaan naast TR34/L98H, en de prevalentie van azoolresistentie 
van 2010 steeg tot 7,2%; 1,4% werd veroorzaakt door TR46/Y121F/T289A. We concludeerden 
dat de prevalentie van azoolresistentie versneld kan toenemen door het ontstaan van dit 
nieuwe resistentiemechanisme, en dat het ontstaan en de verspreiding van dit mechanisme 
de primaire behandeling met voriconazol kan bedreigen.
De algemene discussie van dit proefschrift wordt beschreven in hoofdstuk 7. Beide routes 
van resistentie ontwikkeling/selectie (tijdens medische behandeling van individuele gevallen 
of door de blootstelling aan fungiciden in de omgeving) lijken verschillende karakteristieken 
en specifieke resistentiemechanismen te hebben.
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Klinisch geïnduceerde resistentie heeft vaak betrekking op substituties in Cyp51A, zoals op 
codons G54, P216, F219, M220, en G448. Andere genen (zoals hapE) spelen ook een rol, 
maar er is minder bekend over niet-cyp51A resistentiemechanismen. Bovendien kan er 
meer dan één resistentiemechanisme ontstaan, en resistentie kan accumuleren. Het is nog 
steeds onbekend welke proportie van azoolbehandelde patiënten resistentie ontwikkelen 
en of specifieke risicofactoren voor resistentie-ontwikkeling geïdentificeerd kunnen 
worden. Patiënten zouden gevolgd kunnen worden voor ontwikkeling van resistentie, zodat 
behandeling zo snel mogelijk na resistentie-ontwikkeling gewijzigd kan worden.
Resistentie door het gebruik van fungiciden (de omgevingsroute van resistentie) is nog 
zorgwekkender. Het voortdurende gebruik van triazool DMI’s in ons milieu met activiteit tegen 
A. fumigatus zorgt ervoor dat resistentie behouden blijft en zal ook mogelijkheden geven voor 
de ontwikkeling en/of geografische verspreiding van nieuwe resistentiemechanismen. Het 
potentieel van globale verspreiding, zoals gezien met het TR34/L98H resistentiemechanisme, 
wijst uit dat fungicide gedreven resistentie ontwikkeling/selectie geen regionaal probleem 
is. Wij verwachten dat, tenzij er effectieve maatregelen genomen worden om omgeving 
gerelateerde resistentie-ontwikkeling en verspreiding tegen te gaan, het klinische gebruik 
van azolen in de (nabije) toekomst ernstig belemmerd zal worden.
Microscopic view of A. fumigatus cultured on Sabouraud agar (picture: Ton Rijs and Simone Camps).
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Paul, bedankt voor je betrokkenheid die toenam naarmate het onderzoek vorderde. In 
het bijzonder bedankt voor onze vrijdagochtendbesprekingen die mij telkens weer nieuwe 
energie gaven en waarin de beste ideeën ontstonden!
Willem, ik heb mogen profiteren van je grote hoeveelheid mensenkennis en grote 
betrokkenheid. Achteraf ben ik erg blij dat je me erop gewezen hebt voor niet al te veel ‘o-zo-
interessante’ zijwegen te kiezen. Door jou ben ik op het ‘rechte pad’ gebleven, en heb ik alles 
op tijd af kunnen ronden. Bedankt voor de laagdrempelige begeleiding, je enthousiasme en de 
vaak snelle reacties op manuscripten en andere stukken, die je allen van scherp commentaar 
hebt voorzien.
Prof. dr. Mihai Netea, prof. dr. Nicole Blijlevens en prof. dr. Bas Zwaan wil ik bedanken voor 
de bereidheid hun tijd en expertise ter beschikking te stellen en zitting te nemen in de 
manuscriptcommissie.
Ton, grote hulp in het lab en een fijn luisterend oor. Bedankt dat je altijd voor me klaar stond 
en dat ik gebruik heb mogen maken van je onuitputtelijke kennis over de macroscopische en 
microscopische determinatie van schimmels. Hein, ook bij jou kon ik altijd terecht voor mijn 
vragen, wat extra hulp of ‘gewoon’ voor een wijze les. Bedankt daarvoor.
Jan (van der Linden) en Eveline, het was erg leuk jullie als ‘roommates’ te hebben tijdens 
het eerste deel van mijn promotie. We bleken bijzonder goed in het over en weer geklaag 
over het benauwde hok waar we ons in bevonden. Eveline, wat heb ik een geluk gehad met 
jou als voorganger. Je bevindingen vormden een stevige basis voor mijn proefschrift. Jan, 
bedankt voor de Itra- en SCARE studies waar je zoveel tijd aan hebt besteed. Hiermee haalde 
je tientallen interessante isolaten naar Nijmegen waar ik veel profijt van heb gehad. Het was 
leuk samen met je de Acropolis in Athene te bezoeken, al was het vliegensvlug, om vervolgens 
bijna aangereden door een taxi, precíes op tijd bij de openingsceremonie van het congres te 
kunnen verschijnen.
Rita, een half-Duitse Griekse in Nederland, bedankt voor alle hilarische situaties waar 
iedereen om kon lachen, behalve jezelf… Heel veel succes in de USA.
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Diane, al was je veelal druk in de weer in het lab, het was leuk een kantoor met je te delen 
tijdens de laatste twee jaar van m’n promotie.
Jan (Zoll), bedankt voor de praktische ondersteuning, vooral voor het cyp51A expressie 
experiment tijdens mijn periode van verlof. 
Amir, it was very nice to get to know you and good luck with your further research.
Dewi, wij begonnen ongeveer gelijktijdig bij de MMB. Bedankt voor de gezelligheid en veel 
succes met je onderzoek en opleiding tot microbioloog.
Alle moleculaire-diagnostiek medewerkers, in het bijzonder Judith B, Judith K en Cindy, 
bedankt voor de introductie in de wereld van moleculaire microbiologie diagnostiek en het 
bestellen van de benodigde materialen en primers. 
Claudia, de grappenmaker van het huis en gezellig trein-maatje gedurende de beginjaren, het 
was gezellig met je!
Ferry, bedankt voor de ‘minicursus’ InDesign in een half uurtje, het heeft me goed op weg 
geholpen bij de vormgeving van mijn proefschrift. 
Ook het secretariaat bedankt voor het eindeloos maken en verplaatsen van afspraken. Het 
was altijd gezellig even bij jullie rond te hangen wanneer Paul ‘bijna’ klaar was met zijn 
bespreking.
Ik kan hier helaas niet iedereen persoonlijk noemen, maar ik wil graag ook alle andere 
collega’s binnen het PZL bedanken voor de gezelligheid in de laboratoria en in het MMB Café.
Samenwerking met diverse disciplines is essentieel gebleken voor geslaagd wetenschappelijk 
onderzoek.
Gert, Theo en Els, bedankt dat ik bij jullie in Wageningen van de MLII labfaciliteiten gebruik 
mocht maken. Gert, bedankt voor de samenwerking met betrekking tot de fungiciden. Els, 
bedankt voor het regelwerk hieromheen. Theo, fijn dat je altijd geïnteresseerd was in mijn 
werk. En ik zal nooit vergeten dat je serieus voorstelde ergens een ligbed te plaatsen, zodat ik 
tijdens mijn zwangerschap tussendoor even kon rusten. Gelukkig was het nog nét niet zo erg 
met me gesteld. Tot ‘carnaval 2014’ in Venray!
Martijn en Bas, bedankt voor de prettige samenwerking en jullie waardevolle bijdrage aan 
‘het HapE stuk’. I also wish to thank Anna for her work on the Cyp51A homology model. Paul 
and Céline, it was very nice to visit you in Nottingham. I appreciate your contribution to one 
of my papers and thank you very much for sending the isolates we used for sexual crossing 
experiments. Corné, bedankt voor het maken van de STR-bomen. Het heeft prachtige plaatjes 
opgeleverd. Mihai and Louis, thank you for the interesting immunogenicity studies. Peter, 
bedankt voor de broodnodige humor tijdens meetings en conferenties. Ik vond het leuk en 
leerzaam af en toe een paper te mogen reviewen voor ‘Journal of Invasive Fungal Infections’.
Dank aan het gehele NCMLS medical microbiology lab. Fijn dat ik mijn werk kon doen in het 
MLI lab en mijn plasmides vervolgens in één van de ‘U-tjes’ verder kon opzuiveren. In het 
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bijzonder wil ik Ben bedanken, omdat je me met zoveel kennis en kunde hebt geholpen met 
de Southern blots. 
Studenten Peter en Yi. Peter, het was een gezellige tijd en ik vond het leuk dat je later nog 
eens terug kwam om te een praatje te maken. 
Yi, thanks for your great help as a student. It was very nice getting to know you and to learn 
some interesting facts about your home country, China. I hope you enjoyed staying with us 
in the lab.
Alle mensen betrokken bij het Innowator project. Frank, Astrid, Ania, Annemie, Marloes, en 
David van Pentair-Filtrix; Simon, Bendert en Laura van Vitens; Astrid van Wetsus. Innowator 
was een geweldig project waar ik met veel plezier aan gewerkt heb. Bedankt voor de leuke 
samenwerking en voor de gezelligheid in Liverpool en Genève. Ik zal later zeker nog eens 
terugdenken aan de hectische terugreis van Genève, waarbij we het voor elkaar kregen al 
rennend en zonder vliegtickets de douane te passeren. Een race tegen de klok! 
Ook dank aan HIP’ers Leo en Esther voor hun hulp bij het Innowator project.
Ontspanning is tijdens een promotie-traject ook heel belangrijk. Lieve Sjabbes (Sarah, Jeroen, 
Karlijn, Manuel, Juul, Ineke, Bram, Mariëlle, Jan, Ellen, Gemma, Inge, Har, ‘rooie’ Inge, Ralf, Kiki, 
Niek, Irene, Hans, Janna, Iwan, Sander en Lara) en lieve Sjabbe-kindjes (Senna, Rafa, Mees, Tim, 
Max, Puk en Pleun), bedankt voor alle gezelligheid en ontelbaar veel mooie herinneringen. 
Sjabbes, bedankt voor jullie interesse in mijn werk (vooral de seksende schimmels bleken een 
interessant kroeg-onderwerp!). Dat de weekendjes weg, vrijdagmiddag-club, wandelingen, 
feestjes, theedrinkmomenten en alle andere activiteiten nog héél lang voortgezet mogen 
worden. Kiki, tevens bedankt voor je hulp bij het ontwerp van de cover!
Ten slotte wil ik ook mijn familie bedanken. In het bijzonder mijn ouders die mij een solide 
basis hebben gegeven en veel interesse hebben getoond tijdens mijn promotie. 
Falco, jou wil ik bedanken voor je steun, liefde en eindeloos geduld. Dat we nog lang samen 
mogen genieten van het leven. Lieve Lisa, onze kleine meid, ik heb je lief!
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